Scientific Committee on Consumer Safety

SCCS

THE SCCS NOTES OF GUIDANCE FOR THE TESTING OF COSMETIC INGREDIENTS AND THEIR SAFETY EVALUATION

11TH REVISION

The SCCS adopted this guidance document at its plenary meeting on 30-31 March 2021
# TABLE OF CONTENTS

ACKNOWLEDGMENTS ........................................................................................................... 1  
Main changes in 11th REVISION of the SCCS Notes of Guidance (NoG) .................................. 4  
1. INTRODUCTION ................................................................................................................. 5  
2. THE SCIENTIFIC COMMITTEE ON CONSUMER SAFETY, SCCS ...................................... 7  
   2-1 BACKGROUND ............................................................................................................... 7  
   2-2 MANDATE ..................................................................................................................... 7  
   2-3 RULES OF PROCEDURE ............................................................................................... 7  
   2-4 OPINIONS ..................................................................................................................... 7  
   2-4.1 The "Notes of Guidance" ......................................................................................... 7  
   2-4.2 SCCS Cosmetic ingredient dossiers .......................................................................... 8  
   2-4.3 Specific issues taken up in NoG .............................................................................. 9  
3. SAFETY EVALUATION OF COSMETIC INGREDIENTS .................................................. 10  
   3-1 SAFETY EVALUATION OF COSMETIC INGREDIENTS AS APPLIED BY THE SCCS ...... 10  
   3-2 CHEMICAL AND PHYSICAL SPECIFICATIONS OF COSMETIC INGREDIENTS ...... 13  
      3-2.1 Chemical identity ................................................................................................. 13  
      3-2.2 Physical form ....................................................................................................... 14  
      3-2.3 Molecular weight ............................................................................................... 14  
      3-2.4 Identification and purity of the chemical and isomer composition ..................... 14  
      3-2.5 Characterisation of the impurities or accompanying contaminants .................. 15  
      3-2.6 Relevant physicochemical specifications ............................................................ 15  
      3-2.7 Solubility ............................................................................................................. 15  
      3-2.8 Partition coefficient (Log Pow) .......................................................................... 16  
      3-2.9 Homogeneity and stability ................................................................................... 16  
   3-3 EXPOSURE ASSESSMENT ............................................................................................. 17  
      3-3.1 Functions and uses of cosmetic ingredients ........................................................... 17  
      3-3.2 Identification of relevant exposure scenarios ....................................................... 17  
      3-3.3 Identification of the targeted dose for safety evaluation ..................................... 17  
      3-3.4 External exposure ................................................................................................ 18  
         3-3.4.1 Exposure models and tiered approach .............................................................. 18  
            3-3.4.1.1 Dermal exposure models ....................................................................... 19  
            3-3.4.1.2 Oral exposure models ........................................................................... 19  
            3-3.4.1.3 Inhalation exposure models ................................................................. 20  
         3-3.4.2 Model parameters ............................................................................................ 23  
            3-3.4.2.1 Daily use amounts and retention factors .................................................. 23  
            3-3.4.2.2 Concentrations ...................................................................................... 27  
            3-3.4.2.3 Parameters specific for inhalation exposure .......................................... 27  
         3-3.4.3 Aggregate exposure ......................................................................................... 27  
      3-3.5 Internal Exposure .................................................................................................... 29
3-3.5.1 Toxicokinetics (ADME) ................................................................. 29
3-3.5.1.1 Dermal/percutaneous absorption ............................................ 30
3-3.5.1.2 Absorption after ingestion ...................................................... 33
3-3.5.1.3 Inhalation ........................................................................... 33
3-3.5.2 Differences in metabolism for different routes .......................... 34
3-3.5.2.1 Systemic metabolism ............................................................ 34
3-3.5.2.2 Dermal metabolism ............................................................... 35
3-3.5.2.3 Lung metabolism .................................................................. 35
3-3.5.3 PBPK modelling ...................................................................... 36
3-3.5.4 Calculation of the systemic exposure dose (SED) ....................... 38
3-3.5.4.1 Calculation of the inhalation SED (SEDinh) ............................... 39
3-3.5.5 Aggregation of the systemic dose .............................................. 40
3-3.5.6 Human biomonitoring .............................................................. 40
3-3.5.6.1 Definition ........................................................................... 41
3-3.5.6.2 Fields of application ............................................................. 41
3-4 RELEVANT TOXICOLOGICAL TOOLS FOR THE SAFETY EVALUATION OF COSMETIC INGREDIENTS ................................................................. 42
3-4.1 New Approach Methodology (NAM) and Next-Generation Risk Assessment (NGRA) ......................................................................... 42
3-4.2 Adverse Outcome Pathway (AOP) .................................................. 44
3-4.3 In silico Assessment of Toxicological Hazard ............................... 45
3-4.3.1 In silico Toxicity Models ............................................................ 45
3-4.3.2 Read-across .......................................................................... 46
3-4.4 Acute toxicity ............................................................................ 47
3-4.4.1 Acute oral toxicity ................................................................. 48
3-4.4.2 Acute dermal toxicity .............................................................. 48
3-4.4.3 Acute inhalation toxicity ......................................................... 49
3-4.5 Skin corrosion and skin irritation ................................................. 49
3-4.5.1 Skin corrosion ...................................................................... 49
3-4.5.2 Skin irritation ...................................................................... 49
3-4.6 Serious eye damage and eye irritation .......................................... 50
3-4.7 Skin sensitisation ..................................................................... 52
3-4.7.1 Skin Sensitisation Quantitative risk assessment (QRA) ............ 55
3-4.7.2 Next-Generation Risk Assessment Approach (NGRA) ......... 56
3-4.8 Repeated dose toxicity ............................................................... 57
3-4.8.1 The use of uncertainty factors (UFs) for extrapolation for study duration ........................................................................... 58
3-4.8.2 Selection of PoD .................................................................. 59
3-4.9 Reproductive toxicity ................................................................. 59
3-4.10 Mutagenicity / Genotoxicity ....................................................... 60
3-4.10.1 Definitions .......................................................................... 60
3-4.10.2 Mechanisms ...................................................................... 61
3-4.11 Carcinogenicity ......................................................................... 68
The “Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation by the SCCS” is a document compiled by the members of the Scientific Committee on Consumer Safety (SCCS, replacing the former SCCP, SCCNFP and SCC). The document contains relevant information on the different aspects of testing and safety evaluation of cosmetic substances in Europe. The emphasis of this guidance is on cosmetic ingredients, although some guidance is also indirectly given for the safety assessment of finished products. It is designed to provide guidance to public authorities and to the cosmetic industry in order to improve harmonised compliance with the current cosmetic EU legislation. An important development in recent years was the full implementation of the cosmetic legislation, Regulation (EC) No 1223/2009, meaning that the animal testing and marketing bans fully apply from 2013 onwards: no in vivo testing of finished products after 11 March 2004; no in vivo testing for local toxicity after 11 March 2009 and no in vivo testing for repeated dose toxicity (including sensitisation) toxicokinetics and developmental toxicity from 11 March 2013 onwards for the purpose of cosmetics. For this reason, the SCCS has closely followed the progress made with regard to the development and validation of alternative methods, with emphasis on replacement methodology.

The "Notes of Guidance" are regularly revised and updated in order to incorporate the progress of scientific knowledge in general, and the experience gained, in particular in the field of testing and safety evaluation of cosmetic ingredients.

The previous revision of the Notes of Guidance took place in 2018 (SCCS/1602/18). Since then, several new addenda, opinions and memoranda of importance to the content of this guidance document have been adopted and they form the basis of this new revision. Focus is on exposure and the application of alternative methods, more specifically on non-animal methods/new approach methodology (NAM).

As was also the case in previous revisions, individual opinions are not provided in detail but, where relevant, are briefly summarised and clearly referred to.

The "Notes of Guidance" have been compiled to provide assistance in the complex process of the testing and safety evaluation of cosmetic ingredients in the EU.

Input of scientists from the Scientific Committee on Health and Environmental and Emerging Risks (SCHEER) and Cosmetics Europe (CoE) is gratefully acknowledged.

The Chairperson
ACKNOWLEDGMENTS

SCCS members listed below are acknowledged for their valuable contribution to the finalisation of this guidance document.

**SCCS members**

Dr U. Bernauer  
Dr L. Bodin  
Prof. Q. Chaudhry (SCCS Chair)  
Prof. P.J. Coenraads (SCCS Vice-Chair)  
Prof. M. Dusinska  
Dr J. Ezendam  
Dr E. Gaffet  
Prof. C. L. Galli  
Dr B. Granum  
Prof. E. Panteri  
Prof. V. Rogiers (SCCS Vice-Chair and rapporteur)  
Dr Ch. Rousselle  
Dr M. Stepnik  
Prof. T. Vanhaecke  
Dr S. Wijnhoven

**SCCS external experts**

Dr A. Koutsodimou  
Prof. W. Uter  
Dr N. von Goetz

All Declarations of Working Group members are available on the following webpage:  
Register of Commission expert groups and other similar entities

The SCCS Notes of Guidance document is not open for commenting period as it remains a living document, which is regularly updated. Any observation may be sent to SCCS mailbox (SANTE-C2-SCCS@ec.europa.eu) for further consideration by the SCCS.

Keywords: SCCS, SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, 11th revision, SCCS/1628/21.

About the Scientific Committees

Two independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are the Scientific Committee on Consumer Safety (SCCS) and the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), and they are made up of independent experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCS

The Committee shall provide Opinions on questions concerning health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

Scientific Committee members

Ulrike Bernauer, Laurent Bodin, Qasim Chaudhry, Pieter Jan Coenraads, Maria Dusinska, Janine Ezendam, Eric Gaffet, Corrado Lodovico Galli, Berit Granum, Eirini Panteri, Vera Rogiers, Christophe Rousselle, Maciej Stepnik, Tamara Vanhaecke, Susan Wijnhoven

Contact:
European Commission
Health and Food Safety
Directorate C: Public Health
Unit C2: Health information and integration in all policies
L-2920 Luxembourg
SANTE-C2-SCCS@ec.europa.eu

© European Union, 2021

ISSN
ISBN
Doi
ND

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm
Applicants are invited to visit the SCCS website: 
https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions_en 
where Applicants will find a checklist 
for submitting a safety dossier of a cosmetic ingredient.

Applicants are invited to visit the following website for further legislative information: 
MAIN CHANGES IN 11TH REVISION OF THE SCCS NOTES OF GUIDANCE (NOG)

The whole NoG have been revised and updated with a particular emphasis on the following:

- Inhalation models
- *In silico* methodology for genotoxicity/carcinogenicity
- General updating of NAMs
- Scientific concerns for the safety of the nanomaterials
- Update of ED section
- Discussion on uncertainty factors
- Updating of references in general
- Appendix 1: complying with the testing & marketing bans
- Appendix 9: guidelines on microbiological quality of the finished product
- Appendix 10: free access to *in silico* mutagenicity/genotoxicity databases
- Appendix 11: inhalation parameterisation
- Appendix 12: Lifetime Cancer Risk Approach
- Appendix 13: PoD used for TTC derivation
1. INTRODUCTION

Since July 2013, Regulation (EC) No 1223/2009 applies for cosmetic products. Their safety-in-use is, as was also the case for Directive 76/768/EEC, established by controlling the safety of the ingredients.

For those ingredients for which some concern exists with respect to human health (e.g. colourants, preservatives, UV-filters, hair dyes), safety evaluation is done at the Commission level by the Scientific Committee on Consumer Safety (SCCS). These substances are addressed in the Annexes of Regulation (EC) No 1223/2009.

For the safety evaluation of cosmetic ingredients, all available scientific data are considered, taking into account the testing and marketing bans in force under Regulation (EC) No 1223/2009. This includes the physical and chemical properties of the compounds under investigation, exposure via relevant exposure routes, \textit{in silico} data such as results obtained from (Q)SAR \textit{(Quantitative Structure Activity Relationship)} modelling, chemical categories, grouping, read-across, Physiologically Based PharmacoKinetics (PBPK) /ToxicoKinetics (PBTK) modelling, \textit{in vitro} and \textit{ex vivo} experimental results and data obtained from animal studies \textit{(in vivo)} that have been carried out for the purpose of cosmetics before the testing and marketing bans. The animal testing ban on finished cosmetic products applies since 11 September 2004; the testing ban on ingredients or combination of ingredients applies since 11 March 2009. The marketing ban applies since 11 March 2009 for all human health effects with the exception of repeated-dose toxicity, reproductive toxicity, and toxicokinetics. For these specific health effects, the marketing ban applies since 11 March 2013, irrespective of the availability of alternative non-animal methods. In addition, clinical data, epidemiological studies, information derived from accidents, data from Post-Marketing Surveillance (PMS) or other human data are also taken into consideration.

In the present update, the state-of-the-art with respect to the validated methods of the 3Rs (Refinement, Reduction and Replacement) strategy of Russell \textit{et al.} (1959), is incorporated with emphasis on New Approach Methodologies (NAMs). In view of the testing and marketing bans in the cosmetic regulation, the SCCS gives special attention to those alternative methods that are suitable for the safety testing of cosmetic substances. New methodologies for risk assessment of chemicals without using animal experimentation are worldwide being explored. Attention is given here to Next-Generation Risk Assessment (NGRA) as a possible framework for the safety evaluation of cosmetic ingredients and the NAMs that would fit into this structure (Rogiers \textit{et al.}, 2020). Risk assessment of cosmetics and their ingredients is shifting towards a strategic combination of NAMs and new technology with historical animal data, if available, to come to a Weight of Evidence (WoE) decision making approach.

Although the "Notes of Guidance" are concerned with the testing and safety evaluation of the cosmetic substances listed in the Annexes of Regulation (EC) No 1223/2009 and those for which safety concerns have been expressed, they could be also of interest for all substances intended to be incorporated in a cosmetic product. Even though the "Notes of Guidance" have not been written for the latter purpose, they can indeed be of practical use in making a Product Information File (PIF) for a finished cosmetic product as currently required by Regulation (EC) No 1223/2009.

The European Chemicals Agency (ECHA) can ask for animal studies even if the substance is foreseen only for cosmetic use (see Appendix 1, section 3). The applicant can submit these animal data to ECHA, but cannot use these in the cosmetic product safety report (CPSR) for the product information file (PIF) and cannot submit these to the SCCS for risk assessment of the ingredient under consideration. If SCCS knows about the existence of such a file at ECHA, they can request access to these studies and consider whether the results have an impact on the risk assessment of the substance and change their view.

The "Notes of Guidance" should not be seen as a prescriptive procedure, but rather as an approach that may need to be adapted on a \textit{case-by-case} basis when evaluating the safety
of the Annex substances. However, when major deviations from standardised protocols/procedures in the safety evaluation process have been adopted, it is essential that Applicants provide scientific justification.

The "Notes of Guidance" will be revised as scientifically required on the basis of scientific advances in toxicology and validated alternative methods or legislative changes.
2. THE SCIENTIFIC COMMITTEE ON CONSUMER SAFETY, SCCS

2-1 BACKGROUND

The Commission Decision C(2015)5383 of 7.8.2015\(^1\) established the new Scientific Committees in the field of public health, consumer safety and the environment. Members were appointed\(^2\) for a five-year term (2016-2021) and a reserve list\(^3\) was created. The term was extended until end of 2026 due to Covid-19. The Principles and Working Procedures of the Scientific Committees are stated in their establishing Decision and in the Rules of Procedure adopted by their members (April, 2016)\(^4\).

For more information, see Appendix 1.

2-2 MANDATE

The SCCS is an advisory body that provides the Commission with scientific advice and safety evaluations for Annex substances and compounds for which some concern for human health exists. Its consultation for this task is compulsory.

For more information, see Appendix 1.

2-3 RULES OF PROCEDURE

The SCCS works with 3 working groups, dealing with:
- cosmetic ingredients
- methodology
- nanomaterials.

Safety evaluations and advice are taken up in opinions, which are adopted during a plenary meeting (or by written procedure). A commenting period of minimum four weeks (later agreed on eight weeks) is foreseen for draft opinions before they are finalised and published.

For more information, see Appendix 1.

2-4 OPINIONS

Opinions are published on the SCCS website:

For more information, see Appendix 1.

2-4.1 THE "NOTES OF GUIDANCE"

One of the responsibilities of the SCCS is to recommend a set of guidelines to be taken into consideration by the cosmetic and raw material industry in developing adequate studies to be used in the safety evaluation of cosmetic substances.

This is done through the ‘Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation’ (NoG) that are regularly revised and updated in order to incorporate new

---

knowledge and scientific and regulatory advances. Therefore, dossiers submitted to the SCCS should be in accordance with the latest published version of the NoG. The 10th Revision SCCS/1602/18 is now replaced by this 11th Revision SCCS/1628/21.

As cosmetic ingredients are chemical substances, the NoG include the toxicological test procedures reported in Commission Regulation (EC) No 440/2008. The latter describes the basic toxicity testing procedures needed to evaluate different human health-related toxicological endpoints and are internationally accepted as being the result of long-term scientific agreement. Whereas the testing procedures for chemical substances take the 3Rs-principle into consideration, animal experiments for cosmetic purposes are excluded in the EU. For the safety evaluation of cosmetic ingredients only validated non-animal methods/NAMs may be applied. Furthermore, testing procedures in accordance with the Organisation for Economic Co-operation and Development (OECD) Guidelines, and, on a case-by-case basis, well documented scientifically justified alternative methods that may not have been officially validated yet are also carefully considered. Data obtained from animal experimentation for the purpose of cosmetics or other consumer products legislation and generated before the established cosmetic deadlines of the testing and marketing bans (see 1. Introduction) still may be used in the safety evaluation of cosmetics and their ingredients. As regards data generated after the deadlines of the testing and marketing bans, see Section 3 of Appendix 1.

For the SCCS’ safety evaluation, the systemic doses obtained (mostly) after oral administration are used. For local toxicity endpoints, normally only hazard identification is carried out. Safety evaluation is done for intact skin.

2-4.2 **SCCS Cosmetic Ingredient Dossiers**

Regulation (EC) No 1223/2009 requires Annexed cosmetic substances to be notified, safety assessed and adequately labelled before being allowed on the EU market. These annexes lay down clear limitations and requirements for the cosmetic substances concerned. The safety assessment of the cosmetic ingredients in the EU is overseen by the SCCS. The evaluations carried out by the SCCS are based on safety dossiers submitted by Applicants (individual company/associations, Competent Authorities).

In view of the animal testing and marketing bans of cosmetic ingredients/products, two main routes to developing safety dossiers are possible:

- In case a new ingredient is to be used exclusively in a cosmetic product, testing needs to be in compliance with the restrictions on animal testing placed under Regulation (EC) No 1223/2009 and safety data need to be derived from non-animal alternative methods/NAMs.

- When an ingredient has pre-existing safety data derived from animal tests (e.g. an existing cosmetic ingredient) that have been carried out before the regulatory deadlines, it can still be used.

- Animal test data relating to chemical substances to be used also in products other than cosmetics (e.g. food, medicines, biocides, etc.) can also be used for supporting safety assessment of an ingredient intended to be used in a cosmetic product.

Further information is provided in Section 3 of Appendix 1.

**In case of a negative or inconclusive opinion by the SCCS, resubmission of a dossier is only possible when the Applicant provides sufficient (new) evidence to address the concerns raised.**
2-4.3 **SPECIFIC ISSUES TAKEN UP IN NoG**

In addition to the regular revision of the NoG and the study of toxicological dossiers of cosmetic substances for inclusion in one of the Annexes of Regulation (EC) No 1223/2009, in the following sections some specific issues are addressed. Examples include (non-exhaustive list):

- New Approach Methodology (NAM) in the safety assessment of cosmetic ingredients
- Introduction to Next Generation Risk Assessment (NGRA)
- Threshold of Toxicological Concern (TTC)
- Endocrine disruptors’ issues
- CMR (Carcinogenic, Mutagenic, toxic to Reproduction) issues
- Safety assessment of hair dyes and colourants
- Safety assessment of nanomaterials
- Safety of cosmetic ingredients for babies and children
- Fragrance allergy in consumers
- Risk and health effects: miscellaneous
3. SAFETY EVALUATION OF COSMETIC INGREDIENTS

3-1 SAFETY EVALUATION OF COSMETIC INGREDIENTS AS APPLIED BY THE SCCS

- The safety of cosmetic products is based on the safety of the ingredients

The rationale behind the safety of the cosmetic product being based on the safety of its ingredients comes from the fact that many thousands of different cosmetic products on the EU market are all derived from a limited number of substances. Hence, toxicity testing has been concentrated on ingredients, and particularly on those that are intended to react with biological moieties and therefore are of potential concern for human health. This is also the basis for the lists of authorized, banned and restricted substances (Table 1).

<table>
<thead>
<tr>
<th>Annex II</th>
<th>List of prohibited substances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annex III</td>
<td>List of restricted substances</td>
</tr>
<tr>
<td>Annex IV</td>
<td>List of allowed colourants</td>
</tr>
<tr>
<td>Annex V</td>
<td>List of allowed preservatives</td>
</tr>
<tr>
<td>Annex VI</td>
<td>List of allowed UV-filters</td>
</tr>
</tbody>
</table>

**Table 1**: Annexes to Regulation (EC) No 1223/2009

- For the safety evaluation of cosmetic ingredients two channels are functional

The safety of the Annex substances is evaluated by the SCCS; the safety of cosmetic products with all their ingredients is evaluated by the industry placing them on the EU market. Thus, the Annex substances fall under the responsibility of the SCCS (left part of Figure 1). All the ingredients in cosmetic products are the responsibility of the “Responsible Person, RP”, as defined by Regulation (EC) No 1223/2009, through the safety assessor (right part of Figure 1).

**Figure 1**: Human health safety evaluation of cosmetic ingredients in the EU.

PIF: Product Information File
- This guidance, in principle, equally applies to the safety evaluations carried out by the SCCS as by the safety assessors of the cosmetic industry.

Safety evaluation is generally performed taking into account the data provided by the industry or in some cases by Members States authorities. The SCCS also has the opportunity to add relevant data from the open literature or other relevant sources.

In general, the safety evaluation of cosmetic ingredients by the SCCS is based upon the principles and practice of the risk assessment process universally applied for chemical substances with the challenge that only validated replacement methods (or demonstrated to be scientifically valid) should be used when testing for the purposes of the EU cosmetic legislation.

A typical safety evaluation procedure comprises the following elements:

1) **Hazard identification** is carried out to identify the intrinsic toxicological properties of the substance, i.e. whether it has the potential to damage human health. It is based on the results of *in vivo* studies, *in vitro* and *ex vivo* tests, *in silico* methodology, *in chemico* methodology and read-across, clinical studies, case reports, epidemiological studies and data from Post-Marketing Surveillance (PMS). Intrinsic physical and chemical properties of the substance under consideration are also taken into account.

2) **Exposure assessment**

   Human exposure is calculated based on the declared functions and uses of a substance as a cosmetic ingredient, the amount present in the respective cosmetic product categories and their frequency of use.

   The single product exposure describes the exposure to a cosmetic ingredient in one product category via one route.

   The aggregate exposure, in the context of the NoG, is the sum of all relevant single product exposures, so that it describes the exposure from all product categories in which the cosmetic ingredient is used and all relevant exposure routes.

   Where necessary, exposure of vulnerable consumer groups could be assessed separately (e.g. children, pregnant woman, etc.).

   Generally, only exposures from the use of a substance as cosmetic ingredient are considered, with the exception of CMR compounds, for which non-cosmetic uses should also be taken into account (see section 3-6.6 and Appendix 5).

3) **Dose-response assessment**

   For the relationship between the exposure and the toxic response, a Point of Departure (PoD) is determined. The PoD is defined as the dose-response point that marks the beginning of a low-dose extrapolation (for threshold and non-threshold compounds). In most Opinions a No Observed Adverse Effect Level (NOAEL) has been used as PoD.

   The SCCS considers that, where usable *in vivo* data are available, the preferred method for both threshold and non-threshold cosmetic ingredients is to express the dose metric as BenchMark Dose (BMD). Both the European Food Safety Agency (EFSA) and the World Health Organization (WHO) also recommend that the BMD approach for deriving the PoD should be used as a starting point for human health risk assessment.

   The BMD approach has a number of advantages over using NOAEL. It makes complete use of the available dose - response data
   - it takes into account the shape of the dose - response curve
   - it is less dependent on dose spacing
it enables quantification of the uncertainties in the dose-response data using statistical methodology (EFSA, 2016).

For compounds with a threshold, the PoD can be a NOAEL, a Lowest Observed Adverse Effect Level (LOAEL), or a BMD Lower limit (BMDL) (for details of the NOAEL and BMD approach, see Sections 3-4.8, 3-5.1)

4) Risk characterisation

In risk characterisation, the focus in the NoG is on systemic effects. In the case of a threshold effect, the Margin of Safety (MoS) is mostly calculated from oral toxicity studies, unless robust dermal toxicity data are available. In the case of an oral toxicity study, the following equation (1) is used:

\[
\text{MoS} = \frac{\text{PoD}_{\text{sys}}}{\text{SED}}
\]  

(1)

The PoD_{sys} is a dose descriptor for the systemic exposure to a substance and is calculated from the oral PoD by use of the proportion of the substance systemically absorbed. SED represents the Systemic Exposure Dose (see also Section 3-3.5.4). In this equation, PoD is BMDL or, alternatively, NOAEL or LOAEL, where BMDL cannot be calculated.

For non-threshold effects (e.g. a non-threshold carcinogenic effect), the lifetime risk is often based on the BMD10 (benchmark dose response for a 10% response). The risk assessment of carcinogens is described in Section 3-4.11.

Risk characterisation is followed by risk management and risk communication, which are not in the remit of the SCCS, but of the European Commission or the RP, the latter when a finished cosmetic product and its ingredients are involved (Figure 1).

Besides the normal procedure when the industry or Member States or their representatives submit a complete dossier, in some cases, either upon request of the Commission or on a voluntary basis, industry provides additional data on cosmetic ingredients that have been assessed in the past. An evaluation exclusively based on additional reports, together with summaries of earlier submissions, however, may not be adequate. Therefore, complete dossiers may be required case by case, even though a re-evaluation of only a part of a dossier appears necessary. Dossiers and full studies should be submitted in common formats such as pdf or Word and need to be readable and searchable.

Other common formats that allow copy/paste actions are accepted. Scanned documents that are not readable/searchable are not accepted.

It is beyond the scope of the NoG to discuss the whole process of risk assessment. Numerous review articles and textbooks exist on this topic. The aim is to highlight some key aspects to explain why certain data and test results should be provided in the dossiers on the cosmetic substances presented to the SCCS for evaluation.

An example of the framework of a typical dossier is given in Appendix 3.

---

5 For the case that a dermal repeated dose toxicity study is used, see Section 3-4.8 and 3-5.1
The contact point for dossier submissions and regulatory/risk management questions is: GROW-F2@ec.europa.eu
The SCCS address for scientific requests is: SANTE-C2-SCCS@ec.europa.eu

3-2 CHEMICAL AND PHYSICAL SPECIFICATIONS OF COSMETIC INGREDIENTS

Physical and chemical properties of substances are considered as crucial information, since they may indicate potential risks. For example, a small Molecular Weight (MW) hydrophobic compound is more likely to penetrate through the skin than a high MW hydrophilic compound. Physical and chemical properties also identify physical hazards of the substance (e.g. corrosiveness as indicated by pH of aqueous solution, volatility, explosiveness, flammability).

In addition, some QSAR (Quantitative Structure Activity Relationship) programmes and empirical models require physical and chemical property values as inputs for in silico estimation of properties and potential biological effects.

The basic and minimal specifications for any cosmetic ingredient to be evaluated are:

1) Chemical identity;
2) Physical form;
3) MW;
4) Characterisation and purity of the chemical, including isomer composition whenever relevant for safety assessment;
5) Characterisation of the impurities or accompanying contaminants;
6) Solubility;
7) Partition coefficient (Log P_{ow});
8) Vapour pressure (volatile liquids);
9) Homogeneity and stability;
10) Further physical and chemical properties if relevant for safety evaluation.

For nanomaterials, special requirements for provision of physicochemical data apply (see Section 3-6.8). Original data on all these points must be included in each toxicological dossier and information and documentation for all analytical data should be provided. The appropriate certificate of analysis must also be presented for the test chemical used to generate the data as submitted in the dossier to the SCCS.

Preference is clearly given to measured parameters of relevant batches on the market over calculated values (e.g. log P_{ow}) or literature data (where often batches are tested that differ from the batches used in toxicological tests and therefore may have different composition / impurity profiles).

In the following section, the methods are (where relevant) accompanied by their corresponding reference number in Regulation (EC) No 440/2008 (2008/440/EC).

3-2.1 CHEMICAL IDENTITY

The precise identity and chemical nature of the substance under consideration and its structural formula must be given. The Chemical Abstracts Service (CAS) number of the chemical, the International Nomenclature of Cosmetic Ingredients (INCI) name or Common Ingredient Nomenclature (CIN) name and the EC number (see Appendix 2 for more details) should be provided.

With regard to substances that cannot be identified in terms of their structural formula, sufficient information should be provided on the method of preparation (including all physical,
chemical, enzymatic, (bio)technological or microbiological steps) and the materials used in 
their preparation to enable assessment of the probable structure and activity of the 
compound(s).

For the safety evaluation of a complex mixture (e.g. an extract), complete information should 
be provided on the origin of the source materials (e.g. part of a plant), extraction method 
and any additional processes and/or purification steps used (see Section 3-6.1) to establish 
a standardised material as representative of the extract present in commercial products.

In case of a mixture, components must be described in terms of qualitative and quantitative 
formulae. These could be: main components, preservatives, antioxidants, chelators, buffering 
agents, solvents, other additives, impurities and/or additional external contamination.

When a cosmetic ingredient and its derivatives (salt, ester, ...) are submitted for evaluation, 
this must be clearly specified in the dossier, because the chemical form can determine the 
safety evaluation. The physical and chemical properties of all specific chemical forms must be 
provided, and the same specific substances must be used in the toxicological studies 
performed for the safety evaluation. Any deviations must be justified.

3-2.2 PHYSICAL FORM

A description of the physical form should be given: powder, paste, gel, liquid. For 
nanoparticles, further information as specified in Section 3-6.8 should be given, including the 
particle size and its distribution.

For polymer ingredients, the molecular weight distribution should be provided.

3-2.3 MOLECULAR WEIGHT

The MW of each substance should be given in Daltons. In the case of mixtures, the MW must 
be given for the constituents.

3-2.4 IDENTIFICATION AND PURITY OF THE CHEMICAL AND ISOMER COMPOSITION

The degree of purity must be clearly indicated. The validity of the analytical methodology 
used must be shown. When a reference material/standard is used for the determination of 
purity, a certificate of analysis of the reference standard should be submitted (Appendix 6) 
Purity of the active substance based on High Performance Liquid Chromatography (HPLC) 
peak area can only be accepted when:

1) a reference material of known purity is used,

2) the HPLC recovery of the test material is clearly documented,

3) the ultraviolet (UV) detection of the active substance is performed at \( \lambda_{\text{max}} \), in an 
   appropriate mobile phase, and

4) peak purity of the active substance is clearly documented.

The experimental conditions of the techniques used for the chemical characterisation UV, 
Infra Red (IR) and Nuclear Magnetic Resonance (NMR) spectroscopy, Mass Spectrometry 
(MS), chromatographic techniques e.g. Gass Chromatography (GC), elemental analysis, etc.) 
as well as the resulting spectra, chromatograms etc. should be provided.

The substance(s) used in physical and chemical tests, toxicity studies, etc., mentioned in the 
dossier, must be either exactly the same material(s) under consideration or justifiably 
representative of the substances present in commercial products.
When a substance is a mixture of isomers, only the relevant isomer(s) used as a cosmetic ingredient should be included in the safety assessment. The other isomer(s) is/are considered as an impurity or impurities. Information on isomer composition should be provided.

**3-2.5 CHARACTERISATION OF THE IMPURITIES OR ACCOMPANYING CONTAMINANTS**

In addition to the purity of the substance under consideration, identity in terms of the chemical nature and concentration of impurities that may be present must also be stated. Impurities should be characterised and quantified by an appropriate analytical method, e.g. by HPLC-PDA (Photometric Diode Array), LC-MS/GC-MS, NMR spectroscopy etc., using reference standards with documented purity, where appropriate. Validated analytical procedures should be used for impurity testing. There is no specific recommendation available to assess the limit of acceptable non-CMRs impurities for cosmetic products.

Small changes in the nature of some impurities may considerably alter the toxicity of substances. In general, results of safety studies on a particular substance are only relevant when they refer to that substance used, with its own specific purity and impurity profile. The scientific validity of tests performed on batches of the substance with diverging purities deserves careful interpretation. Therefore, it must be ensured that neither other impurities nor an increased level of impurities are present in the representative commercial material. For this, the stability of the synthesis process, including any purification measures, is important. A change in these processes will need careful re-evaluation of the impurities, even if the level of purities remains the same.

**3-2.6 RELEVANT PHYSICOCHEMICAL SPECIFICATIONS**

A typical physicochemical dataset consists of:

- Physical state (solid, liquid, gas)
- Organoleptic properties (colour, odour, taste if relevant)
- Solubility (EC A.6) in water and relevant solvents, including receptor fluids (at ... °C)
- Partition coefficient (EC A.8) (Log P<sub>ow</sub>, at ... °C), if applicable
- Flash point (EC A.9)
- Physical properties depending on the physical state:
  - for liquids: boiling point (EC A.2), relative density (EC A.3) (at ... °C), pK<sub>a</sub> (at ... °C), viscosity (at ... °C), vapour pressure [EC A.4] (at ... °C), ....
  - for solids: morphological form (crystal form, amorphous, ...), melting temperature (EC A.1), pK<sub>a</sub> (...% in ..., at ... °C), ...
  - for gases: density (EC A.3) (at ... °C and pressure), auto-ignition temperature (EC A.15)
- In case of a UV-absorbing substance, the UV-absorption spectrum of the compound should be included. It is self-evident that for UV filters, the UV spectrum is indispensable.
- For nanomaterials and nanoparticles special requirements apply (see Section 3-6.8).

**3-2.7 SOLUBILITY**

The solubility (EC A.6) of the substance in water and/or in any other relevant organic solvent should be stated (in g/l at ... °C). Some substances are sparingly soluble or insoluble in aqueous media or other solvents. These should be clearly stated. In Table 2, different solubility terms have been defined.
Where the solubility of the active substance in water is low (according to EU Method A.6), a highly sensitive and selective analytical technique (such as LC/MS) should also be used to document the solubility and to rule out that the soluble material may be an impurity (or impurities) in the test material. Similarly, solubility of substances that are poorly soluble in various solvents should be measured by highly sensitive and selective analytical technique (such as LC/MS). In cases of low solubility of the active substance in reverse phase HPLC mobile phases, sensitive detection systems, such as MS, should be applied, or another normal phase chromatography should be used.

The solubility of the active substance in the solvent systems used in various studies should also be clearly presented.

**Table 2:** Definition of solubility terms (adapted from USP38/ USP38–NF33* and General Notices (Ph. Eur. 10\textsuperscript{th} Ed.)

<table>
<thead>
<tr>
<th>Term*</th>
<th>Parts of Solvent Required for 1 Part of Solute*</th>
<th>Solubility defined in g/L (deduced by SCCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very soluble</td>
<td>Less than 1 part</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Freely soluble</td>
<td>1 to 10 parts</td>
<td>100-1000</td>
</tr>
<tr>
<td>Soluble</td>
<td>10 to 30 parts</td>
<td>33.3-100</td>
</tr>
<tr>
<td>Sparingly soluble</td>
<td>30 to 100 parts</td>
<td>10-33.3</td>
</tr>
<tr>
<td>Slightly soluble</td>
<td>100 to 1000 parts</td>
<td>1-10</td>
</tr>
<tr>
<td>Very slightly soluble</td>
<td>1000 to 10000 parts</td>
<td>0.1-1</td>
</tr>
<tr>
<td>practically insoluble, or insoluble</td>
<td>&gt;10000, or equal to 10000 parts</td>
<td>&lt; 0.1 or = 0.1</td>
</tr>
</tbody>
</table>

*Under USP38/ USP38–NF33: practically insoluble is used in USA; in EU: insoluble

**3.2.8 Partition coefficient (Log P\textsubscript{ow})**

The n-octanol/ water partition coefficient (EC A.8) should be given, along with the pH and temperature conditions.

In the case of a calculated value, the method used for estimation should be specified. LogP\textsubscript{ow} values often depend on the pH, especially for ionisable molecules, zwitterions, etc. Therefore, a single calculated value of Log P\textsubscript{ow}, without any reference to the respective pH, cannot be correlated to the physiological conditions and the pH conditions of the dermal absorption studies.

**3.2.9 Homogeneity and stability**

Homogeneity data of the test solutions with respect to the content of the test substance, under experimental conditions, should be provided.

Data on the stability of the test substance under the experimental conditions of the reported studies and under conditions of use should be provided. Validated analytical procedures should be used to determine stability of the test substance. In addition, the stability of the test substance relating to its thermal stability and, if applicable, sensitivity to moisture or oxygen under storage conditions and in typical cosmetic formulations should also be provided. Any degradation products should be chemically characterised. In this regard, it is important that the storage conditions and the lengths of studies chosen should be sufficient to cover the storage, shipment, and subsequent use. The stability studies should also be conducted on the test substance packaged in a container, which is the same as the container intended for storage and distribution for marketing.
3-3 EXPOSURE ASSESSMENT

3-3.1 FUNCTIONS AND USES OF COSMETIC INGREDIENTS

For substances that are evaluated as cosmetic ingredients, the concentration, function and way of achieving that function in marketed cosmetic products should be reported. In particular, it should be explicitly mentioned whether substances are meant to be included in sprays or aerosols since consumer exposure via inhalation is then probable and needs to be taken into consideration in the overall risk assessment.

In addition, other uses of the substance (e.g. in consumer products, industrial products) and, wherever possible, the concentrations involved in such uses should be described.

3-3.2 IDENTIFICATION OF RELEVANT EXPOSURE SCENARIOS

In order to assess exposure of the end users, relevant exposure scenarios have to be identified that comprise all the important functions and uses of a cosmetic ingredient (see Section 3-3.1). These scenarios need to describe "reasonably foreseeable exposure conditions" (Cosmetics Regulation (EC) No 1223/2009, Article 16 f), under which these the cosmetic product should be safe.

The following parameters describe an exposure scenario. However, the list is not exhaustive, and further parameters may need to be taken into account. Note that all routes of exposure (dermal, oral and inhalation) should be considered in view of the intended use of the product.

- cosmetic product type (s) in which the ingredient may be used
- method of application as detailed as possible, e.g. rubbed-on, sprayed, applied and washed off, etc.; considerations whether the product is a rinse-off or leave-on product and which retention factor should be applied
- concentration of the ingredient in the marketed cosmetic product
- quantity of the product used at each application
- frequency of use
- total area of skin contact
- duration of exposure
- target consumer groups (e.g. children, people with sensitive, damaged or compromised skin) where specifically required
- application on skin areas exposed to sunlight
- location of use (indoors/outdoors) and ventilation

3-3.3 IDENTIFICATION OF THE TARGETED DOSE FOR SAFETY EVALUATION

The hazard identification can either point to systemic effects that require comparison to a SED or local effects, like skin/eye irritation, skin sensitisation, sun-induced skin reactions or effects on the lungs, which mostly are dependent on the amount of substance acting on the surface tissues of the respective body part and require comparison to a Local External Dose (LED).

In the exposure assessment, first the LEDs are calculated that are expected at the specific body entrances and available for uptake. The most important body entrances for substances in cosmetics are the skin, the inhalatory tract and the mouth. These correspond to the uptake routes for internal exposure (dermal route, inhalation route and oral ingestion). For selected
products other entrances are possible, e.g. via the eyes (e.g. eye makeup), or via genital regions (e.g. intimate spray, intimate creams).

As an example, the LED in the lung (the amount of compound per g of lung tissue) can be compared to a “local” NOAEL, and a local MoS can be calculated for effects on the lungs.

The external exposure can further be used to calculate internal (or systemic) exposure which corresponds to an internal dose (see Section 3-3.5.4). For the calculation of the SED, absorption (or uptake) specific to the respective exposure route has to be taken into account.

For risk assessment, the MoS (see Section 3-5.1) is based on the internal dose, i.e. the SED.

3.3.4 EXTERNAL EXPOSURE

3.3.4.1 EXPOSURE MODELS AND TIERED APPROACH

Exposure is calculated based on exposure scenarios by using appropriate exposure models. Generally, external exposure is calculated by multiplying the concentration/fraction of a substance in a source with the amount of the source that is applied on, or reaches, a specified site. To save time and resources, a tiered approach is normally followed that first investigates exposure based on generic exposure scenarios with conservative point values as model parameters (screening level).

Where necessary, these conservative exposure estimates are refined in a higher tier by using probabilistic approaches or other means of refinement (Meek et al., 2011).

For the safety evaluation of cosmetics, such a screening level approach is the calculation of aggregate exposure according to the NoG. The parameter values presented there can be used as the basis for a deterministic first-tier assessment. If a refinement is necessary, a probabilistic approach can be followed by the use of appropriate models and/or tools. However, this needs to be clearly justified. For regulatory purposes, the probabilistic approach needs to be conservative but realistic and transparent.

In particular, for probabilistic assessments the SCCS recommends the following:

- Habits and practices in a population regarding the use of product categories may be treated probabilistically, under the assumption that they will not change rapidly over time.
- The target protection goal will be the 95th percentile of the European population. Therefore, for a probabilistic assessment the relevant SED for deriving the MoS will be the 95th percentile of the probabilistically assessed population exposure.
- Ingredient concentrations in product categories should normally cover the worst case, i.e. for ingredients with restrictions on concentrations and applicability domains (Annex III of the EU Cosmetic Regulation), also in the probabilistic assessment the maximal allowed concentrations should be used, and for other ingredients the maximal concentrations that are realistically foreseeable in a specific product category. This is because product formulations may be highly variable over time, so that an assessment of ingredient concentrations at a specific point in time may not cover the use of the ingredient in the future.
- For reasons of transparency, the model equations and the input parameters need to be provided together with the exposure estimates, so that the exposure calculation is reproducible. If this is not possible, because a specific tool has been used, the original input file containing used distributions and all settings, and the original output file need to be provided by the Applicant. The output file needs to contain the date of the assessment, the relevant model settings and parameters for this assessment and the associated results, ideally not only in tabular form by giving relevant percentiles of the exposure distribution, but also by graphical visualisation.
3-3.4.1.1 DERMAL EXPOSURE MODELS

For cosmetics, the dermal route is often the most important one.

Apart from the general approach, the calculation of dermal exposure needs to take into account that only a fraction of the product is retained on the skin. Therefore, a retention factor \( f_{\text{ret}} \) is used that represents the fraction available for uptake. For leave-on cosmetics (e.g. creams, body lotion, etc.) mostly a fraction of 1 (100%) is used, while for rinse-off cosmetics (e.g. shower gel, shampoo, etc.) a smaller fraction is used that depends on the respective product. In Tables 3A and 3B retention factors are listed that are applied by the SCCS.

External dermal exposure \( (E_{\text{dermal}}) \) per day for a substance from a certain product category \( x \) can be calculated according to:

\[
E_{\text{dermal } x} = C_x \times q_x \times f_{\text{ret } x} \quad (3)
\]

- \( E_{\text{dermal } x} \) (mg/day): external exposure available for dermal uptake from product category \( x \)
- \( x \): product category
- \( C_x \) (mg/g): concentration/ fraction of a substance in a product category \( x \)
- \( q_x \) (g/day): amount of product category that is applied/received per day
- \( f_{\text{ret } x} \): retention factor specific to product category \( x \)

The daily amount \( (q_x) \) and retention factor \( (f_{\text{ret } x}) \) are specific to the product category under consideration, and do not depend on the substance. When multiplied, they yield the daily effective amount per product category, \( E_{\text{product } x} = q_x \times f_{\text{ret } x} \), which is listed in Tables 3A and 3B for the most important product categories. Multiplied with the concentration or fraction of a substance in a product, they yield the external dermal exposure to a substance per product category \( E_{\text{dermal } x} \), as shown in equation (3).

This external exposure can be used to calculate the SED by multiplying with the chemical- and route-specific uptake rate and normalisation by the bodyweight (see chapter 3-3.5.4). In cases where the amount per day \( q_x \) is not given or if more detailed probabilistic assessments should be performed, the amount per day can be calculated from the frequency of application (Table 4) and the amount per application. In Appendix 7 (Table A.7) a literature review can be found listing studies which provide detailed external exposure values to different cosmetic products. These are given for specific countries. Furthermore, the external daily exposure per product category can be used to derive a LED (2). Normally, local dermal effects depend on the surface load, so that the total dermal exposure is normalised by the Skin Surface Area of application (SSA).

3-3.4.1.2 ORAL EXPOSURE MODELS

The same principles as described for dermal exposure can be applied for oral exposure. Ingestion can be calculated according to equation (3) by applying adequate retention factors. Such oral retention factors are needed to take into account that only a fraction of the orally applied products will be ingested. Since orally applied cosmetics such as toothpaste, mouthwash or lipstick are normally not intended to be ingested, such retention factors will normally be small.
Cosmetic substances can be inhaled in the form of powder, vapor, aerosolised droplets or aerosolised particles.

For powders, the principles are very similar to spray products. Inhalation exposure to cosmetic powders during intended use usually is limited and the safety of airborne particles depends in particular on the aerodynamic diameter of the particles. In the safety evaluation of powders, the robustness of the exposure data plays a major role (Steiling et al., 2018).

Vapours result from the transfer of volatile substances into the air after dermal or spray application of products or due to evaporation of substances. Non-volatile substances can be transferred into the air mechanically by spraying, where they are initially present in the form of small droplets or particles.

External exposure to vapour can be calculated directly based on the concentration of the substance in the air.

Aerosolised particles and droplets normally result from spraying or other mechanical dispersion. Their deposition efficiency in the respiratory tract is size-dependent but also depends on density, and hygroscopicity (ability of a substance to attract and hold water molecules from the surrounding environment) and is influenced by the local anatomy and airflow (Braakhuis et al., 2014). However, particle and droplet size is generally regarded as the most important influencing factor for deposition. The size of the particles/droplets after spraying is influenced by the actual formulation (surface tension) and by the vapour pressure of the different solvents and propellants used in the formulation. It is also closely related to the geometry of the spray nozzle and the can size.

Generally, there are two types of spray application devices: propellant driven aerosol sprays and pump sprays. According to Bremmer et al. (Bremmer et al., 2006a; Bremmer et al., 2006b), propellant driven aerosol sprays are often developed to produce a fine mist, with often a relevant fraction of particle/droplet size <10 μm, compared to pump sprays, which in general produce larger particles/droplets. However, also for pump sprays the size of the droplets produced depends on the spray nozzle and studies e.g. by Quadros and Marr (Quadros and Marr, 2011) have shown that pump sprays can even produce particles/droplets in the nano size range. Another important consideration in relation to the airborne droplets/particles is that they can dry off quickly while airborne and become small enough to become respirable due to evaporation of the solvents/ formulants. It is therefore recommended that safety assessment of the sprayable products should take into account not only the size distribution of the generated aerosol droplets but also their size distribution just before settling. This is especially important for spray/sprayable cosmetic products containing nanomaterials, for which measured droplet size as well as size distribution of the dried residual particles will need to be provided. For more detailed considerations, see Guidance on the Safety Assessment of Nanomaterials in Cosmetics (SCCS/1611/19).

A sprayed formulation generally consists of droplets and/or particles of different sizes, which change their number and size distribution with time (e.g. by aggregation of particles and evaporation of solvent) before they reach the airways. The size fraction comprising droplets/particles with a Mass Median Aerodynamic Diameter (MMAD) of ≤100 μm is generally regarded as inhalable. As rodents inhale and exhale to a much larger extent through their nostrils than humans, particles are more likely to reach the lung in rodents.

For humans, usually three main fractions of the airborne aerosol are distinguished: the inhalable fraction, the thoracic fraction, and the respirable fraction. These particle size fractions are defined in the EU-standard EN 481 for measurements in workplaces (CEN, 1993). Estimates for adults and children during typical activities with both nasal and oral inhalation have been determined by Brown et al. (Brown et al., 2013).
It should be noted that after mucociliary clearance, further intake of insoluble particles or their components via the oral route may occur in humans.

The level of exposure can be directly measured under standard exposure conditions or estimated by using mathematical models. When measuring exposure, it is important to do it during the relevant exposure period after spraying, under relevant conditions (Carthew et al., 2002; Rothe et al., 2011).

When using mathematical models, a tiered approach should be followed. Default equations can be used as a conservative, worst case approach, and as a first estimate (ECHA, 2012b). For a more realistic assessment 1- or 2-Box models, as well as higher-tier models, can be considered. In a classical 1-Box model it is assumed that the entire spray amount is instantaneously released into the air and distributed in a box of a specific size, which e.g. simulates the breathing zone (Box A in Figure 2). The resulting air concentration is then multiplied by the breathing rate and the time spent in the box to calculate the exposure. A 2-Box model takes into account the dilution of the substance over time. As in the 1-Box model, the assumption is that the spray is instantly released and distributed in a box A around the head. There the aerosol is present for exposure over a defined time, after which the full amount of aerosol in the first box is transferred to a larger second box B (see Figure 2), where it is available for inhalation for a second defined time period. For a conservative approach, the air exchange (fresh air getting in, exhaust air getting out) can be assumed as zero. An example for a 2-Box model is given in Rothe et al., 2011.

Figure 2: Deterministic 2-Box model (according to Stelling et al., 2014); copyright from Elsevier, first published in Toxicology Letters 227, 2014.

For higher tier assessment, one of the tools that can be considered for calculating exposure estimates is the ConsExpo model (www.consexpo.nl).

This tool comprises two modules for inhalation: 1) exposure to vapour and 2) exposure to sprays.

The spray module calculates the exposure based on the inhalable fraction of the generated aerosols. For conventional (non-nano) substances, it is assumed that these are homogeneously distributed in the box through the generated aerosols.

For that reason, in the experiments carried out for the calibration of ConsExpo, aerosols with a size <1 µm have not been taken into account, because ConsExpo is mass-based and the mass of aerosol droplets <1µm is negligible compared to the aerosols present in the inhalable fraction of 1-20 µm.
In ConsExpo, key parameters in the calculation of the inhalation exposure are room volume, spray duration, ventilation rate, exposure duration and product specific parameters, such as “mass generation rate” (rate at which mass is released by spraying), airborne fraction, aerosol size distribution, and weight fraction of the ingredient. Note that since nanoparticles had not been measured in the calibration data set underlying the model, ConsExpo Spray cannot be used directly for nanoparticles.

Inhalation is not the intended route of exposure for cosmetic exposure. Therefore, the flow chart (see Figure 3) can be followed to determine whether assessment of inhalation exposure is necessary for a given cosmetic formulation.

Figure 3: Basic principles for the tiered safety assessment of inhalable cosmetic products and their ingredients. Modified from Steiling et al. (2014); grey = related to ingredients; yellow = related to product exposure.
3-3.4.2 Model Parameters

For the parameter values, either point values (deterministic assessment) or distributions (probabilistic assessment) can be used. Regardless of the method, the calculation needs to be conservative. In the case of a deterministic assessment this means that higher percentiles should be used for most parameters. In order not to be overly conservative, for some parameters, such as the body weight, a mean or a standard value can be chosen.

3-3.4.2.1 Daily Use Amounts and Retention Factors

Upon request of the SCCS, Cosmetics Europe has provided a large-scale use study for the most important consumer product categories (based on frequency and amount of use in the general population) among consumers in different European Member States. These Member States were Spain, Great Britain, France, Germany and Denmark, where the population of Spain represented the populations of southern European countries, such as Spain, Italy, Portugal and Greece; Great Britain represented those of the United Kingdom and Ireland. The population of France represented only the one of France, whereas the population of Germany represented mid-European countries such as Germany, Belgium, Luxembourg, the Netherlands and Austria. The population of Denmark represented the northern European countries i.e. Denmark, Finland and Sweden. Prediction for the European population was realised by generating daily applied amounts using probabilistic analysis for 11 product categories, i.e body lotion, deodorant, facial moisturiser, shampoo, lipstick, toothpaste, mouthwash, shower gel, liquid foundation, hand cream and hair styling products (Hall et al., 2007; McNamara et al., 2007, Hall et al., 2011). The publications report consumed amounts of cosmetic products per day and per kg bodyweight. They do not differentiate between frequency of application and amount per application based on the assumption that for regularly used products the frequency and amount are inversely correlated.

In Table 3A conservative point values for the estimated amount $q_x$ are listed that can be used to assess exposure in a first tier. From the amount distributions generated in the probabilistic assessments (Hall et al., 2007, Hall et al., 2011), the P90 was chosen for both daily and relative daily amount applied to the skin, respectively. These amounts were multiplied with the respective retention factors $f_{ret}$ (derived in SCCNFP/0321/00) to yield the effective exposure to a product category ($E_{product}$). For deriving the relative amounts and exposures reported in Table 3A, bodyweight distributions from the European countries included in the study were used in a Monte Carlo approach explained in Hall et al., 2007 and McNamara et al., 2007. From the $E_{product}$ derived below, the dermal exposure $E_{dermal}$ to a substance can be calculated according to equation (4):

\[
E_{dermal} = E_{product} \times C_x
\]  

(4)

where $C_x$: substance concentration in a product category.
**Table 3A**: Daily exposure levels for different cosmetic product categories in Europe, calculated by multiplying daily amounts (Hall *et al.*, 2007, 2011) and \( f_{\text{ret}} \).

<table>
<thead>
<tr>
<th><strong>Product type</strong></th>
<th><strong>Estimated daily amount applied</strong> ( q_x ) (g/d)</th>
<th><strong>Relative daily amount applied</strong> ( q_x / bw ) (mg/kg bw/d)</th>
<th><strong>Retention factor</strong> ( f_{\text{ret}} )</th>
<th><strong>Calculated daily exposure</strong> ( E_{\text{product}} ) (g/d)</th>
<th><strong>Calculated relative daily exposure</strong> ( E_{\text{product}} / bw ) (mg/kg bw/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bathing, showering</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shower gel</td>
<td>18.67</td>
<td>279.20</td>
<td>0.01</td>
<td><strong>0.19</strong></td>
<td><strong>2.79</strong></td>
</tr>
<tr>
<td><strong>Hair care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shampoo</td>
<td>10.46</td>
<td>150.49</td>
<td>0.01</td>
<td><strong>0.11</strong></td>
<td><strong>1.51</strong></td>
</tr>
<tr>
<td>Hair styling products</td>
<td>4.00</td>
<td>57.40</td>
<td>0.10</td>
<td><strong>0.40</strong></td>
<td><strong>5.74</strong></td>
</tr>
<tr>
<td><strong>Skin care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body lotion</td>
<td>7.82</td>
<td>123.20</td>
<td>1.00</td>
<td><strong>7.82</strong></td>
<td><strong>123.20</strong></td>
</tr>
<tr>
<td>Face cream</td>
<td>1.54</td>
<td>24.14</td>
<td>1.00</td>
<td><strong>1.54</strong></td>
<td><strong>24.14</strong></td>
</tr>
<tr>
<td>Hand cream</td>
<td>2.16</td>
<td>32.70</td>
<td>1.00</td>
<td><strong>2.16</strong></td>
<td><strong>32.70</strong></td>
</tr>
<tr>
<td><strong>Make-up</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid foundation</td>
<td>0.51</td>
<td>7.90</td>
<td>1.00</td>
<td><strong>0.51</strong></td>
<td><strong>7.90</strong></td>
</tr>
<tr>
<td>Lipstick, lip salve</td>
<td>0.057</td>
<td>0.90</td>
<td>1.00</td>
<td><strong>0.057</strong></td>
<td><strong>0.90</strong></td>
</tr>
<tr>
<td><strong>Deodorant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deodorant non-spray</td>
<td>1.50</td>
<td>22.08</td>
<td>1.00</td>
<td><strong>1.50</strong></td>
<td><strong>22.08</strong></td>
</tr>
<tr>
<td>Deodorant spray</td>
<td>0.69</td>
<td>10.00</td>
<td>1.00</td>
<td><strong>0.69</strong></td>
<td><strong>10.00</strong></td>
</tr>
<tr>
<td><strong>Oral hygiene</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toothpaste (adult)</td>
<td>2.75</td>
<td>43.29</td>
<td>0.05</td>
<td><strong>0.138</strong></td>
<td><strong>2.16</strong></td>
</tr>
<tr>
<td>Mouthwash</td>
<td>21.62</td>
<td>325.40</td>
<td>0.10</td>
<td><strong>2.16</strong></td>
<td><strong>32.54</strong></td>
</tr>
</tbody>
</table>

1. The specific body weight of the persons involved in the study is used and not the default value of 60 kg.
2. The retention factor \( f_{\text{ret}} \) was introduced by the SCCNFP to take into account rinsing off and dilution of finished products by application on wet skin or hair (e.g. shower gels, shampoos) (SCCNFP/0321/00); \( f_{\text{ret}} \) has no units.

The large-scale study cited above only included the most frequently used 12 cosmetic products. Deterministic amounts and exposure data for further cosmetic products had been provided earlier for normal and extensive use (Colipa 16.01.97 BB-97/007, SCCNFP /0321/00). **Table 3B** lists conservative use levels for some cosmetic products based on female usage (higher than for males) and extensive use reported by SCCNFP.
Table 3B: Estimated daily exposure levels in Europe for additional cosmetic product categories, which are not covered by Hall et al., 2007, 2011 (SCCNFP/0321/00; Steiling et al., 2012; Colipa 16.01.97 BB-97/007).

<table>
<thead>
<tr>
<th>Product type</th>
<th>Estimated daily amount applied $q_x$ (g/d)</th>
<th>Relative daily amount applied $q_x$/$bw$ (mg/kg bw/d)</th>
<th>Retention factor $f_{ret}$</th>
<th>Calculated daily exposure $E_{product}$ (g/d)</th>
<th>Calculated relative daily exposure $E_{product}$/$bw$ (mg/kg bw/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hair care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hair conditioner$^2$</td>
<td>3.92</td>
<td>-</td>
<td>0.01</td>
<td>0.04</td>
<td>0.67</td>
</tr>
<tr>
<td>Semi-permanent hair dyes (and lotions)$^2$</td>
<td>35 ml (per application)</td>
<td>-</td>
<td>0.1</td>
<td>Not calculated $^3$</td>
<td>-</td>
</tr>
<tr>
<td>Oxidative/permanent hair dyes$^2$</td>
<td>100 ml (per application)</td>
<td>-</td>
<td>0.1</td>
<td>Not calculated $^3$</td>
<td>-</td>
</tr>
<tr>
<td><strong>Make-up</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Make-up remover$^2$</td>
<td>5.00</td>
<td>-</td>
<td>0.10</td>
<td>0.50</td>
<td>8.33</td>
</tr>
<tr>
<td>Eye shadow$^2$</td>
<td>0.02</td>
<td>-</td>
<td>1.00</td>
<td>0.02</td>
<td>0.33</td>
</tr>
<tr>
<td>Mascara$^2$</td>
<td>0.025</td>
<td>-</td>
<td>1.00</td>
<td>0.025</td>
<td>0.42</td>
</tr>
<tr>
<td>Eyeliner$^2$</td>
<td>0.005</td>
<td>-</td>
<td>1.00</td>
<td>0.005</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Deodorant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deodorant aerosol spray (ethanol-based)$^4$</td>
<td>1.43</td>
<td>20.63</td>
<td>1.00</td>
<td>1.43</td>
<td>20.63</td>
</tr>
</tbody>
</table>

1 The retention factor ($f_{ret}$) was introduced by the SCCNFP to take into account rinsing off and dilution of finished products by application on wet skin or hair (e.g. shower gels, shampoos, …) (SCCNFP/0321/00). Being a fraction between 0 and 1, $f_{ret}$ has no units.
2 Product categories not covered by Hall et al., 2007, 2011.
3 Daily exposure value not calculated due to the low frequency of application.
4 Steiling et al., 2014: ‘ethanol-based’ are products containing ethanol as the principal ingredient.
5 The specific body weight of the persons involved in the study is used and not the default value of 60 kg.

Alternatively, if daily use data are not available, the daily use can be calculated from the frequency of the application event and the amount per event. For calculating the amount per event e.g. the surface area of body parts can be helpful. Therefore, in Table 4 human surface areas (Bremmer et al., 2006a; Bremmer et al., 2006b) and the frequency of application are provided. For calculating a first tier, the maximum frequency per day should be multiplied by the maximally applied amount. For daily amounts per body weight these amounts can be divided by the default human body weight of 60 kg.
Table 4: Mean exposed skin surface area per product category (Bremmer et al., 2006a; Bremmer et al., 2006b) and frequency of application per product category

<table>
<thead>
<tr>
<th>Product type</th>
<th>Surface area for application SSA (cm²)</th>
<th>Body areas</th>
<th>Frequency of application</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bathing, showering</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shower gel</td>
<td>17500</td>
<td>total body area</td>
<td>1.43/day</td>
</tr>
<tr>
<td>Hand wash soap</td>
<td>860</td>
<td>area hands</td>
<td>10/day²</td>
</tr>
<tr>
<td>Bath oil, salts, etc.</td>
<td>16340</td>
<td>area body- area hands</td>
<td>1/day</td>
</tr>
<tr>
<td><strong>Hair care</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shampoo</td>
<td>1440</td>
<td>area hands+ ½ area head</td>
<td>1/day</td>
</tr>
<tr>
<td>Hair conditioner</td>
<td>1440</td>
<td>area hands+ ½ area head</td>
<td>0.28/day</td>
</tr>
<tr>
<td>Hair styling products</td>
<td>1010</td>
<td>½ area hands+ ½ area head</td>
<td>1.14/day</td>
</tr>
<tr>
<td>Semi-permanent hair dyes (and lotions)</td>
<td>580</td>
<td>½ area head</td>
<td>1/week (20min.)</td>
</tr>
<tr>
<td>Oxidative/ permanent hair dyes</td>
<td>580</td>
<td>½ area head</td>
<td>1/month (30min.)</td>
</tr>
<tr>
<td><strong>Skin care</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body lotion</td>
<td>15670</td>
<td>area body-area head (female)</td>
<td>2.28/day</td>
</tr>
<tr>
<td>Face cream</td>
<td>565</td>
<td>½ area head (female)</td>
<td>2.14/day</td>
</tr>
<tr>
<td>(+applied on neck)</td>
<td>320¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+ applied on back of neck)</td>
<td>80²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hand cream</td>
<td>860</td>
<td>area hands</td>
<td>2/day</td>
</tr>
<tr>
<td><strong>Make-up</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid foundation</td>
<td>565</td>
<td>½ area head (female)</td>
<td>1/day</td>
</tr>
<tr>
<td>Make-up remover</td>
<td>565</td>
<td>½ area head (female)</td>
<td>1/day</td>
</tr>
<tr>
<td>Eye shadow</td>
<td>24</td>
<td></td>
<td>2/day</td>
</tr>
<tr>
<td>Mascara</td>
<td>1.6</td>
<td></td>
<td>2/day</td>
</tr>
<tr>
<td>Eyeliner</td>
<td>3.2</td>
<td></td>
<td>2/day</td>
</tr>
<tr>
<td>Lipstick, lip salve</td>
<td>4.8³</td>
<td></td>
<td>2/day</td>
</tr>
<tr>
<td><strong>Deodorant/antiperspirant</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deodorant spray and non- spray</td>
<td>200</td>
<td>both axillae</td>
<td>2/day</td>
</tr>
<tr>
<td><strong>Fragrances</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eau de toilette spray</td>
<td>200</td>
<td>total body area</td>
<td>1/day</td>
</tr>
<tr>
<td>Perfume spray</td>
<td>100</td>
<td>area hands</td>
<td>1/day</td>
</tr>
<tr>
<td><strong>Men’s cosmetics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaving cream</td>
<td>305</td>
<td>¼ area hand (male)</td>
<td>1/day</td>
</tr>
<tr>
<td>Aftershave</td>
<td>305</td>
<td>¼ area hand (male)</td>
<td>1/day</td>
</tr>
<tr>
<td><strong>Sun care cosmetics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunscreen lotion/cream</td>
<td>17500</td>
<td>total body area</td>
<td>2/day</td>
</tr>
</tbody>
</table>

1 If the *in vitro* dermal absorption assay was not performed under in-use conditions, an additional correction factor can be introduced.
Besides these European values, it should be noted that the US EPA also published default values for Skin Surface Areas (SSAs) of relevant parts of the human body (US EPA, 1997).

Danish Ministry of the Environment, Environmental Protection Agency: Survey of liquid hand soaps, including health and environmental assessments.

Daily exposure value not calculated due to the low frequency of exposure

Steiling et al., 2014: ‘ethanol-based’ are product categories containing ethanol as the principal ingredient.

The SCCS emphasises that it is not the intention to provide parameter values and exposure estimates for all cosmetic product categories. Only for the most common categories are default values provided. For all other cosmetic product categories, the individual companies and/or the qualified safety assessors need to make a case-by-case assessment of the daily exposure level and/or the frequency of application. Exposure values, frequency of application and other relevant information for individual cosmetic product categories can be found in Appendix 7.

For sunscreen products, an application of 18.0 g/d is used in the MoS calculation (see also 3-6.4).

3-3.4.2.2 Concentrations

As parameter values for concentration, the maximal allowed levels need to be taken into account. If different levels are allowed in different product categories, the category-specific levels should be considered.

3-3.4.2.3 Parameters specific for inhalation exposure

For spray products - both propellant and pump sprays - the relevant concentration to calculate exposure is not the concentration in the formulation, but the concentration in the spray mist, which can be inhaled (3-3.4.1.3). The droplet size distribution should also be considered. Finally, according to the explanations in 3-3.4.1.3 (inhalation models), another important parameter is the deposition rate. Deposition rates have, for example, been determined in an International Commission Radiological Protection project (ICRP, 1994).

In Appendix 11, possible parameterization for a 2-Box inhalation model is given as an example and needs to be adapted to the specific exposure scenario. Taking into account the small timeframe of the calculation and large variation in room ventilation, for a conservative estimate it should be assumed that no ventilation occurs.

3-3.4.3 Aggregate exposure

Aggregate exposure is obtained by aggregating (adding up) the exposures to a cosmetic ingredient contained in several single product categories (e.g. shampoo, hand cream, etc). It needs to be calculated when several product categories contribute. For the calculation of LEDs, the aggregation is specific to the investigated site and if a risk assessment should be conducted for local exposure, the cosmetic ingredient single doses need to be added up for the specific investigated site. In the absence of a valid approach for a quantitative risk assessment of the local effect (which is e.g. the case for skin sensitisation), the assessment is hazard-based. If the external aggregate exposure should serve to calculate SEDs, aggregation needs to take into account all product categories that can be taken up by a specific route. For each route a specific aggregate external exposure needs to be provided. If aggregation over routes is necessary, because different routes (e.g. dermal and inhalation route) contribute, aggregation over routes needs to be calculated on the level of internal exposure.
For aggregate dermal exposure as a first tier, the SCCS recommends to calculate the LEDs and SEDs based on the product category-specific exposures $E_{\text{product}}$ given in Table 5. For preservatives and other substances that are regulated with the same maximal concentrations in all product categories, the LEDs or SEDs can be directly derived by multiplying the aggregate $E_{\text{product}}$ with the maximal allowed concentration ($C_x$) by skin surface area (SSA in cm$^2$). For other cosmetic ingredients the respective $E_{\text{product}}$ needs to be multiplied with the maximal concentration specific to the product category.

Whenever available, the values in Table 5 were taken from the $E_{\text{product}}$ presented in Table 3A. For some product categories probabilistic data were not available and for these categories earlier information provided by Cosmetics Europe was used (Table 3B). Note, that the $E_{\text{product}}$ for the oral care products in this context is used for calculating the dermal exposure (via mucosa) and not oral exposure. Oral exposure, if applicable, needs to be calculated separately.

**Table 5:** Product exposures for the deterministic calculation of aggregate exposure for preservatives through cosmetic use.

Note that these values can also be used for other ingredients when aggregate exposure calculations are needed for one or more classes of cosmetic products.

<table>
<thead>
<tr>
<th>Type of cosmetic product exposure</th>
<th>Product category</th>
<th>Daily Exposure $E_{\text{product}}$ (g/d)</th>
<th>Relative daily exposure $E_{\text{product}}/\text{bw}$ (mg/kg bw/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rinse-off skin&amp; hair cleansing products</strong></td>
<td>Shower gel</td>
<td>0.19</td>
<td>2.79</td>
</tr>
<tr>
<td></td>
<td>Hand wash soap</td>
<td>0.20</td>
<td>3.33</td>
</tr>
<tr>
<td></td>
<td>Shampoo</td>
<td>0.11</td>
<td>1.51</td>
</tr>
<tr>
<td></td>
<td>Hair conditioner</td>
<td>0.04</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>Leave on skin&amp; hair cleansing products</strong></td>
<td>Body lotion</td>
<td>7.82</td>
<td>123.20</td>
</tr>
<tr>
<td></td>
<td>Face cream</td>
<td>1.54</td>
<td>24.14</td>
</tr>
<tr>
<td></td>
<td>Hand cream</td>
<td>2.16</td>
<td>32.70</td>
</tr>
<tr>
<td></td>
<td>Deodorant non-spray</td>
<td>1.50</td>
<td>22.08</td>
</tr>
<tr>
<td></td>
<td>Hair styling</td>
<td>0.40</td>
<td>5.74</td>
</tr>
<tr>
<td><strong>Make-up products</strong></td>
<td>Liquid foundation</td>
<td>0.51</td>
<td>7.90</td>
</tr>
<tr>
<td></td>
<td>Make-up remover</td>
<td>0.50</td>
<td>8.33</td>
</tr>
<tr>
<td></td>
<td>Lipstick</td>
<td>0.06</td>
<td>0.90</td>
</tr>
<tr>
<td></td>
<td>Eye make-up</td>
<td>0.02</td>
<td>0.33</td>
</tr>
<tr>
<td></td>
<td>Mascara</td>
<td>0.025</td>
<td>0.42</td>
</tr>
<tr>
<td></td>
<td>Eyeliner</td>
<td>0.005</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Oral care Products$^2$</strong></td>
<td>Toothpaste</td>
<td>0.14</td>
<td>2.16</td>
</tr>
<tr>
<td></td>
<td>Mouthwash</td>
<td>2.16</td>
<td>32.54</td>
</tr>
<tr>
<td><strong>Aggregate exposure</strong></td>
<td></td>
<td><strong>17.4</strong></td>
<td><strong>269</strong></td>
</tr>
</tbody>
</table>

1. The specific bw of the persons involved in the study is used and not the default value of 60kg
2. Oral care product categories are not corrected and are presumed here to only represent dermal exposure (mucosa)
The consumer may also be exposed to cosmetic substances through inhalation (e.g. through spray applications) or oral exposure. These exposure routes are not considered for Tables 3A, 3B, 4 and 5 since the inhalation and oral risk is assessed on a case-by-case basis.

For CMR 1A and 1B substances, according to Art. 15d of the Cosmetic Regulation, the consideration of aggregate exposure from all sources (including non-cosmetics) is required.

3-3.5  **INTERNAL EXPOSURE**

Internal exposure can either be measured in humans or calculated from external exposure e.g. by applying route-specific absorption factors that translate the amount of substance entering the body into the amount that is available in the bloodstream and constitutes the dose acting on organ level. In this guidance, this dose is called the SED. There are also other ways to calculate this internal dose, e.g. by more realistically describing the toxicokinetics and applying different kinds of PBPK models.

3-3.5.1  **TOXICOKINETICS (ADME)**

The term "toxicokinetics" is used to describe the time-dependent uptake, distribution and fate of a substance entering the body. This includes Absorption, Distribution, Metabolism and Excretion (ADME). All of these processes need to be known to understand the fate of substances once they come in contact with the body. The testing guidelines for toxicokinetics, including dermal absorption (EC B.36 Toxicokinetics, EC B.44 Skin absorption: *in vivo* method, EC B.45 Skin absorption: *in vitro* method; corresponding with OECD 417 (toxicokinetics), 427 (*in vivo* method), 428 (*in vitro* method), respectively), are designed to elucidate particular aspects of the fate and the potential toxicity of the substance under test. The results may assist in the design of further toxicity studies and their interpretation. Moreover, after absorption of a substance under consideration, its metabolic transformation and fate can have an important effect on its distribution in the body and its excretion, as well as on the toxic potential. Therefore, in specific cases, *in vivo* or *in vitro* biotransformation studies are required. However, the conduct and use of *in vivo* studies is restricted due to the animal testing ban for cosmetic ingredients in the EU.

Apart from data on dermal absorption, further toxicokinetic data for cosmetic ingredients are only available under certain circumstances, but their relevance may be high for extrapolating both *in vivo* and *in vitro* animal data to the human situation.

Any route-to-route extrapolation of toxicity can be performed in a case-by-case manner based on expert judgement of scientific information, including available toxicokinetic information. It can, however, only be performed in the case of systemic toxicity. In this regard, not only the degree of absorption, but also metabolism should be considered (ECHA, 2012a, 2015).

A review of the current status of toxicokinetics in the safety evaluation of cosmetics and their ingredients can be found in several JRC reports (Adler et al., 2011, JRC Scientific and Policy Report 2013a, 2014a, b, 2015, 2016, 2017 (more specific to toxicokinetics), 2018, 2019, 2020). At present, no validated alternative methods that completely cover the field of ADME exist. Some *in vitro* models could be suitable for contributing to the assessment of the absorption of substances from the gastro-intestinal tract (e.g. Caco-2 cell cultures) or the biotransformation of substances (e.g. isolated hepatocytes, HepaRG™ cells, and their cultures), but most of the existing models have not been officially validated (Adler et al., 2011; Eskes et al., 2005; JRC Scientific and Policy Report 2013a, 2014a, 2014b, 2015, 2016, 2017, 2018, 2019, 2020).

In a limited number of cases, human toxicokinetic study results are available to the SCCS for cosmetic ingredients, e.g. zinc pyrithione (SCCS/1512/13), cyclpentasiloxane D5 (SCCS/1549/15), phenoxyethanol (SCCS/1575/16), salicylic acid (SCCS/1602/18) and aluminium (SCCS/1613/19). It would be a step forward to include more human toxicokinetic
studies in the dossiers of Annex substances provided that a) risk assessment cannot ade
quately be performed by use of other data/methodologies and b) such human studies are ethi
cally acceptable.

3-3.5.1.1 DERMAL/PERCUTANEOUS ABSORPTION

Human exposure to cosmetic substances occurs mainly via the skin. In order to reach the circulation (blood and lymph vessels), cosmetic ingredients must cross a number of cell layers of the skin, of which the rate-determining layer is considered to be the stratum corneum.

A high number of factors influence this process, including the molecular weight, charge, lipophilicity of the compounds, the thickness and composition of the stratum corneum (which depends on the body site), the duration of exposure, the amount of topically applied product, the concentration of target compounds, occlusion, vehicle, skin integrity, etc.

Recommended procedures and advice with respect to dermal absorption have been given by several international bodies (ECETOC, 1993; US EPA, 1996a; OECD, 2004; WHO, 2006; OECD, 2011a, EFSA 2017; SANTE 2018; OECD 2019). Sometimes, different terminology is used.

a. Guidelines for dermal absorption studies

Skin absorption studies can be performed in principle in vivo (OECD 427) or in vitro (OECD 428). Detailed guidance on their performance is available (OECD 2004, 2011a, OECD 2019), although no OECD test guideline is available to describe how to conduct in vivo human dermal absorption studies. In addition, the SCCNFP (Scientific Committee on Cosmetics and Non-Food Products) adopted a first set of “Basic Criteria” for the in vitro assessment of dermal absorption of cosmetic ingredients back in 1999 (SCCNFP/0167/99). The SCCS updated this Opinion in 2010 (SCCS/1358/10). A combination of OECD 428 guideline with the SCCS "Basic Criteria" (SCCS/1358/10) is considered to be essential for performing appropriate in vitro dermal absorption studies for cosmetic ingredients.

b. The SCCS "Basic Criteria"

The purpose of in vitro dermal absorption studies of cosmetic substances is to obtain qualitative and/or quantitative information on the compounds that may enter the systemic compartment of the human body under in-use conditions. These amounts can then be taken into consideration to calculate the MoS during risk characterisation.

Numerous specific parameters or working conditions need to be taken into consideration:

1) The design of the diffusion cell (technicalities and choice between static and flow through system).
2) The choice of the receptor fluid (physiological pH, solubility and stability of chemical in receptor fluid should be demonstrated, no interference with skin/membrane integrity, analytical method, etc.).
3) The skin preparations should be chosen and treated with care. Human skin from an appropriate site remains the gold standard. If not available, pig skin is an alternative (Gerstel et al., 2016).
4) Skin integrity is of key importance and should be verified. Poor barrier quality may lead to high dermal absorption values. Skin integrity can be measured using a variety of methods (Guth et al., 2015, Fasano et al., 2002, Lehman et al., 2017).
5) Skin temperature has to be ascertained at normal human skin temperature.
6) The test substance has to be rigorously characterised and should correspond to the substance that is intended to be used in the finished cosmetic products.

7) Dose and vehicle/formulation should be representative for the in-use conditions of the intended cosmetic product including contact time. Several concentrations, including the highest concentration of the test substance in a typical formulation, should be tested.

8) Regular sampling is required during the whole exposure period, taking into account delayed penetration into skin layers.

9) Appropriate analytical techniques should be used. Their validity, sensitivity and detection limits should be documented in the report.

The test compound is to be determined in all relevant compartments:

- product excess on the skin surface (dislodgeable dose),
- stratum corneum (e.g. adhesive tape strips),
- living epidermis (without stratum corneum),
- dermis,
- receptor fluid.

10) Mass balance analysis and recovery data are to be provided. The overall recovery of test substance (including metabolites) should be within the range of 85-115%.

11) An appropriate number of controls (for in vitro studies: diffusion cells) should be used to determine the background level. In cases where there is a high background level and a high variability of the background level, it may be necessary to determine it for every single donor in an appropriate number of repetitions.

12) Treatment of non-detects: if measurements are below the Limit Of Detection/ Limit Of Quantification (LOD/LOQ) or below the background level for the calculation of absorption, either the lower bound (zero) or upper bound (LOQ/LOD) can be used. The choice of either upper or lower level needs to ensure that the highest possible absorption value is calculated. Variability / validity / reproducibility of the method should be discussed. The SCCS considers that for a reliable dermal absorption study, 8 skin samples from at least 4 donors should be used. The absorption needs to be calculated for each single diffusion cell and these values should be used to derive the mean absorption. An appropriate number of repetitions should be used for each donor.

13) Radioactive labelling of the substance under consideration is often used in order to increase sensitivity. Justification should be given for the type and site of labelling chosen e.g. present or not in ring structure(s) or side chain(s), use of single or double labelling, etc. This information is important with respect to the biotransformation and stability of the compound.

14) The technical ability of the performing laboratory and the validity of the method used should be assessed at regular intervals, at least twice per year, by using reference compounds like caffeine or benzoic acid. These data should be included in the study report (OECD, 2004; Van de Sandt et al., 2004).

15) Sample application in vitro should mimic human exposure, normally 1-5 mg/cm² for a solid and up to 10 µl/cm² for liquids (OECD 428).

Exceptions may exist, e.g., oxidative hair dyes, where 20 mg/cm² are usually applied for 30-45 minutes (depending on the intended use).

Experience has shown that in vitro measurements using less than 2 mg/cm² are not technically feasible while the amounts of cosmetic products applied to the skin usually do not exceed 1 mg/cm² under in-use conditions. Thus, the in vitro tests are performed with applied amounts exceeding the intended use conditions and, if the resulting dermal absorption given in percent of the test dose is used to calculate SED, they may result in an underestimation of systemic exposure.
It is important to know whether the formulation can affect the bioavailability of one of its compounds. There are many penetration enhancers and excipients (such as liposomes) that may be specifically added to a cosmetic formulation to facilitate the dermal absorption of certain ingredients.

It is advised to perform dermal absorption studies in the risk assessment process. In the absence of experimentally determined dermal absorption, a 50% default value is used. This conservative value may also be used in cases where only inadequate dermal absorption data are available.

The amounts measured in the dermis, epidermis (without stratum corneum) and the receptor fluid will be considered as dermally absorbed and taken into account for further calculations. In the case of substances with very low dermal absorption and limited permeation (e.g. colourants or UV-filters with high molecular weight and low solubility), the epidermis may be excluded from the calculations (e.g. opinion on Polyaminopropyl Biguanide (PHMB) - Submission III, SCCS/1581/16) when it is demonstrated that no movement of the chemicals from the skin reservoir to the receptor fluid occurs (Yourick et al., 2004; WHO, 2006). Adequate detection of substances that are poorly soluble in water is important in the receptor fluid of an in vitro dermal absorption study to ascertain that the dermal absorption concerns the active substance and not the impurities.

For nanomaterial, it is also important to ascertain whether the substance absorbed through the skin was in nanoparticle form or in a dissolved chemical state.

Where studies correspond to all of the basic requirements of the SCCS, the mean +1SD (Standard Deviation) will be used for the calculation of the MoS. In case of significant deviations and/or very high variability, the mean + 2SD may be used. Where the deviation is too high, the study is not accepted and is excluded.

Especially for substances intended to be used as UV-filters, studies have been submitted to the SCCS using damaged skin (e.g. SCCS/1594/18; SCCS/1546/15). So far, there is no standard protocol for the investigation of dermal absorption through damaged skin, or a common understanding of “damaged skin” (wounded, physically damaged, sunburnt, etc.). Therefore, the SCCS prefers study results obtained with intact skin. Information from damaged skin can only be considered as supporting information.

It should be noted that when experimental values have been derived from a limited number of data points (N), standard deviation is calculated using 'N'. Only in cases where the number of data points is > 30, can 'N-1' be used.

**c. Substances with very low dermal absorption**

A retrospective study of the Annex substances present in the Opinions (2000-2014) of the SCCS and its predecessors has shown that the cosmetic ingredients characterised by the following physicochemical properties may be indicative of very low dermal absorption (Ates et al., 2016):

- MW>500 Da,
- High degree of ionisation,
- Log P<sub>ow</sub> ≤-1 or ≥ 4,
- Topological polar surface area >120 Å<sup>2</sup>,
- Melting point > 200°C

For dealing with data on very low dermal absorption, see Section 3-6.11.
3-3.5.1.2 Absorption after Ingestion

For products intended for oral use, like toothpastes and mouthwashes, inevitably some amount will be ingested. If no experimentally derived data are provided, the SCCS will take the conservative absorption value of 100%.

Although not officially recognised as a validated alternative method, Caco-2 cells, derived from human colon carcinoma, have been most widely proposed as representing a cell culture model for oral permeability screening. Given the high number of variables involved in the complex process of intestinal absorption (Turco et al., 2011), it is of key importance to work under well-documented and standardised conditions in order to be able to draw valid conclusions when such in vitro models are being applied (SCCS Expert Methodologies meeting, 2011). It is therefore necessary to report on all aspects of the experimental setup and provide detailed information on the control of the variables. Caco-2 and similar models indeed have a number of advantages and disadvantages (Grès et al., 1998; Le Ferrec et al., 2001; Thomas et al., 2008; Adler et al., 2011, Fredlund et al., 2017). Great attention is particularly required in cases where non-suitability of the in vitro model has been reported, e.g. for highly lipophilic compounds, substances with poor absorption, substances with a carrier-mediated transport or when first-pass metabolism is involved (Thomas et al., 2008, Beloqui et al., 2016). Study of the predictive capacity of two in vitro cellular systems—the Caco-2/ATCC parental cell line and the Caco-2/TC7 clone concluded that good prediction is obtained only for highly absorbed compounds (100% correctly classified), while moderately and poorly absorbed compounds are frequently overestimated (Prieto et al., 2010). The model has been a subject of improvement (Shah et al., 2014, Takenaka et al., 2017, Di Marco et al., 2017).

3-3.5.1.3 Inhalation

Cosmetic ingredients might be inhaled as gases, vapours, (liquid) aerosols or powders and enter the respiratory tract. The physical form of the ingredient plays a decisive role in the absorption process. Further, absorption via inhalation is governed by respiratory patterns and the physiology of the respiratory tract, which consists of the nasopharyngeal, the tracheobronchial and the pulmonary regions.

Gases and vapours are absorbed in the pulmonary region. However, if gases are reactive or very water soluble, they might not reach the pulmonary region due to reaction with cell surface components of the naso- or tracheobronchial region or due to solution into the aqueous mucus layer of the respiratory tract (eventually followed by out-partitioning). Thus, hydrophilic vapours/gases are more prone to be removed from the upper respiratory tract whereas lipophilic substances are more likely to reach the deep lung. There, absorption into the bloodstream may occur when the molecule is sufficiently lipophilic to dissolve in the lipophilic alveolar mucus and to cross the alveolar and capillary membranes.

The rate of absorption of a gas into the circulation is governed by the blood to gas partition coefficient (the ratio of the concentration of a chemical in blood and the concentration of the chemical in the gas phase).

Once deposited in the lung, (partially) soluble particles dissolve (partially) in the lining fluid (mucus layer) of the epithelium where inert particles might form non-dissolved but colloidal suspensions. For further considerations of particle behaviour refer to the Guidance on the Safety Assessment of Nanomaterials in Cosmetics (SCCS/1611/19).

If information on the extent of inhalation absorption is available from experimental studies and/or physico-chemical parameters, this information is used. However, if no data are presented, the SCCS considers that for the calculation of inhalation exposure an absorption of 100% should be used.
3-3.5.2 DIFFERENCES IN METABOLISM FOR DIFFERENT ROUTES

3-3.5.2.1 SYSTEMIC METABOLISM

Metabolism of xenobiotic substances in mammals mainly occurs via phase I and/or phase II reactions mediated by Xenobiotic Metabolising Enzymes (XMEs). This can also involve active transport of substances in (Phase 0) and/or out of the cells (Phase 3). Phase I reactions such as oxidation, reduction, hydrolysis etc. introduce functional groups into the molecule (functionalisation). Phase II reactions render the xenobiotic substance or its metabolite(s) more hydrophilic so that they can be better eliminated via bile or urine, by conjugation mainly with glutathione, glucuronic acid or sulfate. In most cases, phase I metabolites that may be reactive are also inactivated by these conjugation reactions.

Metabolism of xenobiotic substances may differ from species to species due to different protein structures and substrate specificities of XMEs and different levels of expression and regulation of the subfamilies of XMEs (isoenzymes) as well. These potential species differences are in general considered in risk assessment by the use of an interspecies default factor for toxicokinetics including metabolism (see Section 3-5.1.3). However, the use of a fixed factor may under certain circumstances lead to errors in risk assessment if large interspecies differences of metabolism between laboratory animals and humans are not recognised and/or not adequately accounted for. Although such cases seem to be rare, some well-characterised substances have been described as possessing different carcinogenic potencies due to the different metabolisms of laboratory species compared and humans (Oesch and Hengstler, 2014).

In mammals, expression and regulation of XMEs depend on many factors, including genetic factors (polymorphisms), external causes (e.g., enzyme inducers or inhibitors), individual factors such as gender, age, nutrition, health status (disease), pregnancy and several other factors. These potential individual differences are considered in risk assessment by the use of an intraspecies default factor for toxicokinetics (including metabolism) (see Section 3-5.1). This intraspecies factor may need to be adapted if substance-specific information is available (e.g., human XME polymorphisms).

In general, metabolic capacity of XMEs in mammalian liver is much higher than in extra-hepatic tissues including skin, when based on metabolic capacity per gram of tissue. In addition to quantitative differences in metabolic capacity there are also major differences in the constitutive expression and regulation of XMEs between mammalian liver and extra-hepatic tissues including skin (Oesch et al., 2007; Gundert-Remy et al., 2014; Oesch et al., 2014). Therefore, in some cases, when an XME isoenzyme form is not active in rodent liver such as human N-acetyltransferase 1 (NAT1), extrahepatic metabolism including skin may qualitatively differ from that in the liver (e.g., hair dyes p-Phenylenediamine (A7) SCCS/1443/11 and 6-Amino-m-cresol (A75) SCCS/1400/11).

Although data on systemic or dermal metabolism is not a regular requirement for SCCS safety evaluation, such data is helpful and sometimes required to complete the toxicity profile of a cosmetic ingredient.

Data on metabolism of a substance is primarily obtained by in vitro or ex vivo methods using cellular or tissue materials from laboratory animals and increasingly from human sources. Much progress has been made during the last years in preserving metabolic capacity and regulation of XMEs in cells in culture, for instance by developing 3D-cultivation techniques. At present, these methods are still under development (Anton et al., 2015; Baptista et al., 2016; Fang and Eglen, 2017; Chen et al., 2018).

Extrapolation from in vitro metabolism data to the in vivo situation may be difficult although some progress has been made, in particular in combination with Physiologically Based PharmacoKinetic (PBPK) modelling (Coecke et al., 2013; Wilk-Zasadna et al., 2014; see also Section 3-3.5.3). Often, in vivo data from laboratory animals, or even more from humans, is helpful or even indispensable in order to clarify if or to which extent relevant metabolites are formed (see OECD 417 on toxicokinetics).
Because of the species differences of XMEs, human in vivo data are the gold standard, however, it should be considered as the last resort and in view of the Memorandum on the use of human data (SCCS/1576/15).

3-3.5.2.2 Dermal metabolism

Skin is both a physical and a biochemical barrier to the absorption of chemicals, microorganisms and particulate materials. Besides the role of the stratum corneum as the most critical structure with a barrier function, there is growing evidence that XMEs may have physiological functions in addition to defence of xenobiotic substances. Hence, constitutive expression and regulation (induction) of XMEs is tissue-specific, also in skin. Most of the major enzymes found in the liver may also be present in the skin but often at lower activity levels. Phase II reactions in skin apparently play a greater role than phase I reactions of which the metabolic capacity is considered very low. It is plausible to assume that the role of phase II enzymes in skin is primarily to inactivate exogenous substances, thus supporting the barrier function of skin (Oesch et al., 2007; SCCP/1171/08; Oesch et al., 2014; Gundert-Remy et al., 2014; Kazem et al., 2019).

There are examples that only small percentages of substances are metabolised in skin. On the other hand, in some cases nearly complete biotransformation during dermal absorption was observed. Whereas the fate of chemicals in the skin with regard to the type and degree of metabolism was considered a matter of uncertainty (SCCP/1171/08), much progress has been made in the characterisation of XMEs in human skin and cutaneous metabolism, including the metabolic competence of cutaneous cell types, such as keratinocytes and dendritic cells. Moreover, the development and metabolic characterisation of in vitro skin models has made progress. The comparison of XME activities of native human skin, 2D- and 3D-models (e.g. EpiDerm™ and SkinEthic™ Reconstructed human Epidermis (RhE) models) and monolayer cultures of HaCaT cells showed promising similarities (Hewitt et al., 2013; Oesch et al., 2014; Wiegand et al. 2014; Kazem et al., 2019). These models are now well-established, but additional work is still necessary as none of these skin models has yet been officially validated for metabolism.

These skin models may help in the future to clarify important questions e.g. oxidative bioactivation of prohaptns to haptns (Bergström et al., 2007; Karlberg et al., 2008, 2013; SCCS/1459/11, Urbisch et al., 2015 and 2016).

3-3.5.2.3 Lung metabolism

The lung is a complex organ comprised of anatomically different parts (trachea, bronchi, bronchioli and lung alveoli) accommodating a large number of different cell types which might contribute to xenobiotic metabolism. As in skin, the expression of xenobiotic metabolizing enzymes in the lungs is lower compared to liver. Nevertheless, there are certain metabolising enzymes which are preferentially expressed in the lung (e.g. CYP2A13, CYP2F1). Both functionalising and conjugating enzymes have been identified mainly in bronchiolar epithelium but also in pneumocytes, alveolar macrophages, Clara cells, respiratory epithelium and serous cells. Cytochrome P450 (CYP) enzymes involved in xenobiotic metabolism have been identified in lung tissues from different species including humans (overview, Gundert et al., 2014; Oesch et al., 2019).

They can vary considerably between humans. Amongst conjugating enzymes, Glutathione S-Transferases (GSTs), Uridine diphosphate GlucuronosylTransferases (UGTs) and arylamine-N-AcetylTransferases (NATs) have been identified, as well as, partially, their local distribution in the lung. Other enzymes present in lung are epoxide hydrolases and certain transporters such as Multidrug Resistance Proteins (MDR1 and MRP1) or Breast Cancer Resistance Protein (BCRP) (Gundert-Remy et al., 2014).
3-3.5.3 **PBPK modelling**

PBPK models are quantitative descriptions of the Absorption, Distribution, Metabolism and Excretion (ADME) of chemicals in biota, based on interrelationships among key physiological, biochemical and physicochemical determinants of these processes (WHO, 2010).

These models are not only used to translate external exposures into an internal (target) dose in the body, but are also developed to help with:

- Intra- and interspecies extrapolation (variability issues)
- Route-to-route extrapolation
- Dose extrapolation
- Replacement of default assessment factors by more specific, substance-derived factors

Physiological, anatomical, biochemical and physicochemical parameters are necessary to build up PBPK models in which ADME processes are represented by equations and organs by body compartments. Whereas physiological and anatomical parameters are readily available, biochemical (e.g. metabolic rate constants) and physicochemical parameters (e.g. partition coefficients) are substance-specific and can be measured values or estimated values (the latter e.g. obtained by fitting processes using the PBPK model). The use of estimated values in further modelling might, however, increase uncertainties associated with a model.

The PBPK model should be capable of predicting the observed basic pharmacokinetics of the chemical (parent compounds or metabolites) before the model can be used for simulations of specific scenarios. Moreover, the acceptable prediction of dose metric should follow the acceptance criteria as indicated in the World Health Organisation (WHO) guidance (IPCS, 2010), i.e. the ratio between simulated and observed data should be on average within a factor of 2. If the ratio between simulated and observed data (parent compounds and/or metabolites) is not within a factor of 2, it will be necessary to refine and update the model with further ADME data.

If a metabolic scheme is available, evaluation on how well the model describes the respective metabolic/biochemical processes (number of metabolites, metabolites tree) should be performed.

**Sensitivity analysis** is an important component of model verification, especially for uncertain parameters with a high potential to influence the outcome of the simulation. A sensitivity analysis needs to be performed for all parameters. It provides a quantitative evaluation of how input parameters influence the dose metrics or other model output of relevance to the risk assessment, or to the problem as defined at the beginning (WHO/IPCS, 2010).

Note that: Sensitivity analysis results are expressed as absolute values of a normalised coefficient and are:

- High: $0.5$ ≤ medium $< 0.5$
- Low: $0.1$ ≤ low $< 0.2$

**Uncertainty analysis** must be performed by the Applicant. It evaluates the impact of the lack of precise knowledge of parameter values and model structure on dose metric simulations (WHO/IPCS, 2010). For parsimony, uncertainty analysis could be limited to the parameters identified through the sensitivity analysis as the ones that have the highest likelihood to affect the result of the model calculations.

The notion of uncertainty encompasses both true uncertainty (i.e. in model parameter value) and variability (i.e. from population variability). Variability refers to inherent heterogeneity that is distributed within a defined population, such as body weight. In contrast, true uncertainty refers to a parameter that has a single value, which cannot be known with precision due to measurement or estimation error, such as partition coefficient.
The level of uncertainty is determined based on the ratio of the 95th Percentile (P95) over the median value (P50) for the selected dose metric \( i.e., \) Area Under the Curve (AUC), Maximum Concentration (Cmax), etc.

Uncertainty analysis results are either summarised as having a high uncertainty (value could be a factor of 2 or higher); a medium uncertainty (value could be a factor between 0.3 and 2) or a low uncertainty (value could be a factor of 0.3 or lower).

The outcome of sensitivity and uncertainty analyses might inform the reliability of a model to provide dose metric predictions of use in risk assessment, as illustrated in Figure 3 (WHO/IPCS, 2010).

**Figure 3**: Illustration of the role of sensitivity and uncertainty analyses in determining the reliability of PBPK model predictions of dose metrics for safety evaluation (WHO/IPCS, 2010)

Note that uncertainty and sensitivity analysis are generally necessary for any type of model calculation.

The reliability of the model predictions of dose metrics for the safety evaluation, where feasible, are based on the level of sensitivity of the predictions to the model parameters and the level of uncertainty of the parameter values.

If the highly sensitive parameters are also the ones that are highly uncertain, then the reliability of the model would be questionable (WHO/IPCS, 2010).

When estimated data from PBPK models are submitted to SCCS which are intended to be used for MoS calculation, \( i.e., \) for quantitative safety evaluation, then it should also be demonstrated that the model correctly predicts experimental data that have not been used to build the model, preferably in the form of a peer-reviewed publication. Further, all equations - input parameters and information about software used should be provided – preferably in a tabular form.

In conclusion, SCCS will use data from PBPK models for quantitative risk assessment only if sufficient details (see below) are provided so that the calculations can be evaluated. Otherwise, the data may only be used as supporting information. In this respect, the following are needed:

1) Model structure and characterisation that involves the development of conceptual and mathematical descriptions of the relevant compartments of the human or animal body as well as the exposure and metabolic pathways related to the chemical under study.

2) Model parameterisation that involves obtaining quantitative estimates of measures of the mechanistic determinants \( e.g., \) anatomical, physiological, physicochemical, biochemical parameters;

3) Mathematical and computational implementation

4) Model simulation, \( i.e., \) simulation of the kinetics;
5) Model evaluation and validation that involves comparison of the *a priori* predictions of the PBPK model with experimental data as well as conducting uncertainty, sensitivity and variability analyses.

It should be noted that PBPK modelling has usually been based on experimental data, often animal data, to build up the model. It needs to be stressed that such modelling results will only be acceptable if data from animal tests have been used within the relevant regulatory restrictions.

### 3.3.5.4 Calculation of the systemic exposure dose (SED)

The SED can be calculated following different tiers. In a first tier, the SED is calculated deterministically from the first tier conservative external exposure estimates by multiplication with a conservative point value for the absorption fraction. Normally, the major route of exposure will be *via* the skin. Therefore, the following equations specifically treat the calculation of first tier exposure *via* skin but can be adapted for other routes accordingly. Higher tier calculation of the SED can be derived e.g. from external exposure distributions derived with probabilistic models (see Section 3.3.4).

#### Calculations of the SED

There are two ways of calculating the SED, depending on the way the dermal absorption of a compound is reported:

- It is preferably based on the **absolute amount** bioavailable (µg/cm²) after a certain time period, based on the highest anticipated concentration. In that case, the default value of involved SSA needs to be known per product type (see Table 4 in Section 3.3.4.2) to estimate the systemic availability of the substance.

- It may also be based on the **percentage** dermally absorbed. This depends on the amount of finished product applied on the skin (see Table 3A and Table 3B in Section 3.3.4.2 for default values per product type).

1) **Dermal absorption of test substance reported in µg/cm²:**

   For calculating the SED (5), the skin surface has to be taken into account that should be treated with the finished cosmetic product containing the substance under study, as well as the frequency of product application per day. All other variables should have been taken into consideration in the proper design of the dermal absorption study itself (SCCP/0970/06).

   
   \[
   \text{SED} = \frac{D_{Aa} \times 10^{-3} \times SSA \times f_{appl}}{60\text{kg}}
   \]

   Where:
   
   - **SED (mg/kg bw/d)**: Systemic Exposure Dose
   - **DAa (µg /cm²)**: Dermal Absorption as amount per surface, resulting from an assay under in-use mimicking conditions
   - **SSA (cm²)**: Skin Surface Area expected to be treated with the finished cosmetic product (see Table 4 in Section...
2) **Dermal absorption reported as a percentage of the amount of substance applied** (6):

It is clear that the percentage of dermal absorption will only be of value when calculated from *in vitro* studies with doses, concentrations and amounts mimicking, but not exceeding the intended use conditions. Otherwise, the studies may result in an underestimation of the penetration.

\[
\text{SED} = \text{E}_{\text{product}} \times \frac{C}{100} \times \frac{\text{DA}_p}{100}
\]  

(6)

Where:

- SED (mg/kg bw/day) Systemic Exposure Dose
- E\text{product} (mg/kg bw/day) Estimated daily exposure to a cosmetic product per kg body weight, based upon the amount applied and the frequency of application (for calculated relative daily exposure levels for different cosmetic product types, **Tables 3A** and **3B**, Section 3-3.4.2).
- C (%) Concentration of the substance under study in the finished cosmetic product on the application site
- DA\text{p} (%) Dermal Absorption expressed as a percentage of the test dose assumed to be applied in real-life conditions

If the actual number of applications differs from the standard application frequency assumed for deriving the default values in **Tables 3A** and **3B**, the SED for the respective product category will have to be adapted accordingly.

3-3.5.4.1 **Calculation of the inhalation SED (SED\text{inh})**

Inhalation can occur after volatilisation of a dermally applied substance or after spraying a pump or propellant spray.

For calculating inhalation exposure to a substance after volatilization (7), the daily product exposure can be multiplied by the substance concentration and a suitable, conservative evaporating fraction (the worst-case parameter value for SED\text{inh} would be 1).

\[
\text{SED}_{\text{inh}} = \text{E}_{\text{product}} \times \frac{C}{100} \times \text{f}_{\text{evap}}
\]  

(7)

Inhalation exposure after spraying can be calculated by assuming instant release in a defined box (1-Box model) or a 2-Box model according to (for calculations for the 1-Box model a\text{inh-2} is zero):

\[
\text{f}_{\text{evap}} = \frac{1}{1 + \frac{\text{BW}}{\text{BW}_{\text{avg}}}}
\]  

where

- BW (kg bw) human body weight (default value: 60 kg)
- BW_{avg} average human body weight

3-3.4.2 for SSA values per product type)
By using a 2-Box model the SED\(_{\text{inh}}\) can be calculated according to the equations (8-10) below (adapted from Rothe \textit{et al.}, 2011). For possible parameterization see Appendix 11.

\[
\text{SED}_{\text{inh}} = (a_{\text{inh},1} + a_{\text{inh},2}) \times f_{\text{ret}} \times f_{\text{resp}} \times f_{\text{appl}}/\text{bw} 
\]

(8)

\[
a_{\text{inh},1,\text{inh},2} = a_{\text{expo}} \times f_{\text{inh}} \times t_{1,2} / V_{1,2} 
\]

(9)

\[
a_{\text{expo}} = a_{\text{product}} \times C_{\text{product}} \times f_{\text{air}} 
\]

(10)

With

- \text{SED}_{\text{inh}} (mg/kg bw/d) systemic exposure dose from inhalation exposure
- \(a_{\text{inh},1,\text{inh},2}\) (mg) potential substance amount inhaled during boxes 1 or 2 with \(V_{1,2}\), resp.
- \(f_{\text{ret}}\) fraction of substance retention in the lung (inhaled – exhaled)
- \(f_{\text{resp}}\) respirable fraction (different for pump and propellant sprays)
- \(f_{\text{appl}}\) (day\(^{-1}\)) frequency of application
- \(\text{bw}\) (kg) bodyweight
- \(t_{1,2}\) (min) duration of exposure in Box 1 or 2, respectively
- \(V_{1,2}\) (L) volume of Box 1 or 2, respectively
- \(a_{\text{expo}}\) (mg) amount of substance available for inhalation
- \(f_{\text{inh}}\) (L/min) inhalation rate
- \(a_{\text{product}}\) (g) sprayed amount of product
- \(C_{\text{product}}\) (mg/g) concentration of substance in the product
- \(f_{\text{air}}\) air-borne fraction

For the calculation of EA, the effective concentration of substance in the product should be used by treating the propellant gas as part of the product. Otherwise the propellant fraction can be accounted for as proposed by Rothe \textit{et al.}, 2011.

### 3.3.5.5 Aggregation of the systemic dose

If all product categories have the same uptake rate or fraction, the aggregated SED can be calculated by multiplying the route-specific aggregate external exposure with this uptake rate or fraction. If some product categories are taken up at a different rate than the others, the single external exposures need to be multiplied with the specific uptake rates, and then aggregated.

If aggregation should be done over routes, the route specific SEDs can be added up. In some cases (like \textit{e.g.} when metabolism is different for the different routes), a PBPK model needs to be applied for aggregating over routes.

### 3.3.5.6 Human biomonitoring

In most risk assessment frameworks for chemicals, the default approach to calculate exposure is to assess intake from different sources and different routes of exposure. Different sources and routes are often assessed separately without aggregating exposure. This approach includes various uncertainties and depending on the scope of the assessment may over- or underestimate the real uptake. Overestimation may result from combining several conservative parameters in a deterministic assessment, whereas real-life exposure may be underestimated by not taking into account all relevant sources.

Human Bio Monitoring (HBM) is therefore an important tool to survey the real life internal exposure of humans resulting from ‘total’ exposure to chemicals \textit{via} different routes (lung, skin, digestive tract). By providing more accurate data on actual internal exposure, inclusion of HBM data could improve human health risk assessment to consumer products for both the general population (exposure \textit{via} air, consumer products, drinking water and food) as well as
for workers (exposure via inhalation and/or skin), separately, or as part of the population (Santonen, 2018).

3-3.5.6.1 Definition

HBM is a systematic, continuous, or repetitive collection of biological samples for analysis of chemical substances, metabolites or specific non-adverse biological effects to assess exposure and health risk of exposed subjects, comparing the data observed with reference levels and, if necessary, leading to interventions (Zielhuis, 1984).

For the assessment of non-adverse biological effects the term "Effect-Monitoring" is also used.

3-3.5.6.2 Fields of Application

Besides the use of HBM for exposure assessment, population based HBM has emerged to investigate the possible association between internal exposure to certain substances and human health status and trends of exposure over time.

For cosmetic ingredients, the risk of systemic effects is largely determined by skin absorption, which can be measured in vitro (OECD 428) (Section 3-3.5.1.1 In case of uncharged small-size lipophilic substances, there may be a significant absorption, which may be a cause of concern for low-dose biologically active molecules. In that situation, studies measuring the unchanged compound or its metabolite in urine or blood of volunteers may be valuable. For aggregate exposure, biomonitoring data may be useful to estimate the internal dose of exposure resulting from different sources and routes of exposure (CMRs, Section 3-6.6). These studies may provide an accurate estimate of the systemic effective dose in humans under in-use conditions. Quantification by using biomarkers of exposure is increasingly used to provide an integrated measure of a person’s multiple chemical-specific exposures. Pharmacokinetics should also be taken into account (e.g. non-persistent, semi-volatile chemicals are metabolised quickly).

It is difficult with HBM to determine the contribution of a specific source (e.g. exposure to a substance in a cosmetic product) to the overall measured internal dose of exposure when other (non-cosmetic) sources for uptake and exposure also contribute considerably to the overall exposure. In such a case, HBM data and aggregate exposure modelling could support each other in risk assessment. Aggregate exposure modelling serves to determine the relative contribution of a product to the overall exposure, whereas HBM serves to evaluate whether the model over- or underestimates the real exposure. Back-calculation from biomonitoring data to external exposure data is possible but this requires additional information (e.g., toxicokinetic data in humans).

HBM data may also provide insight into the biotransformation and elimination of the substance in humans i.e. toxicokinetic aspects that with the ban of animal studies will be increasingly difficult to document. If adequately applied (i.e. toxicokinetics and metabolism of a substance are taken into account), HBM data can support and complement information on all aspects of ADME of a cosmetic substance, which are addressed in the safety evaluation dossier. HBM may also complement the results of further in vitro methods and animal studies, which are usually used for exposure assessment and for risk assessment.

Especially in view of the prohibition of in vivo animal studies on cosmetic substances, HBM makes it possible support risk assessment by providing in vivo information, also directly in humans without the need for interspecies extrapolation, or the limitation of a small number of subjects involved in human volunteer studies. If sufficient experimental animal data are available, interspecies variation between animals and humans can also be addressed using HBM.
3-4 RELEVANT TOXICOLOGICAL TOOLS FOR THE SAFETY EVALUATION OF COSMETIC INGREDIENTS

The SCCS has been closely following the progress made with regard to the development and validation of alternative methods and updated its NoG on a regular basis taking progress into consideration.

Besides validated alternatives, the SCCS may also accept, on a case-by-case basis, methods that are scientifically valid as new tools (e.g., “-omics” technology) for the safety evaluation of cosmetic substances. Such valid methods may not have necessarily gone through the complete validation process, but the Committee may consider them acceptable when there is a sufficient amount of experimental data proving relevance and reliability and including positive and negative controls.

According to the Cosmetics Regulation, the experimental studies have to be carried out in accordance with the principles of Good Laboratory Practice (GLP) laid down in Council Directive 87/18/EEC. All possible deviations from this set of rules should be explained and scientifically justified (SCCNFP/0633/02).

3-4.1 NEW APPROACH METHODOLOGY (NAM) AND NEXT-GENERATION RISK ASSESSMENT (NGRA)

Whereas the terminology of “Alternative Test Methods (ATMs)” does not cover all available tools e.g., in silico methodology, the more general term, New Approach Methodology (NAM) has been introduced. As for cosmetics and their ingredients, testing and marketing bans apply with respect to animal use and also the obligation exists to only use validated replacement alternatives, the need for validated non-animal alternative methods for chemical hazard assessment is much more important in Europe for compliance with the Cosmetics Regulation than for other regulatory frameworks. NAMs may include in vitro, ex vivo, in chemico and in silico methods, read-across, as well as combinations thereof. Therefore, before any testing is carried out for safety evaluation, all information on the substance under consideration should be gathered from different available means. A set of criteria, universal across initiatives, to evaluate NAMs fit-for-purpose was developed by a multi-stakeholder group and may support greater consistency across different initiatives (Parish et al., 2020).

Many efforts are ongoing to modernise toxicological safety evaluation and to look for non-animal methodology that can be used for the risk assessment of compounds that after long-term exposure could be at the origin of systemic toxicity. One of these approaches is referred to as NGRA (USEPA, 2014). The principles underpinning the application of an NGRA to cosmetics have been defined by the International Cooperation on Cosmetics Regulation (ICCR), a platform of regulators and cosmetics industry from the EU, the US, Japan, Canada and Brazil (Dent et al., 2018). NGRA is a human-relevant, exposure-led, hypothesis-driven risk assessment designed to prevent harm. It integrates several NAMs to deliver safety decisions relevant to human health without the use of experimental animals. An NGRA should be conducted using a tiered and iterative approach, following an appropriate literature search and evaluation of the available data, and using robust and relevant methods and strategies. Given the novelty of NGRA and the current lack of regulatory guidance on the use of a variety of NAMs in decision-making, it is important that the assessment should be transparently documented and explicit about the logic of the approach and sources of uncertainty (Dent et al., 2018). A general NGRA workflow is described in Figure 5 (Berggren et al., 2017). The tools useful for safety evaluation of cosmetic ingredients, which could also be used in case NGRA would be taken as a possible workflow in the future, are described in chapters 3-4.2 to 3-4.14. Threshold of Toxicological Concern (TTC) and internal TTC (iTTC) approaches as a risk assessment tools are described in 3-5.2.
The Methodology Working Group of the SCCS organised a workshop in February 2019 to discuss the key issues with regard to the use of NAMs for the safety evaluation of cosmetic ingredients (Rogiers et al., 2020). The aim was to progress from concept to the practical use of NGRA with focus on systemic toxicity. The already existing NGRA for skin sensitisation was not covered in the workshop. The progress made in this field is taken up under 3-4.7.2. Several case studies were presented showing the feasibility of conducting NGRA for systemic effects of cosmetic ingredients e.g. coumarin in face cream and body lotion (Baltazar et al., 2020), highlighting some critical aspects such as the need for sufficient biological coverage in terms of the mechanisms of action and cell types used, and the presence of a clear tiered workflow. Physiologically based kinetic (PBK) modelling and characterisation of some stress pathways involved were hereby applied (Moxon et al., 2020; Hatherell et al., 2020). Other examples given were parabens (EU-ToxRisk project under Horizon 2020) and the hair dye 2-methyl-1,4-benzenediamine (Goebel et al., 2014). The conclusion was that progress was clearly made, but that more examples were needed to create confidence that NGRA is protective, also for new compounds (Rogiers et al., 2020).

As NGRA for cosmetic ingredients does not try to predict toxicity thresholds, but rather looks for a safe concentration of an ingredient in a particular product, the question of how to prevent off-target toxicity was posed in a Cosmetics Europe Workshop on safety pharmacology screening for cosmetic relevant chemicals, which took place 21-22 November 2020. The initiative was taken to discuss whether “secondary pharmacology”, as used by the pharmaceutical industry in early drug development of lead compounds, using a relatively limited panel including transporters, ion channels, enzymes, nuclear receptors, etc., could be explored for its utility for cosmetic ingredients. It could open additional ways to create trust in the NGRA approach of safety evaluation. More meetings will follow. The cosmetic industry will use the term “pharmacology profiling”.

A number of case studies outside the cosmetic field, in which NGRA was applied, have been published. This was done for the hazard characterization of the triazole fungicides (Van der Ven et al., 2020) and the industrial chemical benzene (Luijten et al., 2020). For the assessment of genomic damage of substances in general, a conceptual framework for a next generation testing strategy was made available (Dearfield et al., 2017).
**Fig. 5.** Framework of the New Generation Risk Assessment (NGRA) (adopted from Berggren et al., 2017 and Dent et al., 2018). TTC: Threshold of Toxicological Concern; MoA: Mode of Action. Copyright from Elsevier, first published in Computational Toxicology, 4, 2017.

### 3-4.2 Adverse Outcome Pathway (AOP)

An AOP is an analytical construct that describes a sequential chain of causally linked key events at different levels of biological organisation that lead to an adverse health or ecotoxicological effect. An AOP starts with a Molecular Initiating Event (MIE), which is the chemically induced perturbation of a biological system at the molecular level that eventually leads to a specific adverse outcome. The MIE triggers a sequence of Key Events (KEs) that occur at the cellular or organ level and are causally linked to the adverse outcome. The AOP framework has been taken up by the OECD, providing a website to follow new developments on this subject ([https://aopwiki.org/](https://aopwiki.org/)). OECD 2017a, 2018 give guidance on how to document, present and assess the relevance and adequacy of an AOP. The AOP concept has been applied to a number of human-relevant toxicological endpoints including skin sensitisation (OECD, 2012b) (see Section 3-4.7). The quantitative aspect is, however, still a weak point or even absent.

AOPs can be used to support the development of Integrated Approaches to Testing and Assessment (IATA) and Defined Approaches (DA) (OECD 2012b, 2014b, 2017a, 2017b; Tollefsen et al., 2014).

An **IATA** is a pragmatic approach that exploits and weighs existing information, including human data and exposure information, alternative methodologies, such as *in chemico* and *in vitro* assays, and tailored strategies for the purpose of chemical evaluation with applications in risk assessment (Tollefsen et al., 2014; Patlewicz et al., 2015). While IATAs provide a platform for data integration and a means for targeted testing for a specific purpose, it is not necessarily framed by a mechanistic rationale. AOPs could be used to provide this mechanistic basis and thus to identify data gaps or to contextualise a diverse range of existing data (Tollefsen et al., 2014; Delrue et al., 2016: OECD 2017b; Sakuratani et al., 2018).
A DA consists of a fixed-data interpretation procedure applied to data generated with a defined set of information sources to derive a result that can either be used on its own, or together with other information sources within an IATA, to satisfy a specific regulatory need (OECD, 2017b).

3-4.3 **In silico** Assessment of Toxicological Hazard

In the absence of a recourse to *in vivo* testing, various *in silico* methods can offer a rapid, cost-effective, and ethical approach for estimating the toxicological hazard of a cosmetic ingredient. The *in silico* models and tools are based on principles, rules and structural alerts that have been derived from the relationship(s) between chemical structure and toxicity of a group of related substances.

The field of *in silico* toxicology has undergone a lot of scientific developments over the past few decades with the availability of large property/effect databases, powerful data-mining tools, diverse statistical algorithms and soft-computing techniques. These include predictive computational models based on Structure-Activity Relationship (SAR) and Quantitative Structure-Activity Relationship (QSAR), as well as computational tools for read-across of data from structurally or functionally similar substances to a target (untested) substance. This has also led to the development of hybrid models that derive toxicity estimates from a combination of knowledge-based rules and statistically derived models (Benfenati, 2012).

A number of toxicity expert systems are also available that are based on a combination of structure-activity rules, structural alerts, and/or (Q)SAR models (see below). A number of *in silico* models and tools is currently available that cover a wide variety of chemical types and many of the key toxicological endpoints that are required for risk assessment of chemical substances. Out of these, those that fulfil the quality and reliability criteria, as set out by the OECD (2014), can be considered for use in regulatory hazard/risk assessment.

3-4.3.1 **In silico** Toxicity Models

The toxicity estimates derived from a non-testing approach, such as a (Q)SAR model, can only be as reliable as the chemical and toxicological data and the rules/algorithms used to build it, the degree to which it was tested and validated, and depending on whether the query substance is covered within its applicability domain (*i.e.* the model’s prediction space). Because each model/system has a finite number and type of chemical structures behind it, there will always be a limit to its applicability domain. In this regard, an *in silico* model/system is only considered appropriate for regulatory use if it has been developed in accordance with the stringent quality criteria and the validation principles laid down by the OECD in 2004 ([www.oecd.org/chemicalsafety/risk-assessment/37849783.pdf](http://www.oecd.org/chemicalsafety/risk-assessment/37849783.pdf)). This means that a (Q)SAR model/system not only needs to have been based on high quality chemical and toxicological data, but it should also address a defined endpoint, be based on unambiguous rule(s)/algorithm(s), clearly define the applicability domain, provide appropriate measures of the goodness-of-fit, robustness and predictivity, and where possible, also provide a mechanistic interpretation.

A few such models/systems are available in the form of both commercial and free-access software platforms that may be considered for use in regulatory hazard/risk assessments. The EU project ANTARES has carried out assessment of the validation characteristics of a range of (Q)SAR models for various (eco)toxicological and environmental endpoints relevant to data requirements under the chemical legislation REACH (Registration, Evaluation, Authorisation and restriction of Chemicals). The project’s website ([http://www.antares-life.eu/](http://www.antares-life.eu/)) provides a list of the currently available free-access and commercial *in silico* models and tools.

ECHA (2016) has published a document on how to use and report results from QSAR models.
Examples of the free-access *in silico* systems include the OECD QSAR ToolBox that provides a versatile suite of programs for the prediction of different toxicity endpoints based on categorisation, (Q)SAR models, and read-across ([www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm](http://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm)). Other examples of free-access *in silico* models/systems include Hazard Evaluation Support System (HESS) for the assessment of repeated-dose toxicity ([www.nite.go.jp/en/chem/qsar/hess-e.html](http://www.nite.go.jp/en/chem/qsar/hess-e.html)); and the expert systems such as Cramer Decision Tree (Lapenna and Worth, 2011) that is based on structural alerts and expert knowledge; the Benigni-Bossa Rule Base (Benigni et al., 2008) that is based on structural alerts and QSARs for genotoxicity and carcinogenicity; the Toxicity Estimation Software Tool (T.E.S.T.) that is based on an ensemble of QSAR models ([www.epa.gov/chemical-research/toxicity-estimation-software-tool-test](http://www.epa.gov/chemical-research/toxicity-estimation-software-tool-test)); and the VEGA QSAR platform that is based on (Q)SARs and other *in silico* tools ([www.vega-qsar.eu](http://www.vega-qsar.eu)).


A QSAR Model Reporting Format (QMRF) has also been developed by the JRC and EU Member State authorities for summarising and reporting key information on QSAR models, including the results of any validation studies. The information is structured according to the OECD validation principles.

The ICCR has reviewed the use of *in silico* methods for safety evaluation of cosmetic ingredients. The ICCR report (2014) has concluded that the current use of *in silico* approaches for safety evaluation of cosmetic ingredients is largely limited to internal decision making both at the industry and at the regulatory levels, and that they have not yet been adopted as a mainstream alternative to testing methods.

This is because different models and systems may have been built using different datasets, rules and/or algorithm(s), and therefore interpret chemical structures and toxicological data in different ways. Each model/system also reflects a different level of uncertainty and variability associated with the data used for developing it, the modelling process used, and the differences in the applicability domains. In view of this, a high quality *in silico* model/system needs to provide not only the toxicity estimates but also a measure of uncertainty in the results.

The SCCS has published a Memorandum on the use of *in silico* methods for assessment of chemical hazard (SCCS/1578/16). The memorandum has identified a number of limitations and barriers in regard to the use of *in silico* models/systems in regulatory risk assessment of chemicals. These include the fact that regulatory risk assessors use data mainly from ‘validated’ methods for risk assessment, they also consider that virtually none of the currently available *in silico* models/systems carries an authoritative ‘validation’ tag. Other limitations of *in silico* methods include inability of most of the free-access models/systems to make precise estimates of the toxicity of different stereo isomers of chemical substances, inorganic substances, and some other types of materials (*e.g.* nanomaterials). However, despite the limitations in regard to official validation of *in silico* methods, some of the currently available high - quality models and tools can provide additional supporting evidence that can be used as part of the weight of evidence for risk assessment of cosmetic ingredients. The outcome of *in silico* assessment can also provide useful insights to help identify a toxicological hazard that can further guide the planning of more focused further (*in vitro*) testing.

### 3-4.3.2 Read-across

Read-across methods derive the estimates of toxicity of a query (untested) substance from the existing data on other structurally or mechanistically ‘similar’ compounds.

A number of computational tools are available that allow the selection of closely-similar analogues for data read-across on the basis of structure-activity principles and rules

---

*Mention of any *in silico* model/system in this document does not constitute an approval of its quality, or recommendation for use by the SCCS.*

---

46
In this regard, *in silico* models based on k-Nearest Neighbour (kNN) algorithm identify analogous compounds that are most closely related to the target compound. Examples of *in silico* platforms that incorporate kNN based models include VEGA and TEST. A number of other programs have been designed specifically for read-across (Patlewicz et al., 2017). Examples include ToxRead (www.vegahub.eu/download/toxread-download/) which also shows chemical analogues in a graphic format, gives reasoning for relevance of the effect to the target compound, and provides a description of the statistical importance of each rule.

The OECD toolbox also provides a means for read-across from its comprehensive databases and/or additional datasets that can be added by the users. Similarly, AMBIT (http://cefic-lri.org/toolbox/ambit/) and Toxmatch (https://eurlevam.jrc.ec.europa.eu/laboratoriesresearch/predictive_toxicology/qsar_tools/txoxmatch) also provide useful means for identifying similar substances and read-across.

It needs to be emphasised that read-across should be carried out using appropriate systems/tools that allow impartial selection of closely related analogues on the basis of structure-activity based rule/algorithm. This is of utmost importance to avoid any subjective selection and use of only a few analogues selected randomly on the basis of personal choices or judgement.

Furthermore, the most crucial prerequisite for a reliable read-across is the appropriate selection of similar/analogous substances. Thus, for the outcome of a read-across to be reliable, the database used needs to be of high quality and sufficiently large to provide a reasonable number of the analogues belonging to the same type/class and/or the mode of action, and the *in silico* tool/system used needs to be transparent in terms of searching the database for the analogues. Unlike (Q)SAR models, only a few closely related structural/mechanistic analogues are generally sufficient for the purpose of read-across. However, all analogues that are found within the generally accepted criteria for similarity (appropriately ≥70% match), should be analysed and documented. The final conclusion of read-across should be justified by expert opinion, and the exclusion of any analogue from read-across (e.g. due to a structural or mechanistic anomaly) must be explained and justified.

In summary, whilst *in silico* models and read-across methods provide a useful non-testing means for deriving estimates of toxicity of untested compounds that do not use animals, each model can have certain limitations that can impact the reliability of the results, especially when assessing different chemical types and toxicological endpoints. Therefore, the SCCS considers the use of a single *in silico* model/system to be inadequate and recommends the use of more than one relevant model/system to increase the reliability of the derived toxicity estimates. Wherever possible, a combination of *in chemico* (e.g. grouping and other chemical analogy approaches), *in silico* (e.g. QSAR models) and read-across methods should be applied to derive estimates of toxicity before any experimental testing is considered. In the view of the SCCS, the results of *in silico* toxicity assessment are more useful for hazard assessment when they are integrated with other sources of evidence (e.g. *in vitro* results) into an overall weight of evidence (WoE) (SCCS/1578/16; EFSA, 2017a). It should also be appreciated that the use of *in silico* models and tools, and interpretation of the results, requires expert judgement, appropriate documentation and justification, and therefore must not be treated as the outcome of a ‘black box’ technology.

### 3-4.4 Acute Toxicity

The term **acute toxicity** means those adverse effects occurring following oral or dermal administration of a single dose of a substance, or multiple doses given within 24 hours, or an inhalation exposure of 4 hours (Regulation (EC) No 1272/2008).

In light of the animal testing ban for cosmetic ingredients (see section 1 and **Appendix 3**), data on acute toxicity is not mandatory for assessing the safety of cosmetic ingredients for consumer uses. A WoE approach may be sufficient - such as justified conclusions from
chemical grouping/read-across, (Q)SAR, *in vitro* studies, or when accessible, repeated dose toxicity studies. Relative non-testing information sources on acute toxicity such as available approaches, (Q)SAR software packages, a list of databases from where acute toxicity data may be retrieved, can be found in ECHA-17-G-18-EN. Some generic alternative approaches, mostly referring to read-across and physico-chemical properties, are present in (OECD, 2017c).

If data on acute toxicity *in vivo* are available, these data should be provided. It should be noted, however, that safety evaluation will be based on (sub)chronic toxicity studies.

### 3-4.4.1 Acute oral toxicity

**A. NAMs**

The only validated *in vitro* method existing at present for acute oral toxicity (EURL ECVAM endorsed) is the 3T3 NR (Neutral Red) uptake test, applicable for non-classified chemicals, based on a cut-off of LD50>2000 mg/kg bw (JRC, 2013). EURL ECVAM has issued recommendations concerning the validity and limitations of this *in vitro* test (EURL ECVAM, 2013). An OECD acute toxicity waiver guidance document (OECD 2017c) includes, among other criteria, the possibility to waive the acute oral toxicity study based on the results of an alternative test or test battery, if the LD50 is predicted to be greater than 2000 mg/kg.

**B. *In vivo* methods**

The *in vivo* acute oral toxicity test was originally developed to classify the hazard of chemicals based on their LD50 value. LD50 values are also used to trigger the labelling of compounds with respect to acute toxicity (2008/1272/EC).

The original test method (EC B.1, OECD 401) has been replaced by alternative methods. These are still animal tests. Therefore, results generated via these tests are only allowed when performed before the testing and marketing bans were fully applied, or if the data were obtained in order to be in compliance with other (non-cosmetics) legislation e.g. REACH. The following refinement/reduction tests have been validated and consist of:

- The **fixed dose method** (EC B.1bis, OECD 420) abandons lethality as an endpoint and is designed not to cause death, marked pain or distress to the animals.

- The **acute toxic class method** (EC B.1 tris, OECD 423) allows the determination of a range of exposure doses where lethality is expected. The test follows a complex stepwise dose scheme. Nevertheless, it offers, as a main and important advantage, a significant reduction in the number of animals tested.

- The **up-and-down procedure** (OECD 425) allows an estimation of the LD50-value and confidence intervals. The guideline significantly reduces the number of animals used.

### 3-4.4.2 Acute dermal toxicity

No validated non-animal alternatives for the *in vivo* acute dermal toxicity test (EC B.3,) are currently available, however the updated OECD guideline 402 for the **fixed dose procedure** is more in line with the 3R’s principles. Still, draft OECD TG 434 “Acute Dermal Toxicity, Fixed Dose Procedure” (under drafting) uses fewer animals and less suffering.
3-4.4.3 Acute Inhalation Toxicity

Currently no validated non-animal alternative exists for the replacement of the 'in vivo' acute inhalation toxicity test (OECD 403). The latter was revised in 2009 (OECD 403, EC B.2). Furthermore, a reduction and refinement method (EC B.52, OECD 436), describes the acute toxic class method by the inhalation route. OECD 433 is a guideline of the fixed concentration procedure by inhalation.

3-4.5 Skin Corrosion and Skin Irritation

3-4.5.1 Skin Corrosion

Skin corrosion is defined as irreversible damage to the skin, namely visible necrosis through the epidermis and into the dermis, following the application of a test substance for up to 4 hours. Corrosive reactions are typified by ulcers, bleeding, bloody scabs, and, by the end of observation at 14 days, by discolouration due to blanching of the skin, complete areas of alopecia, and scars (EC B.4, OECD 404).

Corrosivity could occasionally occur after a manufacturing error or product misuse. A cosmetic substance that has the intrinsic property to be corrosive is not necessarily excluded for use in cosmetics. An example is potassium hydroxide KOH, the corrosivity of which depends on the final concentration, the pH, the presence of "neutralising" substances, the excipient used, the exposure route, etc.

A. NAMs

For skin corrosion testing, at present, there are three test guidelines on in vitro replacement alternatives:

1) The Rat Skin Transcutaneous Electrical Resistance (TER) test which uses excised rat skin as a test system and its electrical resistance as an endpoint (EC B.40, OECD 430).

2) The Reconstructed human Epidermis (RhE) Test Method which includes four validated commercialised human skin models i.e. EpiSkin™, EpiDerm™ SCT (EPI-200), SkinEthic™ RHE and epiCS® (former Epidermal skin test 1000). They all consist of reconstructed human epidermal equivalent and use cell viability as an endpoint (EC B.40bis, OECD 431). Only the EpiSkin™ and EpiDerm™ models are included in EC B.40bis.

3) The In vitro Membrane Barrier Test Method (OECD 435), including the Corrositex® test method, which has not been adopted in the European legislation.

B. In vivo methods:

The OECD 404 test is no longer allowed for cosmetics and their ingredients. Data obtained from the in vivo skin corrosion/dermal irritation test should only be provided when already available for a test performed before the animal testing ban or if the data were obtained for the purpose to be in compliance with other (non-cosmetic) legislations.

3-4.5.2 Skin Irritation

Dermal irritation is defined as the production of reversible damage of the skin, following the application of a test substance for up to 4 hours (EC B.4, OECD 404).
A. NAMs

For skin irritation testing, at present, there is one test guideline on in vitro replacement alternatives: The Reconstructed Human Epidermis (RhE) Test Method (OECD 439) includes four commercially available in vitro Skin Irritation Tests (SITs) which have been validated to be used as:

- a stand-alone replacement test for in vivo skin irritation testing, or as
- a partial replacement test, within a tiered testing strategy.

These are: EpiSkin™, EpiDerm™ SIT (EPI-200), SkinEthic™ RHE and LabCyte EPI-MODEL24SIT, EpiCS, Skin+®. Only the first four RhE models are included in EC B.46.

The endpoint used in the RhE test method is the cell-mediated reduction of MTT (3-(4,5)-dimethyl-2-thiazolyl-2,5-dimethyl-2H-tetrazolium bromide). In order to obtain better sensitivity, while maintaining similar specificity, a second endpoint, interleukin-1α (IL-1α) production, has been suggested. The in vitro test for skin irritation has been found useful by the SCCS for the testing of cosmetic ingredients. However, when reducing substances, hair dyes and colourants are present, which could interfere with the formazan colour evaluation (Lelièvre et al. 2007, SCCS/1392/10), HPLC separation prior to quantification should be carried out (SCCS/1392/10) for coloured and non-coloured test chemicals (Alépée et al., 2015). OECD 431 and 439 support this methodology.

OECD has developed a Guidance Document No. 203 on an IATA for skin corrosion and irritation (OECD, 2014b). The Guidance Document has two aims: i) to propose an integrated approach for replacing the strategy provided in the in vivo test guideline (OECD 404) and ii), to provide consistent information on key performance characteristics of each of the individual information sources comprising the IATA, and to provide guidance for decision making within the approach.

B. In vivo methods:

The OECD 404 test is no longer allowed for cosmetics and their ingredients. Data obtained from the in vivo skin corrosion/dermal irritation test should only be provided when already available for a test performed before the animal testing ban or if the data were obtained for the purpose to be in compliance with other (non-cosmetic) legislations.

3-4.6 Serious eye damage and eye irritation

Serious eye damage is tissue damage in the eye, or serious deterioration of vision, following application of a test substance to the anterior surface of the eye, which is not fully reversible within 21 days of application (EC B.5; OECD 405).

Eye irritation is defined as the occurrence of changes in the eye following the application of a test substance to the anterior surface of the eye, which are fully reversible within 21 days of application (EC B.5; OECD 405).

An IATA of this endpoint is available. The evaluation of serious eye damage and eye irritation should be carried out according to OECD Guidance (OECD 263).

A. NAMs

For serious eye damage testing and/or identification of chemicals not triggering classification for eye irritation or serious eye damage, at present, there are five OECD in vitro test guidelines adopted, which are subdivided in 3 groups (a, b, c). These are:
a) **organotypic test methods**, making use of tissues obtained from slaughterhouses (OECD 2011b):

1) The Bovine Cornea Opacity Permeability (BCOP) test method measures the ability of a test chemical to induce opacity and permeability in an isolated bovine cornea (EC B.47; OECD 437). In 2020, TG 437 was updated to allow the use of a LaserLight-Based Opacitometer (LLBO) next to the standard OP-KIT device that was used for opacity measurements in the validation of the BCOP test method. Also, the list of proficiency substances has been updated.

2) The Isolated Chicken Eye (ICE) test method evaluates the ability of a test chemical to induce toxicity in an enucleated chicken eye (EU B.48; OECD 438). Since the revision of TG 438 (June 2018), histopathological observations may also be used as an additional endpoint to improve the prediction of some specific products, i.e. non-extreme pH (2<pH<11.5) detergents and surfactants. A modified version of the decision criteria for chemicals requiring classification for eye hazard has also been included.

Both the BCOP and ICE test methods are able to identify:

(i) Chemicals that induce serious eye damage {Cat. 1 according to the United Nations Globally Harmonised System of Classification and Labelling of Chemicals (UN GHS) definitions}.

(ii) Chemicals that do not require classification for eye irritation or serious eye damage (No Category according to UN GHS definitions).

Two other organotypic assays, i.e. the Isolated Rabbit Eye and Hen's Egg Test-Chorio Allantoic Membrane (HET-CAM), have been developed but not implemented as an OECD guideline and may be useful in providing supportive evidence (JRC 2019, JRC 2020).

b) **cytotoxicity and cell function-based in vitro tests**, including 2 OECD guidelines:

3) The Short Time Exposure (STE) test method uses a rabbit corneal cell line to evaluate the eye irritation potential of a chemical by measuring its cytotoxic effect (EU B.68, OECD 491). The STE test method can be used to identify chemicals inducing serious eye damage (Cat. 1) and chemicals not requiring classification for eye irritation or serious eye damage. The STE test has limitations with respect to highly volatile chemicals and solid chemicals other than surfactants.

4) The Fluorescein Leakage (FL) test measures the toxic effects after a short exposure time of the test substance by an increase in permeability of sodium fluorescein through the epithelial monolayer of MDCK kidney cells cultured on permeable inserts (OECD 460). The FL test is recommended as part of a tiered-testing strategy for regulatory classification and labelling of severe eye irritants (Cat. 1), but only for limited types of chemicals (i.e. water-soluble substances and mixtures; strong acids and bases, cell fixatives and highly volatile chemicals have to be excluded).

For the Cytosensor Microphysiometer (CM) test method, the regulatory acceptance procedure has been discontinued because of lower priority.

c) **reconstructed human tissue (RhT)-based test methods**:

5) The Reconstructed Human Cornea-like Epithelium (RhCE) test method (EU B.69, OECD 492), evaluates the ability of a test chemical to induce cytotoxicity via the MTT assay. The adopted TG includes the HPLC/UPLC technique for measuring the formazan formation, for the evaluation of chemicals which may interfere with MTT-formazan measurement by direct reduction of MTT or colour interference. RhCE models can be used as in vitro methods to identify chemicals not requiring classification and labelling for eye irritation or serious eye damage. Consequently, these models are not suitable
for determining the potency of eye irritancy. At present, four validated eye irritation test (EIT) methods using commercially available RhCE models have been adopted: the EpiOcular™ EIT, the SkinEthic™ Human Corneal Epithelium (HCE) EIT, the LabCyte CORNEA-MODEL 24 EIT and the MCTT HCE™ EIT.

6) The Vitrigel-EIT method (OECD 494) is an in vitro assay using a hCE model fabricated in a Collagen Vitrigel Membrane (CVM) chamber. The eye irritation potential of the test chemical is predicted by analyzing the ability of the chemical to induce damage to the barrier function of the hCE model via measuring relative changes in TransEpithelial Electrical Resistance (TEER) over time. The Vitrigel-EIT method can be used to identify chemicals not requiring classification and labelling for eye irritation or serious eye damage within the limited applicability domain of test chemicals having pH > 5.0 (based on 2.5% weight/volume (w/v) preparation).

d) in vitro macromolecular test method, including 1 OECD guideline:

7) The Ocular Irritection® (OI) assay (OECD 496) is an acellular biochemical assay that evaluates the ocular hazard effects of test chemicals based on the premise that eye irritation and corneal opacity after exposure to irritating substances is the result of perturbation or denaturation of corneal proteins. The OI assay is recommended as part of a tiered testing strategy for solid and liquid chemicals under certain circumstances and with specific limitations (i.e. applicable to solid and liquid chemicals whose 10% solution dispersion (v/v or w/v as appropriate) has a pH in the range 4 ≤ pH ≤ 9.

The available replacement alternatives for serious eye damage and eye irritation testing cannot identify any mild eye irritancy potential.

So far, neither a single in vitro assay nor a testing battery has been validated as a stand-alone replacement for the in vivo test. Different decision trees for eye irritation were put forward (McNamee et al., 2009), but none can identify mild, moderate or non-eye irritancy (McNamee et al., 2009; Scott et al., 2010).

New test systems are under development using stem cells. These could generate new alternatives for in vitro ocular toxicity testing (Aberdam et al., 2017).

B. In vivo methods

The in vivo test (OECD 405; EU B.5) has been subject to refinement and reduction measures. It was also indicated that histopathology is an additional endpoint in ocular safety testing. The latest update has mainly focused on the use of analgesics and anesthetics. It is the only in vivo test method to assess the potential of a substance to cause acute serious eye damage / irritation.

The results from this test should be provided if already available from a test that was performed before the animal testing ban or if data were obtained for the purpose of compliance with other (non-cosmetic) legislations, e.g., REACH.

3-4.7 Skin sensitisation

A skin sensitiser is an agent that is able to induce specific immunological reactivity after contact with the skin and penetration into the epidermis. Once a person is sensitised, subsequent skin exposure at a sufficiently high concentration can provoke allergic contact dermatitis.

A. NAMs

In the last years, several NAMs have been developed, validated and regulatory accepted (Ezendam et al., 2016; Hoffmann et al., 2018) that address different KEs of the skin
sensitisation AOP (OECD, 2012) (Figure 6) (see introductory part of Section 3-4.3). This AOP consists of four mechanistic key events (KEs):

**MIE (KE1)** is the covalent binding of the chemical to proteins of the skin, leading to an immunogenic hapten-carrier complex in the epidermis. After this key event is triggered, two cellular events take place: keratinocyte activation (KE2) and dendritic cell activation (KE3). Dendritic cells recognise the hapten-carrier complex and mature to migrate out of the epidermis to the local lymph node. There, the dendritic cells present the small peptides of the hapten-carrier complex to the T cells, leading to T cell activation and proliferation (KE4). A pool of memory T cells is generated, ultimately leading to skin sensitisation (**adverse outcome**).

**Figure 6: AOP Covalent Protein binding leading to Skin Sensitisation** (taken from https://aopwiki.org/aops/40) MIE: molecular initiating event.

An overview of the NAMs for skin sensitisation that are currently included in the OECD and/or EU test guideline program is provided in **Table 6**. The OECD has clustered test methods that address the same KE of the AOP in one test guideline. Currently, NAMs are available that address MIE (442C), KE2 (442D) and KE3 (442E). There are currently no NAMs available in the OECD test guideline program that address KE4 (T cell activation and proliferation) (van Vliet et al., 2018).

Several NAMs for skin sensitisation are still being developed or validated (OECD, 2017b, Ezendam et al., 2016, Hoffmann et al., 2018) (**Table 6**). Three of these have been included in the work plan for the OECD Test Guidelines: the kinetic DPRA (kDPRA), the SENS-IS and Genomic Allergen Rapid Detection test for skin (GARDskin).

- **kDPRA**, is a modification of the standard DPRA (OECD TG 442C). In this test method, several concentrations of the test substance are incubated with the synthetic peptide for several incubation times. The reaction kinetics towards a synthetic cysteine-containing peptide is evaluated to predict the potency of the test substance (Wareing et al., 2017). A validation study for the kDPRA has been conducted and the outcome was submitted to the OECD in 2019 (Wareing et al., 2020).

- **SENS-IS** uses toxicogenomic analysis on 3D reconstituted epidermis (Episkin® RhE) to measure skin sensitisation potency. SENS-IS provides information on hazard as well as potency sub-categorisation (Cottrez et al., 2015). The SENS-IS assay has been validated in an industry-led study (Cottrez et al., 2016) and is under evaluation by EURL-ECVAM.

- **GARDskin** is an *in vitro* model that measures KE3 using gene expression profiling in the MUTZ-3 cell line (Johansson et al., 2011, 2014). The validation study is currently ongoing.
Table 6: NAMs for the assessment of skin sensitisation

<table>
<thead>
<tr>
<th><strong>AOP KE covered</strong></th>
<th><strong>OECD test guideline/ EU test method</strong></th>
<th><strong>Test method</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MIE (KE1): covalent binding to skin proteins</td>
<td>OECD 442C (2020) / EC B.59</td>
<td>Direct Peptide Reactivity Assay (DPRA)</td>
</tr>
<tr>
<td></td>
<td>In chemico skin sensitisation</td>
<td>Amino acid Derivative Reactivity Assay (ADRA)</td>
</tr>
<tr>
<td>KE2: keratinocyte activation</td>
<td>OECD 442D (2018) / EC B.60</td>
<td>ARE-Nrf2 Luciferase KeratinoSens™ Test Method</td>
</tr>
<tr>
<td></td>
<td>In vitro Skin Sensitisation Assays addressing the KE on keratinocyte activation</td>
<td>The ARE-Nrf2 luciferase LuSens test method</td>
</tr>
<tr>
<td></td>
<td>In vitro Skin Sensitisation Assays addressing the KE on activation of dendritic cells.</td>
<td>U937 Cell line Activation Test (U-SENS™)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interleukin-8 Reporter Gene Assay (IL8-Luc assay)</td>
</tr>
</tbody>
</table>

MIE: molecular initiating event; AOP: adverse outcome pathway; KE: key event

The currently available NAMs for skin sensitisation address a single key event of the AOP and are therefore often combined in testing strategies to cover multiple key events. In addition, individual test methods have some known technical limitations, which may lead to false-negative results. DPRA and ADRA, for example, have no metabolic capacity and are therefore unable to identify prohaptens, sensitisers that require metabolism to be activated. The in vitro assays that are currently available are capable of detecting prohaptens, hence, these cell lines do possess metabolic capacity (Patlewicz et al., 2016). For abovementioned reasons, a single alternative method cannot be used as a stand-alone assay for hazard identification and potency sub-categorisation of skin sensitisers. It is therefore recommended to combine these methods and other information sources (e.g., in silico tools) in an integrated approach, such as a DA or IATA. The skin sensitisation AOP is often used in the development of such integrated approaches (OECD, 2017b; Ezendam et al., 2016; Kleinstreuer et al., 2018). Different DAs have been proposed, some of them only provide a binary outcome (skin sensitiser or not), others provide information on potency subcategory or provide a surrogate EC3 value. For the latter, quantitative parameters of NAMs are used to predict potency. Additional work is ongoing to determine how well these in vitro concentration response data can be exploited in integrated approaches to accurately predict human potency.

B. In vivo methods

Three regulatory accepted in vivo laboratory animal test methods have been used to evaluate the potential of a substance to cause skin sensitisation, the Local Lymph Node Assay (LLNA), the Magnusson Kligman Guinea Pig Maximisation Test (GPMT) and the Buehler test (Table 7). The GPMT and Buehler tests are able to provide results on induction and elicitation; the LLNA and its variants only address induction.
Table 7: *In vivo* laboratory test methods for evaluation of skin sensitisation

<table>
<thead>
<tr>
<th>Species</th>
<th>Test method</th>
<th>Endpoint</th>
<th>Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>LLNA (radioactive method)</td>
<td>Cellular proliferation</td>
<td>OECD 429, EC B.42</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI ≥ 3</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>LLNA: DA (non-radioactive</td>
<td>Cellular proliferation</td>
<td>OECD 442A, EC B.50</td>
</tr>
<tr>
<td></td>
<td>method)</td>
<td>SI ≥ 1.8</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>LLNA: BrdU-ELISA (non-</td>
<td>Cellular proliferation</td>
<td>OECD 442B, EC B.51</td>
</tr>
<tr>
<td></td>
<td>radioactive method)</td>
<td>SI ≥ 1.6</td>
<td></td>
</tr>
<tr>
<td>Guinea pig</td>
<td>GPMT</td>
<td>Score of erythema and swelling</td>
<td>OECD 406, EC B.6</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Buehler test</td>
<td>Score of erythema and swelling</td>
<td>OECD 406, EC B.6</td>
</tr>
</tbody>
</table>

LLNA: Local Lymph Node Assay; GPMT: Guinea Pig Maximisation Test; SI: Stimulation Index
LLNA: DA: nonradiolabelled LLNA, modified by Daicel Chemical Industries
LLNA: BrdU-ELISA: nonradioactive modification of LLNA based on cell proliferation measured by 5-Bromo-2'-deoxyUridine

As presented in SCCP/0919/05, results from animal studies can be used to categorise skin sensitisers in three groups according to their sensitising potency: extreme, strong and moderate. The LLNA provides dose-response data that can be used to derive an EC3 value, which is the estimated concentration of a chemical necessary to give a 3-fold increase in lymph node cell proliferation compared to vehicle-treated controls (SI ≥ 3). This EC3 value is used to subcategorise skin sensitisers (Table 8) (ECB, 2002; Basketter *et al.*, 2005).

Table 8: Potency subcategorisation of skin sensitisers

<table>
<thead>
<tr>
<th>Category</th>
<th>EC3 value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extreme</td>
<td>≤ 0.2</td>
</tr>
<tr>
<td>Strong</td>
<td>&gt; 0.2 - ≤ 2</td>
</tr>
<tr>
<td>Moderate</td>
<td>&gt; 2</td>
</tr>
</tbody>
</table>

Because the guinea pig test methods often do not provide dose-response data, the intradermal induction concentration in the GPMT and the topical induction concentration in the Buehler test are used for subcategorisation (ECB, 2002; Basketter *et al.*, 2005). In the absence of LLNA data, this subcategorisation can be used as indicative for potency.

3-4.7.1 **Skin Sensitisation Quantitative Risk Assessment (QRA)**

QRA has been developed for fragrance substances, only. The basic principles of the QRA are presented in SCCP/1153/08. It is based on the dose of a sensitising chemical, not expected to cause induction of sensitisation (No Expected Sensitising Induction Level or NESIL), which may be derived from animal and human data. The NESIL is adjusted by a number of uncertainty factors (Sensitisation Assessment Factors, SAFs) in order to calculate an Acceptable Exposure Level (AEL). In addition, a Consumer Exposure Level (CEL) is calculated. The AEL is then compared with the CEL, whereby, for an acceptable risk, the AEL should be greater than or equal to the CEL. Within the IDEA project (https://www.ideaproject.info/)
the QRA was further refined by including aggregate exposure assessment and revising the SAFs.

A technical dossier describing the revised QRA (QRA 2) was submitted by the fragrance industry to the SCCS. After evaluation of the methodology, SCCS concluded that a lot of progress had been achieved since the initial publication of the QRA. Recently, a peer-reviewed publication on the QRA2 methodology was published (Api et al., 2020), summarising the progress made in this field so far. The SCCS considers that it is not yet possible to use the QRA2 to establish a concentration at which induction of sensitisation of a fragrance is unlikely to occur. Several aspects of the methodology are not clear and the scientific rationale behind the methodology needs to be better described. With some revision, this could be a useful methodology not only for safety evaluation of fragrance allergens, but potentially also for other cosmetic ingredients. (SCCS/1589/17).

In particular, in the case of new substances, post-marketing surveillance would be essential (see also SCCS/1459/11) to monitor that their use in cosmetics does not lead to allergic contact dermatitis in consumers, in line with the SCCS Memorandum on use of human data (SCCS/1576/15).

3-4.7.2 NEXT-GENERATION RISK ASSESSMENT APPROACH (NGRA)

NGRA developed for systemic toxicity of cosmetic ingredients (Berggren et al., 2017, see also Fig 5 under 3-4.1) has been used as a framework for skin sensitisation safety assessment (Gilmour et al., 2020), taking the same principles into consideration. A tiered workflow is applied as illustrated in Fig 7 for skin sensitisation.
**Fig 7:** Framework for skin sensitisation safety assessment (Gilmour *et al.*, 2020). S/NS: safe/not safe; DA: defined approach; WoE: weight of evidence; PoD: point of departure; RA+/RA−: risk assessment positive/negative outcome. Taken from Regulatory Toxicology and Pharmacology, 2020, Volume 116, Gilmour *et al.*, with permission from Elsevier.

For the SCCS, NGRA is a novel conceptual approach that offers the possibility to integrate existing data, read-across information and NAM information in a systematic iterative approach. Until the NGRA is assessed and accepted to be valid by the SCCS, submissions including NGRA for skin sensitisation will be evaluated by the SCCS on a case-by-case basis.

The key aspects of NGRA for skin sensitisation can be found in the publication by Gilmour *et al.*, 2020.

### 3-4.8 Repeated dose toxicity

Repeated dose toxicity studies are performed to investigate toxicological effects (excluding reproductive, genotoxic and carcinogenic effects) occurring as a result of repeated daily dosing with, or exposure to, a substance for a specific part of the expected lifespan of the test species.

**A. NAMs**

No validated alternative methods are available yet for determining the repeated dose toxicity of a substance, which poses a problem for the introduction of new compounds e.g. preservatives on the EU market as this assay usually provides the PoD of the compound under investigation (necessary for MoS calculation). Efforts are being made by the cosmetic industry to develop an NGRA strategy as an alternative for not having a PoD generated via *in vivo* methodology (see 3-4 and 3-4.1). The topic was extensively discussed in the February 2019 SCCS methodology workshop with the aim to progress from concept to the practical use of NGRA with a focus on systemic toxicity (Rogiers *et al.*, 2020). Several case studies were presented and progress has clearly been made, but more case studies and validated NAMs are needed to create the necessary confidence that NGRA is protective for new compounds and that unexpected side effects are not occurring.

**B. In vivo methods**

The following *in vivo repeated dose toxicity studies* with OECD guidelines are available:

1. Sub-acute oral toxicity (28 days) (EC B.7, OECD 407)
2. Sub-acute dermal toxicity study (28 days) (EC B.9, OECD 410)
3. Sub-acute inhalation toxicity study (28 days) (EC B.8, OECD 412)

2. Sub-chronic oral toxicity study: repeated dose 90-day oral toxicity study in rodents (EC B.26, OECD 408)
3. Sub-chronic oral toxicity study: repeated dose 90-day oral toxicity study in non-rodents (EC B.27, OECD 409)
4. Sub-chronic dermal toxicity study: repeated dose 90-day dermal toxicity study using rodent species (EC B.28, OECD 411)
5. Sub-chronic inhalation toxicity study: repeated dose 90-day inhalation toxicity study using rodent species (EC B.29, OECD 413)
In the case of the development of cosmetic ingredients that will be in contact with human skin and mucosae repeatedly, the SCCS is convinced that evaluation of the systemic toxicity is a key element in safety assessment.

3-4.8.1 The use of uncertainty factors (UFs) for extrapolation for study duration

This type of UF is used to take account of probable differences between the experimental setting from which the PoD is taken and the human real life situation (use scenario) in case substance-specific information is lacking.

For some cosmetic ingredients, dermal repeated dose toxicity studies are submitted. These studies, if of good quality, are taken into consideration by the SCCS as it is the most commonly used application route for cosmetics. In practice, however, oral route studies are often used for the MoS calculation to consider (worst case) systemic exposure. Oral repeated dose toxicity studies can be either subacute (28 days), subchronic (90 days) or chronic (taking 85% of lifetime).

The 90-day oral toxicity test in rodents was, historically speaking, the most commonly used repeated dose toxicity test for cosmetic ingredients. Based on the exposure and the short lifetime of cosmetic products (regularly changing ingredients and concentrations), the 90-day test provides a good indication of the target organs and the type of systemic toxicity.

In case only a 28-day study is available, the SCCS recommends applying a factor to take uncertainty into consideration to extrapolate from subacute (28 days) to subchronic (90 days) toxicity. Different values are being proposed and the choice is made on a case-by-case basis taking the strengths and weaknesses of the available studies into consideration. The SCCS commonly uses for such extrapolation a conservative UF of 3. Recently, Escher et al. (2020) provided data showing that in such a case a factor of 1.5 would be sufficient. When a scientifically sound 90-day study is available which allows for the determination of a clear PoD, the SCCS takes this study into account for calculating the MoS. An uncertainty factor is only included when some doubt exists with respect to the quality of the subchronic toxicity study and/or in the absence of further information supporting the PoD from the 90-day study (e.g. availability of a chronic study). Escher et al. (2020) proposed a factor of 1.5.

In other domains (environmental, food, ...) higher factors have been proposed, but these may contribute to a higher variance. In any case, the use of additional UFs needs to be carefully considered. Indeed, many authors warn that a composite UF may lead to over conservatism (Simon et al., 2016; Escher et al., 2020). In particular, in the case of aggregate exposure, using a deterministic exposure assessment multiplication of single UFs may lead to possibly overly conservative estimates (EFSA, 2012a).

The inhalation route was only rarely used in repeated dose toxicity testing of cosmetic ingredients due to the lack of relevance for the majority of cosmetic products. This exposure route is, however, important where a cosmetic ingredient is volatile or a product is intended to be used in an aerosolised, sprayable or powdered form that could lead to exposure of the consumer via inhalation. Because of the likelihood of high uncertainty in regard to different inhalable products and their modes of delivery, the SCCS recommends analysis of uncertainty on a case-by-case basis.

When reproductive toxicity studies are used to determine the PoD, the uncertainty factors for extrapolation for study duration are not used.

In sections 3.5.1.1 and 3.5.1.2 a number of default factors are discussed.
3-4.8.2 SELECTION OF PoD

In repeated dose toxicity studies, the target(s) organ(s) and critical endpoint(s) may be identified. The critical endpoint is defined as the first (in terms of dose level) adverse effect associated with the substance. This effect should be biologically relevant for human health and also in the context of cosmetic exposure. For example, local effects on the gastrointestinal tract, sometimes observed with irritants after oral exposure, are not considered relevant by the SCCS to be used for the MoS calculation. A BMD, NOAEL or LOAEL (PoD) is then derived for each study and the most relevant study in terms of quality, duration of exposure, and available PoD is then selected by the SCCS to be used for the safety evaluation. If the dose regimen of a study was limited to 5 days treatment per week, the derived PoD will be corrected by a factor of 5/7. In analogy, a correction will also be made for longer use periods.

3-4.9 REPRODUCTIVE TOXICITY

The term "reproductive toxicity" is used to describe the adverse effects induced (by a substance) on any aspect of mammalian reproduction. It covers all phases of the reproductive cycle, including impairment of male or female reproductive function or capacity and the induction of non-heritable adverse effects in the progeny such as death, growth retardation, structural and functional effects.

A. NAMs

No validated alternative method is yet available for reproductive toxicity that covers all different phases of the reproductive cycle (JRC 2019, JRC 2020).

Since the field of reproductive toxicity is very complex, it is expected that the various phases cannot be mimicked using one alternative method and that a battery of tests is needed. Three alternative methods, restricted to the embryotoxicity area, have been developed:

- The Whole Embryo Culture test (WEC)
- The MicroMass test (MM)
- The Embryonic Stem Cell Test (EST)

The last two tests were considered scientifically valid by the ECVAM Scientific Advisory Committee (ESAC) for placing a substance into one of the three following categories: non-embryotoxic, weak/moderate-embryotoxic or strong-embryotoxic. The WEC test is still an animal test and is considered scientifically valid only for identifying strong embryotoxic substances (ESAC, 2001).

These three tests might be useful in the CMR strategy for screening out embryotoxic substances. However, they cannot be used for quantitative risk assessment (Marx-Stoelting et al., 2009).

The complex endpoint of reproduction toxicity is not covered by the above systems.

Several in vitro methodologies, each covering one of the three biological components of the reproductive cycle (male and female fertility, implantation and pre- and postnatal development), were developed under the EU project ReProTect.

The tests reflect various toxicological mechanisms such as effects on Leydig and Sertoli cells, folliculogenesis, germ cell maturation, motility of sperm cells, steroidogenesis, the endocrine system, fertilisation, and on the pre-implantation embryo. Nevertheless, more information and research are needed until regulatory acceptance can be envisaged (Schenk et al., 2010).

An extensive review of the actual situation can be found in a JRC report (JRC 2019, JRC 2020). In view of the utmost importance of consumer safety, toxicological evaluation against some complex endpoints, such as reproductive toxicity, still necessitate the use of animals.
B. **In vivo methods**

The most commonly performed *in vivo* reproductive toxicity studies are:

1) Two-generation reproductive toxicity study (EC B.35, OECD 416)
2) Prenatal developmental toxicity study\(^7\) - rodent and non-rodent (EC B.31, OECD 414)

A "Reproduction/Developmental Toxicity Screening Test" (OECD 421) also exists, as well as a "Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test" (OECD 422).

The Extended One-Generation Reproductive Toxicity Study (EOGRTS) has been adopted by the OECD (OECD 443) and a Guidance Document has been established (OECD 2018). It offers several advantages compared to older OECD TGs and is extensively used:

- Compared to OECD TG 416 a significant number of animals can be saved.
- More parameters are addressed (*e.g.* clinical-chemical parameters as in repeated dose studies; developmental immunotoxicity and neurotoxicity in case such cohorts are included). Endocrine disruption endpoints are included- (*e.g.*, nipple retention, anogenital distance at birth, vaginal patency and balanopreputial separation)
- Increased statistical power with respect to parameters for reproductive toxicity
- Possibility for modification *e.g.*, to include new endpoints for the assessment of endocrine active chemicals disrupting the Hypothalamus-Pituitary-Gonad (HPG) axis, the somatotropic axis, the retinoid signalling pathway, the Hypothalamus-Pituitary-Thyroid (HPT) axis, the vitamin D signalling pathway and the Peroxisome Proliferator-Activated Receptor (PPAR) signalling pathway

A study report on reproductive toxicity or on prenatal developmental toxicity is in general only acceptable when it is based on tests that have been carried out before the animal testing ban or when generated for compliance with other (non-cosmetic) legislative frameworks; see Appendix 1, section 3 and Appendix 4).

### 3-4.10 MUTAGENICITY / GENOTOXICITY

#### 3-4.10.1 DEFINITIONS

**Mutagenicity:** a mutation is defined as a permanent change in the amount or structure of the genetic material. The terms ‘mutagenic’ and ‘mutagen’ are used for agents giving rise to an increased occurrence of mutations in populations of cells and/or organisms and applies both to heritable genetic changes that may be manifested at the phenotypic level and to the underlying DNA modifications (including specific base pair changes and chromosomal aberrations).

Germ cell mutations are those that occur during spermatogenesis/ovogenesis and appear in the egg or sperm (germ cells) and therefore can be passed on to the organism’s offspring. Somatic mutations are those that occur in cells other than the germ cells, and they cannot be transmitted to the next generation.

**Genotoxicity:** the more general terms ‘genotoxic’ and ‘genotoxicity’ apply to agents or conditions that alter the structure, information content, or segregation of DNA, including those which cause DNA damage by interfering with normal replication processes, or which alter its replication in a non-physiological manner (temporarily).

---

\(^7\) Often also named teratogenicity test
3-4.10.2  Mechanisms

There are several mechanisms that lead to genotoxicity. In general, DNA damage can arise through either primary or secondary mechanisms (Schins et al., 2007, Magdolenova et al., 2014, Evans et al., 2017). Primary genotoxicity can be either direct, where there is a direct interaction of genotoxic agent with DNA, or indirect, where the genotoxic effect is exerted via intermediate molecules (such as free radicals, as in oxidative stress). Secondary genotoxicity is driven by oxidative stress arising from inflammation caused by activation/recruitment of immune cells such as macrophages or neutrophils. Where the evidence suggests indirect mechanism (oxidative stress), or secondary mechanisms (e.g. inflammation and oxidative stress caused by overexpression of the immune cells) - a threshold may be derived from the toxicological data for use in safety assessment.

Based on recommendations of international groups of scientific experts (Dearfield et al., 2011), and in accord with EFSA (EFSA, 2011a) and the UK Committee on Mutagenicity (COM, 2011), the evaluation of the potential for mutagenicity of a cosmetic substance should include information on 1) mutagenicity at the gene level, 2) chromosome breakage and/or rearrangements (clastogenicity), and 3) numerical chromosome aberrations (aneuploidy). For this task, genotoxicity tests, which measure irreversible mutation endpoints (gene or chromosome mutations) should be used. Genotoxicity Indicator tests, which measure DNA damage without taking into account the consequences of this primary damage, can contribute to the weight of evidence approach but should not be used as stand-alone tests. Finally, before undertaking any testing, a thorough review should be carried out of all available data on the substance under assessment.

A.  NAMs

(i)  *In silico* methods for genotoxicity and carcinogenicity

- Genotoxic carcinogens (DNA reactive)

As explained in the testing strategy for mutagenicity/genotoxicity (Figure 8, section 3-4.10), the use of structure-activity relationship based *in silico* models and read-across can provide a useful indication of the mutagenic/genotoxic and carcinogenic potential of a cosmetic ingredient.

The regulatory requirements for testing certain categories of chemicals have led to a large database on genotoxicity over the past decades, in particular on bacterial reverse mutation (Ames) test, as well as on *in vitro* and *in vivo* micronucleus tests, and chromosomal aberration. As a result, there is a better understanding of the mechanisms of mutagenicity/genotoxicity via direct or indirect interaction of chemical substances with the genetic material, compared to certain other complex toxicity endpoints.

The knowledge deciphered from the available information has indicated that the chemicals that can cause mutagenic/genotoxic effects through direct interaction with DNA are either intrinsically electrophilic, or they can be transformed to electrophilic intermediates. However, some non-electrophilic chemicals may also cause genotoxic effects directly through reaction with nucleophilic moieties of proteins and nucleic acids or through direct or indirect DNA alkylation, acylation or adduct formation, or indirectly through generation of reactive oxyradicals. On the other hand, some chemicals may contain one or more structural alerts for genotoxicity but may not cause genotoxic effects because of their (higher) molecular weight, solubility, chemical reactivity, structural geometry, etc. (Plošnik et al., 2016).

The OECD QSAR Toolbox incorporates a number of databases on mutagenicity/genotoxicity and carcinogenicity that provide a valuable resource for read-across.

- The toolbox on *in vitro* genotoxicity includes bacterial mutagenicity ISSSTY; ECHA REACH; OASIS genotoxicity; EFSA pesticide genotoxicity.

- The databases on *in vivo* genotoxicity include ECHA REACH; ECVAM genotoxicity and carcinogenicity; EFSA pesticide genotoxicity; ISSMIC Micronucleus; OASIS Micronucleus,

- *in silico* methods (structure-activity based) for the prediction of carcinogenicity of chemical substances include the open-source tools LAZAR ([https://openrisknet.org/e-infrastructure/services/110/](https://openrisknet.org/e-infrastructure/services/110/)) and (Q)SAR models such Vega ([www.vegahub.eu/](http://www.vegahub.eu/)).

The availability of large amount of data on mutagenicity/genotoxicity and carcinogenicity has also enabled the identification of key molecular descriptors and structural alerts associated with mutagenicity/genotoxicity (e.g. Ashby and Tennant, 1988; Benigni and Bossa, 2008; Plošnik et al., 2016), and the development of several structure-activity based *in silico* (Q)SAR models and read-across systems. A number of these systems have been developed using high quality data and in accordance with the OECD (2014) criteria and were subjected to stringent assessments to verify their reliability for use in regulatory risk assessments.

- **Non-genotoxic carcinogens (DNA-non reactive)**

In comparison to genotoxic carcinogens, the identification of Non-Genotoxic Carcinogens (NGCs) is much more difficult because, unlike the direct or indirect interaction of genotoxic substances with DNA, the carcinogenic effects of NGCs may manifest from a variety of different mechanisms, not always relevant to humans, such as:

- Peroxisomal proliferation that may lead to increased cell proliferation or decreased apoptosis; inhibition of the gap junction intercellular communication, or DNA methylation
- Induction of oxidative stress that may lead to induction of oxidative stress - either due to increased production of oxyradicals, or decreased cellular antioxidant defences resulting in DNA damage
- Induction of hormonal imbalance
- Agonistic and antagonistic interaction with Aryl hydrocarbon Receptor (AhR).

NGC are thought to have a safe exposure threshold or dose; thus, their use in society is permitted provided that the exposure or intake levels do not exceed the threshold. For these reasons, the *in silico* methods for the identification of NGCs are based on a limited number of structural alerts that have so far been identified.

### Examples of available *in silico* systems

As already mentioned in section 3-4.2, the EU project ANTARES has listed the available free-access and commercial *in silico* models and tools on the project website ([www.antares-life.eu/](http://www.antares-life.eu/)).

The notable free access *in silico* systems for the assessment of mutagenicity/genotoxicity and carcinogenicity (for which more information is present in [APPENDIX 10](#)) include:

- The Danish QSAR database ([http://qsar.food.dtu.dk/](http://qsar.food.dtu.dk/))
- The OECD QSAR Toolbox ([https://qsartoolbox.org/](https://qsartoolbox.org/)),
- VEGA QSAR platform ([www.vegahub.eu/](http://www.vegahub.eu/))
- The US-EPA’s Toxicity Estimation Software Tool (T.E.S.T.) ([www.epa.gov/nrmrl/std/qsar/qsar.html](http://www.epa.gov/nrmrl/std/qsar/qsar.html))
- Lazar ([https://lazar.in-silico.ch/predict](https://lazar.in-silico.ch/predict))
- OncoLogic (US EPA) ([www.epa.gov/oppt/sf/pubs/oncologic.htm](http://www.epa.gov/oppt/sf/pubs/oncologic.htm))

---

8 The list of *in silico* models/systems is not exhaustive, and the mention of any model/system here does not constitute an approval of its quality, or recommendation for use by the SCCS.
A number of **commercial systems** are also available for the assessment of potential mutagenicity/genotoxicity and carcinogenicity. These include QSAR based systems such as SciQSAR® (SciMatics, Inc.) and TopKat® (Toxicity Prediction by Komputer Assisted Technology); molecular fragment-based QSAR expert systems such as CASE-Ultra® (Multicase Inc.) and Leadscope® (Leadscope, Inc.); and expert knowledge-based systems such as Derek Nexus® (Lhasa Ltd.).

Protocols for *in silico* assessment of genetic toxicity have been described by Hasselgren et al. (2019) and a number of studies have assessed the reliability of the *in silico* methods for the prediction of genotoxicity and carcinogenicity. The results have generally confirmed that a number of the *in silico* systems can provide a high degree of reliability for the estimation of genotoxic potential of chemicals (Serafimova et al., 2010; Bakhtyari et al., 2013; [www.antares-life.eu/files/antares_mutagenicity_qsar2012.pdf](http://www.antares-life.eu/files/antares_mutagenicity_qsar2012.pdf)). More recently, Honma et al. (2019) have tested 17 QSAR tools using a proprietary Ames mutagenicity database containing 12140 new chemicals, at least 85% of which were not included in publicly available or commercial databases and had not been used in QSAR modelling under the Ames/QSAR International Challenge Project. Their findings indicate that most tools achieved >50% sensitivity (positive prediction among all Ames positives) and predictive power (accuracy) as high as 80%, which is almost equivalent to the inter-laboratory reproducibility of the Ames tests.

These assessments point out to the potential of *in silico* methods and models to generate supporting evidence on the potential mutagenicity/genotoxicity of cosmetic ingredients to support the WoE on their safety in conjunction with other (*in vitro*) data. As indicated in section 3.4.2, the estimates derived from *in silico* models and read-across can provide useful additional supporting evidence for hazard assessment, especially when the results are integrated with other sources of evidence (e.g. *in vitro* data) into an overall weight of evidence (WoE) for use in risk assessment of cosmetic ingredients.

**(ii) From a 3-test *in vitro** battery to a 2-test *in vitro** battery:**

Evaluation of several databases has demonstrated that an increase in the number of *in vitro* tests performed results in an increase of the number of ‘unexpected positives’ while the number of ‘unexpected negatives’ decreases (Kirkland et al., 2005). The sensitivities of the 2- and 3-test batteries seem quite comparable (Kirkland et al., 2011). Moreover, the combination of the bacterial reverse mutation test and the *in vitro* micronucleus test allowed the detection of all relevant genotoxic carcinogens and *in vivo* genotoxicants for which data existed in the databases that were used (Kirkland et al., 2011). Consequently, EFSA and COM (2011) recommended the use of these 2 tests as a first step in genotoxicity testing. According to the REACH Regulation and ECHA Guidance (2017), in order to ensure that the necessary minimum level of information is provided, at least one further test is required in addition to the gene mutation test in bacteria, namely: an *in vitro* chromosome aberration test (OECD TG 473), or an *in vitro* micronucleus test (OECD TG 487) using mammalian cells. Although *in vitro* chromosome aberration test is considered as a possible alternative option to the *in vitro* micronucleus test under REACH, it is now generally agreed that these tests are not equivalent since the *in vitro* chromosome aberration test is not optimal for measuring numerical chromosome aberrations.

In line with this, the SCCS recommends two tests for the base level testing of cosmetic substances, represented by the following test systems:

- Bacterial Reverse Mutation Test (OECD 471) as a test covering gene mutations. Recently, OECD TG 471 has been revised with CAS reference numbers of strain-specific positive controls.
- *In vitro* Micronucleus Test (OECD 487) as a test for both structural (clastogenicity) and numerical (aneugenicity) chromosome aberrations.

The tests should be performed according to the OECD test guidelines.
Cells should be exposed to the test substance both in the presence and absence of an appropriate metabolic activation system. The most commonly used system is a cofactor supplemented S9-fraction prepared from the livers of rodents (usually rat) treated with enzyme-inducing agents such as Aroclor 1254 or a combination of phenobarbital and β-naphthoflavone. The choice and concentration of a metabolic activation system may depend on the class of chemical being tested. In some cases, it may be appropriate to utilise more than one activation system. For azo dyes and diazo compounds in the gene mutation test in bacteria, the use of a reductive metabolic activation system is recommended (SCCS/1532/14). In cases where the bacterial reverse mutation test is not optimal for the measurement of nanoparticles, biocidal compounds and antibiotics, a scientific justification should be given and a gene mutation test in mammalian cells the \textit{Hprt/Xprt} (OECD 476), or the thymidine kinase \textit{Tk} (OECD 490)} should be performed. Additionally, when testing nanomaterials, evidence is needed to show that the nanoparticles were in contact or internalized by the test system and entered in contact with DNA. For further considerations of particle-related behavior of substances, the Applicants should refer to SCCS/1611/19: Guidance on the Safety Assessment of Nanomaterials in Cosmetics.

\textbf{(iii) Novel in vitro approaches in genotoxicity models:}
The recommendations and conclusions from the International Workshops on Genotoxicity Testing (IWGT) (Martus et al., 2020) concerning different methods are supported by the SCCS:

- The Ames Test:
  - critical issues to be considered to bring TG 471 up to date and make it consistent with other OECD TGs have been identified (Williams et al., 2019; Levy et al., 2019a and 2019b).

- The Mammalian Cell Gene Mutation Assays:
  - \textit{In vitro} TransGenic Rodent (TGR) mutagenicity assays, once validated, could be employed for routine mutagenicity assessment, as they have endogenous metabolic capacity and consequent ability to generate DNA-reactive metabolites - properties lacking in cell lines frequently employed for \textit{in vitro} testing (White et al., 2019);
  - \textit{In vitro} mutagenicity assays based on immortalised cell lines or primary hepatocytes from the Mutamouse or lacZ Plasmid Mouse are at an advanced stage of validation;
  - The Phosphatidylinositol glycan class A gene (\textit{Pig-a}) mutagenicity assay is at an early stage in terms of safety testing and hazard identification (Bemis and Heflich, 2019);
  - The sensitivity of the Mammalian Cell Gene Mutation Assay can be improved by the use of XRCC1\textsuperscript{−/−}/XPA\textsuperscript{−/−}TK6 cells (Ibrahim et al., 2020).

- Novel & Emerging \textbf{in vitro} Mammalian Cell Mutagenicity Test Systems:
  - genome-wide loss-of-function screening, mutation characterisation by next generation sequencing, and fluorescence-based mutation detection can be promising methods (Evans et al., 2019a).

- The 3D Tissues in Genotoxicity Testing (Pfuhler et al., 2020):
  - 3D tissue models simulate \textit{in vivo}-like conditions regarding cell viability, proliferation, differentiation, morphology, gene and protein expression. They can complement classical 2D cell culture-based assays;
  - 3D tissue-based genotoxicity assays can be used as 2\textsuperscript{nd} tier assays to follow-up on positive results from standard \textit{in vitro} assays;
  - For adoption of a tissue model as a 2\textsuperscript{nd} tier assay, ability to detect the full range of genotoxic damage (leading to mutagenicity, clastogenicity, aneugenicity) should be demonstrated;
  - The 72-hour protocol for the 3D Reconstructed human Skin MicroNucleus assay (RSMN) has higher sensitivity than the 48-hour protocol;
  - The 3D skin comet and MN assays are now sufficiently validated to move towards individual OECD Test Guidelines, but an independent peer review of the validation study is still needed.
High Information Content assays:

- adductomics, global transcriptional profiling, error-reduced single-molecule sequencing, and multiplexed phenotypic profiling are promising tools for regulatory purposes (Dertinger et al., 2019).

(iv) In vitro models for secondary genotoxicity:
A significant knowledge gap exists in regard to which in vitro system(s) might be appropriate for assessing secondary (inflammation-driven) genotoxicity (OECD, 2014). Several in vivo-like in vitro models addressing inflammation driven genotoxicity have been developed, ranging from a simple conditioned medium approach (e.g. exposing THP-1 derived macrophages and then transferring the conditioned medium to bronchial cells) to more complex co-culture models (Evans et al., 2017, 2019b; Åkerlund et al., 2019). The most advanced models comprising either two or more different cell types co-cultured with immune cells have been reviewed (Evans et al., 2017) and discussed during the 7th IWGT in Japan 2017 (Pfuhler et al., 2020; Martus et al., 2020). They encompass cell-to-cell interplay, which promotes intracellular signalling and molecular crosstalk, representing more in vivo-like conditions.

(v) Outcome of in vitro tests
If the results from both tests are clearly negative in adequately performed tests, it is very likely that the substance has no mutagenic potential. Likewise, if the results from both tests are clearly positive, it is very likely that the substance has mutagenic potential. In both cases further testing is not necessary.

- If one of the two tests is positive, the substance is considered an in vitro mutagen. Further testing is needed to exclude potential in vivo mutagenicity (and/or clastogenicity) of the substance under investigation.

A general scheme of mutagenicity testing of cosmetic ingredients is presented in Figure 8. Additional information on the in vitro testing can be found in COM2011.

Different and potentially contradicting results may be available from the same test when performed with non-standardized protocols and carried out by different laboratories. In such cases, expert judgement should be used to evaluate and interpret the data. Further tests may be necessary to reach an overall conclusion.

Special attention should be given for poorly soluble chemicals. The determination of solubility in the culture medium prior to the experiment is mandatory. For such substances that are not cytotoxic at concentrations lower than the lowest insoluble concentration, the highest concentration analysed in culture medium should produce turbidity or a precipitate visible by eye or with the aid of an inverted microscope at the end of the treatment with the test chemical. Even if cytotoxicity occurs above the lowest insoluble concentration, it is advisable to test at only one concentration producing turbidity or a visible precipitate because inaccurate effects may result from the precipitate. At the concentration producing a precipitate, care should be taken to ensure that the precipitate does not interfere with the conduct of the test (e.g. staining or scoring).

(vi) Toolbox for further evaluation in a WoE approach
- The comet assay in mammalian cells or on 3D reconstructed human skin can support a WoE approach in the case of a positive or equivocal bacterial or mammalian gene mutation test. In June 2020, the 3D reconstructed human skin comet assay has been presubmitted to EURL ECVAM for assessment. The enzyme-linked comet assay for detection of oxidized DNA bases can be useful for identification of a genotoxicity involving oxidative stress. Standardisation and pre-validation of the method have been conducted recently by the hCOMET consortium (Møller et al., 2020) and the application for an OECD test guideline is in preparation.
To evaluate a positive or equivocal result, RSMN could be considered for dermally applied compounds. The experimental phase of the validation has been finalised (Phfuhrer et al., 2020) and the RSMN has been pre-submitted to EURL ECVAM for assessment. Another tool is the Hen’s Egg test for Micronucleus Induction (HET-MN) which is currently under evaluation (JRC 2019, 2020; Reisinger et al., 2019).

Negative results from these alternative tests alone might not be sufficient to overrule the positive results from a recommended test.

Mechanistic investigations (e.g. toxicogenomics) or internal exposure (toxicokinetics) are tools that may be helpful in a WoE evaluation. Reporter gene assays based on human, animal or bacterial cells are tools supporting a WoE approach. Among such tests are the Green Screen HC™ used to screen the genotoxic and cytotoxic potential of chemicals and ToxTracker™, which when combined with Vitotox (a mutagenicity test that can be used as a surrogate for an Ames test) showed a better performance than observed in the official 2-test battery (Ates et al., 2016). ToxTracker™ was able to accurately classify compounds as genotoxic or non-genotoxic, and could discriminate between DNA-reactive compounds, aneugens and indirect genotoxicity caused by oxidative stress (Brandsma et al., 2020).

The results obtained using a reporter gene assay provide mechanistic information at the molecular level but cannot alone overrule a positive result from an in vitro battery as the assay is based on a limited number of genes.

Another tool to potentially address a positive result in a 2-test battery (in one of the two assays) is transcriptomics analysis in TK6 cells (Li et al., 2015), HepG2 cells (Maghoufopoukou et al., 2012) or HepaRG™ cells (Ates et al., 2018), in which a higher number of genes provide mechanistic information (Dertinger et al., 2019). The level of phosphorylated form of H2AX histone (γH2AX) in cells exposed to a chemical can indicate its potential for induction of DNA damage (Kopp et al., 2019). Assays that simultaneously analyse different biomarkers (e.g., p53, γH2AX, phospho-histone H3 or polyploidy) are being developed to provide mechanistic information on the types of biological damage induced by different classes of substances. Such promising assays are MultiFlow and the Multi-Endpoint Genotoxicity Assay (MEGA-Screen system) (Dertinger et al., 2019).

Despite the possibilities offered by the toolbox, expert judgement may be necessary to be able to come to an overall conclusion.

Intensive work is being carried out on adapting current tests to high-throughput technologies (e.g., micronucleus test, Comet assay, γH2AX assay, high content analysis and other assays) (Collins et al., 2017).

Alternative tests for which no OECD test guideline is currently available should be performed according to the general principles laid down in OECD test Guidelines (OECD 211).

In cases where a clear positive result cannot be overruled in a WoE approach even with additional testing, the substance has to be considered a mutagen. A positive in vitro result in genotoxicity testing is also seen as indicative for the carcinogenic potential of substances.

The SCCS has published an Addendum to the NoG (SCCS/1501/12), in which details such as definitions, critical steps, crucial experimental conditions to be followed, etc. are described (SCCS/1532/14).
Figure 8. Scheme of testing strategy for genotoxicity/mutagenicity of cosmetic ingredients

**Initial considerations**

Read across, chemical categories, QSARs and other *in silico* predictions, physico-chemical properties, impurities, dermal absorption, other toxicological data (e.g. available rodent carcinogenicity data, etc.)

**Main tests**

- Bacterial gene mutation (Ames test) or mammalian gene mutation test
- *In vitro* micronucleus test (clastogenicity and aneugenicity) OECD TG 487

Consider the following before the final assessment:

- Validity of the study
- Reproducibility of the result
- Historical control data
- Potential mode of action
- Factors which can lead to false positive/negative results, e.g. bacteriotoxicity, bacterial specific metabolism, excessive mammalian cell cytotoxicity, capacity of metabolic activation systems, etc.

**Negative results in both tests and no alerts**

Consider:

Factors which may lead to false negative results, e.g., no cytotoxicity, lack of cellular uptake after nanoparticles exposure, etc.

**Equivocal result in any of main tests**

Consider:

- Potential mode of action
- Factors which can lead to false positive results, e.g. bacteriotoxicity, bacterial specific metabolism, excessive mammalian cell cytotoxicity, capacity of metabolic activation systems, etc.

**Positive result in any of main tests**

- Toolbox for conducting additional *in vitro* tests in a WoE approach, e.g. mammalian cell gene mutation (MLA, Xprt, Hprt), chromosomal aberrations, comet assay, comet and micronucleus assays on 3D reconstructed skin models, toxicogenomics, recombinant cell models, models for secondary genotoxicity, HET-MN, Pig-a test, γH2AX, HCA

**Results are inconclusive if the above factors have not been addressed**

**Substance is not mutagenic**

**Insufficient data to conclude on safety of the substance**

- Substance is considered to be an *in vitro* mutagen

* Bacterial gene mutation test is preferable. If not suitable (e.g. in the case of antibiotics, nanomaterials), mammalian cell gene mutation assay should be provided

**Abbreviations:** MLA – Mouse Lymphoma Assay; Xprt – Xanthine-guanine phosphoribosyl transferase gene; Hprt – Hypoxanthine-guanine phosphoribosyl transferase gene; HET-MN – hen’s egg test for micronucleus induction; Pig-a – phosphatidylinositol glycan class A gene; γH2AX – phosphorylated form of H2A histone family member X; HCA – High Content Analysis
B. *In vivo methods*

Animal studies on mutagenicity or genotoxicity are acceptable when data are already available from tests that have been carried out before the animal testing ban or when generated for compliance with other legislative (non-cosmetic) frameworks (see Section 1).

When there is a positive result from an *in vitro* gene mutation test, adequate somatic cell *in vivo* tests are:
- a Transgenic Rodent and Germ cell gene mutation assay (TGR) (OECD TG 488),
- an *in vivo* mammalian alkaline comet assay (OECD TG 489).

It is no longer recommended to perform an Unscheduled DNA Synthesis (UDS) test with mammalian liver cells *in vivo* (OECD TG 486) (EFSA, 2017b).

Adequate somatic cell *in vivo* tests to investigate structural or numerical chromosome aberrations are:
- a mammalian erythrocyte micronucleus test (OECD TG 474),
- a mammalian bone marrow chromosome aberration test (OECD TG 475)
- an *in vivo* alkaline comet assay (OECD TG 489).

An OECD guideline for the Pig-a *in vivo* assay is in progress. According to the experts from the 7th IWGT, the assay can be valuable as a follow-up to *in vitro* positive results (Kirkland et al., 2019).

EFSA concluded that target tissue exposure in *in vivo* studies should be demonstrated, particularly in the bone marrow (e.g., mammalian erythrocyte micronucleus assay). Toxicity to the bone marrow in itself provides sufficient evidence to allow concluding on the validity of a negative outcome of a study. All other direct or indirect evidences of target tissue exposure should be assessed within a weight-of-evidence approach.

The SCCS is aware of work being conducted in the development of new generation framework for assessment of genomic damage (Steiblen et al., 2020; Luijten et al., 2020), however this work is at preliminary stage and no guidance can be delineated at the moment.

3-4.11 **CARCINOGENICITY**

Substances are defined as carcinogenic if, after inhalation, ingestion, dermal application or injection, they induce or increase the incidence of tumours, induce malignancy or shorten the time before tumour occurrence (ECHA 2017).

Carcinogens are often differentiated as "genotoxic carcinogens" (DNA-reactive substances), for which the most plausible mode of carcinogenic action is via genotoxic effects (*i.e.* point mutations and structural chromosomal aberrations), and "non-genotoxic carcinogens", or non-DNA reactive substances that are carcinogenic due to mechanisms other than direct interactions with DNA (ECHA 2017).

A. **NAMs**

(i) **In silico methods for carcinogenicity**:

See under 3-4.10.2 (i): *in silico* methods for genotoxicity and carcinogenicity
(ii) In vitro methods

- **Genotoxic carcinogens (DNA reactive)**
  At present validated alternative *in vitro* methods to determine the carcinogenic potential of substances are not available as OECD test Guidelines. However, there are new *in vitro* approaches which may be helpful in an overall WoE approach to indicate potential genotoxic as well as NGC substances.

For genotoxic substances, *in vitro* mutagenicity tests are well developed. Due to the relation between mutations and cancer, these genotoxicity tests can also be seen as a pre-screening for carcinogenicity. A positive result in one of the *in vitro* mutagenicity/genotoxicity testing battery may be indicative for considering a substance as a putative carcinogen. This indication may be further supported by a positive result in Cell Transformation Assays (CTAs, Guidance documents No 214 and No 231).

Worldwide research is ongoing with regard to *in vitro* toxicogenomics for the detection of mutagens, genotoxic carcinogens, and particularly NGC. By global gene expression profiling *via* microarray technology, gene patterns covering diverse mechanisms of substance-induced genotoxicity can be identified (Schmitz-Spanke, 2019).

These gene patterns/biomarkers can be further used as a follow-up of positive findings of the standard *in vitro* mutagenicity/genotoxicity testing battery (Goodsaid *et al.*, 2010; Doktorova *et al.*, 2012; Magkoufopoulou *et al.*, 2012; Ates *et al.* 2018). In addition to *in vitro* mutagenicity/genotoxicity tests (see above), data from *in vitro* tests combined with toxicogenomics may also be considered in a WoE approach. A multiple-endpoint approach is most probably a more reliable means of assessing carcinogenicity *in vitro* than traditional, single-endpoint tests (Wilde *et al.*, 2018).

- **Non-genotoxic carcinogens (DNA-non reactive)**
  Genotoxic carcinogens either induce mutations in (short term) eukaryotic and prokaryotic mutation assays or induce direct DNA damage in the target organ. Although it has been estimated that 10-20% of recognised human carcinogens classified as Class 1 by IARC act through NGC mechanisms (Hernandez *et al.*, 2009), there are no specific requirements to obtain information on NGC mechanisms of carcinogenicity. As such many NGC will remain unidentified, and as a consequence their risks to human health will not be managed. The overview of NGC mechanisms presented by Jacobs *et al.* (Jacobs *et al.*, 2016) indicates that assays with endpoints capturing early key event mechanisms may provide an individual contribution to the WoE approach of NGC.

(iii) Development of integrated approach to testing and assessment (IATA) for NGC

Using the AOP concept, an OECD expert working group has elaborated a preliminary panel of key hallmarks of NGC and representative international standardised tests that can address IATA for NGC (Jacobs *et al.*, 2020). Using a systematic review approach combined with assay database mining, overall more than 100 *in vitro* assays have been identified so far, within 13 cancer hallmark assay blocks that address early, mid and later key events with consequent increasing associations with adverse outcome. The assays are currently undergoing evaluation by the group including assessment of their readiness for validation in the short, medium and long term.

(iv) Cell Transformation Assays (CTA) as a possible alternative to animal models of carcinogenicity testing

CTA can detect both genotoxic and NGC (Sasaki *et al.*, 2014) and are able to highlight various stages from early (initiation) to late (promotion) phases (OECD 2017, Serra *et al.*, 2019, Jacobs *et al.*, 2020). They address several endpoints. They measure cell transformation, which includes early key events such as transdifferentiation, acquisition of a peculiar morphology, etc., reflecting stages in the multistep cancer process (for more information, see Appendix 8, Table A.8). CTAs thus can be used as phenotypic anchoring for mechanistic
studies (Callegaro et al., 2017). They may provide additional information and may be used as a follow-up for confirmation of in vitro positive results from genotoxicity assays, typically as part of a WoE approach (Doktorova et al., 2012, Creton et al., 2012). When employed in combination with other information, such as genotoxicity data, structure–activity analysis and pharmaco/toxicokinetic information, CTAs could facilitate a relatively comprehensive assessment of carcinogenic potential (Creton et al., 2012, Corvi et al., 2017, Mascolo et al., 2018). Toxicogenomics in combination with in vitro CTAs allow the identification of the transcriptionally activated pathways (Mascolo et al., 2018). This integrated approach has the potential to be considered as part of an IATA for non-genotoxic carcinogenesis (Corvi et al., 2017).

Validated CTAs are the BALB/c 3T3 CTA (EURL ECVAM, 2012), the Syrian Hamster Embryo (SHE) CTA OECD Guidance Document No. 214 (OECD, 2015, Corvi et al., 2017) and the Bhas 42 CTA OECD Guidance Document No. 231 (OECD, 2017, Jacobs et al., 2020). These can be used in a WoE approach in the testing of substances for carcinogenic potential. At present, the carcinogenic potential of a substance cannot be derived from a stand-alone CTA.

B. In vivo methods

An in vivo carcinogenicity study is only acceptable by SCCS when based on tests that have been carried out before the animal testing ban or when carried out for the purpose of compliance with other (non-cosmetic) legislative frameworks.

Usually the carcinogenic potential of a substance is assessed using a 2-year bioassay (OECD 451: carcinogenicity studies). A combined chronic toxicity/carcinogenicity study can also be performed to identify carcinogenic and the majority of chronic effects, and to determine dose-response relationships following prolonged and repeated exposure (OECD 453: C-combined chronic toxicity/carcinogenicity studies). It is now well recognised by the scientific and regulatory community that the use of the rodent cancer bioassay has many limitations in terms of reliability and relevance (Jacobs et al., 2020).

Utilising a mode of action analysis instead of performing the long-term rodent carcinogenicity studies offers a more direct and rational basis for human cancer risk assessment. Such analysis should be performed whenever possible, rather than simple hazard identification (Berry 2018, Goodman 2018).

3-4.12 PHOTO-INDUCED TOXICITY

3-4.12.1 PHOTO-IRRITATION AND PHOTO-SENSITISATION

A. NAMs

The "3T3 Neutral Red Uptake Photo-toxicity Test (3T3 NRU PT)" is a validated in vitro method (EC B.41, OECD 432), based on a comparison of the cytotoxicity of a chemical when tested in the presence and in the absence of exposure to a non-cytotoxic dose of UV/VIS radiation. Its use is mandatory for testing for phototoxic potential. It is not designed to predict other adverse effects that may arise from combined actions of a chemical and light, e.g. it does not address photoclastogenicity/photomutagenicity, photo-allergy or photocarcinogenicity.

In the OECD 432 GD it is indicated that if the Molar Extinction/absorption Coefficient (MEC) is less than 1000 L mol\(^{-1}\) cm\(^{-1}\) (measured in methanol), the chemical is unlikely to be photoreactive and that such chemicals may not need to be tested.

EFSA (2016) concluded that for a light source emitting wavelengths mainly below 320 nm, more guidance is needed on how to interpret the data and on how to perform the test with a light source emitting between 290 and 320 nm. In the OECD TG, it is mentioned that cytotoxicity increases 1000-fold as the wavelength ranges from 313 to 280 nm. Although the data requirement in Reg. (EU) No. 283/2013 are for substances absorbing electromagnetic radiation in the wavelength range 290-700 nm, there are difficulties in testing below 320 nm.
EFSA proposed that the phototoxicity test should not be performed if it has been demonstrated that the test material only absorbs at wavelengths lower than 313 nm and if there is insufficient absorption at longer wavelengths.

As a second tier, the biological effects can be further evaluated on a reconstructed human skin model with some barrier properties (Kandarova, 2011). A positive control should always be included. A negative result for the compound under consideration is usually accepted. To enhance the chance of achieving correctly predicted results of phototoxic potential of chemicals, a more complex screening using UV/VIS radiation spectral analysis and Reactive Oxygen Species (ROS)/micellar ROS (mROS) assays could be used according to Nishida et al., 2015.

Presently, no validated in vitro methods for the detection of photo-sensitisation are available. Nevertheless, it is expected that chemicals showing photo-allergic properties are likely to give positive reactions in the 3T3 NRU PT test. There is also work being conducted on some other in vitro tests for photo-allergic potential such as: photo-hCLAT, NCTC2455 assay, dendritic cell-based assay, or photo-SH/NH2 test (Onoue et al., 2017).

For pharmaceuticals applied to the skin, it is stated in EMA 2012 (updated 2015) that reconstructed human skin models can be used. Under adequate test conditions, a negative result in a reconstructed human skin assay indicates that the direct phototoxicity potential of the formulation can be regarded as low. In that case, generally no further phototoxicity testing is recommended.

B. In vivo methods

At present, no official guideline-based protocols for photo-irritation and photo-sensitisation testing in animals have been evaluated. Several industry reports describe test protocols. For Pharmaceuticals, guidance on such testing is available (FDA, 2015; EMA, 2012). These documents do not, however, specify protocols for the testing of adverse effects of orally or topically applied agents, nor do they give recommendations about the species to be used.

The SCCS guidance is as follows:

UV-VIS spectra of the compound along with the MEC, determined according to a harmonised procedure, should be provided.

There is no requirement for phototoxicity testing of compounds with a MEC below 1000 L mol−1 cm−1.

There is no requirement for in vitro phototoxicity testing if the test material only absorbs at wavelengths lower than 313 nm and if there is insufficient absorption at longer wavelengths.

3-4.12.2 Photomutagenicity / Photogenotoxicity

Photomutagenic or photogenotoxic chemicals are chemicals that absorb visible (VIS) light or UV radiation and, through activation to a more reactive state or release of free radicals, cause damage to DNA and induce gene mutations or chromosome aberrations.

The terms “photomutagenesis” or “photogenotoxicity” are used to describe the ‘indirect’ induction of gene mutations or chromosomal aberrations after transfer of energy or charge from a light absorbing molecule other than DNA (Müller and Gocke, 2013). This includes the genotoxic effects elicited by degradation products and/or radicals generated by VIS and UV wavelengths.

(i) Current status of tests available for photogenotoxicity/photomutagenicity assessment

A previous version of the Notes of Guidance (SCCNFP/0690/03) already mentioned that for the detection of photochemical clastogenicity/mutagenicity, several assays had been adapted
to a combined treatment of chemicals with UV-VIS radiation (Averbeck et al., 1979; Dean et al., 1991; Chetelat et al., 1993a,b, 1996; Gocke et al., 1998; Pflaum et al., 1998; Kersten et al., 2002).

The existing principles and test methods in the field of photomutagenicity/photogenotoxicity was summarised in the report of the Gesellschaft für Umweltmutationsforschung (GUM) Task Force on photochemical genotoxicity (Brendler-Schwaab et al., 2004). The methods described include the photo-Ames test, the photo HPRT/photomouse lymphoma assay, the photomicronucleus test, the photosynchromosome aberration test and the photo-Comet assay. In many cases, the concurrent use of irradiation, while performing a standard mutagenicity/genotoxicity study, does not significantly alter the existing OECD protocol without irradiation. Therefore, the majority of the described photomutagenicity/photogenotoxicity tests are considered as being valid.

In addition to the conclusions of an international workshop (Lynch et al., 2011), a comprehensive review (Müller and Gocke, 2013) concluded that “photomutagenicity is not suitable for a general testing framework within cosmetic or pharmaceutical testing guidelines” and suggested a case-by-case approach

(ii) Guidances for photogenotoxicity/photomutagenicity testing

The COM (COM 2013) recommended that photogenotoxicity testing does not need to be undertaken routinely as part of a photosafety assessment and that photogenotoxicity testing had a negligible impact in the overall assessment for potential of photocarcinogenicity. Moreover, if there is a negative response from the phototoxicity test, no photomutagenicity test is required. However, if the test is positive, no specific guidance is provided.

The International Conference on Harmonisation (ICH) guideline on photosafety evaluation of pharmaceuticals (Step 4 of the ICH Process dated 13 November 2013) stated: ‘Note 2. Testing for photogenotoxicity is not recommended as a part of the standard photosafety testing program as in most cases, the mechanism by which compounds induce photogenotoxic effects is identical to those that produce phototoxicity, and thus separate testing of both endpoints is not warranted.’

The ICH guideline has been adopted in EU by the Committee for Medicinal Products for Human use (CHMP) in December 2015 and issued as EMA/CHMP/ICH/752211/2012 (EMA, 2015) as well as in the USA by the FDA and issued as FDA/2013/D/0068 (FDA, 2015).

In 2016 the EFSA (2016) agreed that photomutagenicity testing is not required for the time being, unless further guidance is provided. Additionally, they concluded that the concern regarding positive results in the phototoxicity test should be raised to the risk managers in the conclusion of the peer review.

In this regard, taking also into consideration the general recommendations regarding the experimental conduct of tests for photogenotoxicity (Gocke et al., 2000), the SCCS guidance is as follows:

- although the validity of photomutagenicity/photogenotoxicity testing is being questioned, in specific cases when the structure of a molecule, its light absorbing potential or its potential to be photo-activated may indicate a photomutagenic/photogenotoxic hazard, then photomutagenicity tests should be provided, including gene mutations and clastogenicity/aneugenicity endpoints; especially when the substance is liable to reach the eyes or light-exposed areas of skin, either by direct contact or through systemic distribution. Additionally, available alternative methods, for example scientifically validated comet assay for detection of oxidized DNA lesions, or in silico methods, can be considered.

- UV-VIS spectra of the compound along with the MEC, determined according to a harmonised procedure, should be provided.

- the phototoxicity test should not be performed if the test material only absorbs at wavelengths lower than 313 nm and if there is insufficient absorption at longer wavelengths.

- no photomutagenicity tests are needed when the phototoxicity tests are negative.
there is no requirement for a photomutagenicity test if the test material only absorbs at wavelengths lower than 313 nm and if there is insufficient absorption at longer wavelengths.

3-4.13 **HUMAN DATA IN HAZARD ASSESSMENT**

Tests in animals and alternative methods may have limited predictive value with respect to the human situation. Therefore, when human data is available, this information is very valuable. Human data can be obtained via various sources. For bioavailability and systemic toxicology information, sources could be: post-marketing surveillance data, results from biomonitoring programs (see Section 3-3.5.6), case reports, occupational surveillance data and occupational disease registries (e.g. from production of the ingredient or when the cosmetic ingredient is also used in non-cosmetic areas), poison centre information, epidemiological studies, clinical studies, tests with human volunteers.

Tests with human volunteers (e.g. skin compatibility tests) confirm that there are no harmful effects when applying a cosmetic product for the first time to human skin or mucous membranes. If considered scientifically and ethically necessary, human tests can only be envisaged, provided that the toxicological profiles of the components are available and no concern is raised. A high degree of safety needs to be ensured. Finished cosmetic products are usually tested in a small group of human volunteers to confirm skin and mucous membrane compatibility, as well as cosmetic acceptability (fulfilment of in-use expectations).

Human studies might also become necessary to build up and validate PBPK models (see Section 3-3.5.3).

The general ethical and practical aspects related to human volunteer compatibility studies on finished cosmetic products, are described in SCCNFP/0068/98 (for skin irritancy) and SCCNFP/0245/99 (for skin sensitisation). For skin sensitisation, human patch test data, if available, have to be taken into account (SCCS/1567/15).

Predictive testing of potentially skin sensitising cosmetic (mixtures of) substances (SCCNFP/0120/99) is more controversial than the irritancy testing, since these tests carry the risk of inducing a long-lasting or permanent immunological sensitisation in the individual. Therefore, serious ethical questions arise.

Despite many years of experience with human sensitisation tests, limited scientific information is available regarding the consequences involved for human volunteers who have developed sensitisation as a result of such testing. Due to the uncertainties mentioned, the SCCS is of the opinion that predictive human sensitisation tests should not be carried out.

The same ethical restrictions apply to human predictive tests on photosensitisation. For photosensitisation, information can be obtained from published clinical studies and case reports. There are no officially adopted guidelines or protocols, but in general the test procedures are quite similar to those used in photo-patch testing in clinical settings (Bruynzeel, 2004). Normally a UV-A dose of 5 – 10 J (and occasionally UV-B in appropriate non-erythemogenic dose) is applied to a skin area that has been exposed to the product or substance during the preceding 24 hours. Adequate control test areas, including a vehicle exposed and an unexposed UV irradiated area, are essential. Readings must be performed at least at 4, 24 and 48 hours after irradiation.

3-4.14 **OTHER CONSIDERATIONS**

When HBM in used in the safety evaluation of consumer product ingredients, the following limitations apply:
- HBM is applicable to substances that are systemically taken up and where the half-life of the biomarker enables sampling and analytical determination.
- HBM is not appropriate when the relevant biomarker is an endogenously formed substance, present in much higher concentrations than those caused by the uptake of a substance from the environment or consumer products.
- HBM is not appropriate when the relevant biomarker is non-specific (e.g., can be formed by different parent compounds such as hippuric acid).
- Various factors influence HBM results, including age, gender, lifestyle, consumer habits, diet, place of residence, etc., as they modify the amounts of chemical substances taken up. Inter-individual differences in the metabolism of chemical substances, excretion of metabolites, health status as well as different compositions of biological materials like varying dilutions of urine etc., even under identical conditions of exposure, may provide different HBM results.
- Other error sources are contamination of samples during collection and handling of the biological samples (Calafat and Needham, 2009).

3-5 GENERAL PRINCIPLES FOR THE CALCULATION OF THE MARGIN OF SAFETY AND THRESHOLD OF TOXICOLOGICAL CONCERN

3-5.1 CALCULATION OF THE MARGIN OF SAFETY OF A COSMETIC INGREDIENT

The last step in the safety evaluation of a cosmetic ingredient is the calculation of the MoS, which is the ratio between a PoD_sys (usually historical NOAEL or BMD values from oral studies) and an estimate of the exposure (11).

Mostly, only a repeated dose toxicity study with oral exposure is available as a surrogate for a study with dermal exposure. For comparison with the PoD_sys, usually an SED for the dermal route is derived as the exposure estimate. For calculation of SED, see 3-3.5.4.

Where possible, a BMD is used as PoD_sys (see also 3-1 (3)).

\[
\text{MoS} = \frac{\text{PoD}_{\text{sys}}}{\text{SED}} \quad (11)
\]

3-5.1.1 THE PoD VALUE

As far as the determination of critical effects in repeated dose toxicity studies is concerned, the available repeated dose toxicity data should be evaluated in detail for characterisation of the health hazards upon repeated exposure. In this process, an assessment of all toxicological effect(s), their dose-response relationships and possible thresholds should be taken into account. The evaluation should include an assessment of the severity of the effect(s), whether the observed effect(s) are adverse or adaptive, irreversible or not - and whether they are precursors or not of significant effects or secondary to general toxicity. Correlations between changes in several parameters (e.g. between clinical or biochemical measurements, organ weights and (histo)pathological effects) will be helpful in the evaluation of the nature of the effects. Further guidance on this issue can be found in several publications (WHO, 1994; WHO, 1999; ECETOC, 2002; ECHA, 2012a).

3-5.1.1.1 DETERMINATION OF NOAEL

The NOAEL is defined as the highest dose or exposure level where no (adverse) treatment-related findings are observed. For cosmetic ingredients, the NOAEL is mainly
derived from a 90-day repeated dose animal study or from a reproductive toxicity animal study.

The BMD approach should preferentially be used as the dose descriptor for the PoD and the MoS calculations (EFSA, 2009). When no BMD can be calculated, usually historical NOAEL values are applied.

If a BMD or a NOAEL cannot be identified from the available data, other dose descriptors such as the Lowest Observed (Adverse) Effect Level (LOAEL) may be used in the MoS calculation. See Section 3-1(3)(4).

3-5.1.1.2 Determination of BMD

Although not limited to in vivo data, it involves first fitting a dose-response model to the data and then interpolating to find the lowest dose that causes a statistically significant response (or alternatively: the dose that corresponds to a low but measurable change in response over the entire dose interval). That dose is defined as the BMD. To account for uncertainty, a two-sided 90% confidence interval for the BMD interval, the BMDU (upper confidence limit of BMD), is sometimes used to calculate the BMDU/BMDL (lower confidence limit of BMD) ratio which provides an estimate of the uncertainty in the BMD value. The BMD/BMDL ratio can also be used for this purpose but is less suitable as it does not take the full uncertainty in the BMD estimation into account (EFSA guidance, 2017c).

With quantal data, also referred to as dose-response data, the outcomes are incidences, e.g. number and gender of animals with signs of toxicity. With such data the BMD is defined as the dose associated with a specific change in the response, the Benchmark Response (BMR) most often defined as either an increased additional risk or extra risk. An extra risk of 10% is recommended as default for the BMR by both EFSA (EFSA, 2016) and US EPA (US EPA, 2010).

Body weight, organ weights and enzyme levels are typical continuous data, also referred to as dose-effect data. For such data each animal has its own magnitude of effect and the arithmetic or geometric means of the different dose groups are usually compared.

EFSA has proposed a preferred default 5% as a BMR, with modifications if required by toxicological or statistical considerations (EFSA, 2017c).

3-5.1.1.3 Choice of models

The most well-known BMD software (BMDS) has been developed by the US EPA (www.epa.gov/bmds) and the National Institute for Public Health and the Environment (RIVM) (the PROAST software, www.rivm.nl/proast). Application of different models to the same data will yield different values for the BMD and BMDL. As a consequence, there are different methods that guide the choice of which BMD and BMDL to use. Current EFSA guidelines suggest that the lowest BMDL among the models that pass a goodness-of-fit test should be used as the PoD (EFSA, 2017c). EPA’s guidelines are less conservative, suggesting that the model with the lowest Akaike Information Criterion (AIC) should be used as the PoD, unless there is a large difference between the BMDL values obtained with the different models (US EPA, 2012).

The AIC takes the likelihood of the model fit into account, but penalizes models with many parameters:

The SCCS considers that there are still practical considerations regarding the use of this approach when evaluating cosmetic ingredients and its application requires a level of expert judgement and modelling expertise.
3-5.1.1.4 ADJUSTMENT FACTORS TO THE PO\textit{D}

Dependent on dosing regimen, adjustment to daily exposure should be performed. For example, if the dose regimen in such a study was only 5 days treatment per week, a PO\textit{D} corrected by a factor of 5/7 should be used for the MoS calculation (ECHA, 2012a).

**When the PO\textit{D} is based on a LOAEL, often an additional assessment factor of 3 is added in the calculation of the MoS.** However, a higher assessment factor of up to 10 may be decided on a case-by-case basis, taking into account the dose spacing in the performed repeated dose toxicity test, the shape and slope of the dose-response curve (and in some cases the extent and severity of the effect(s) seen when LOAEL values are used). In some cases, the study cannot be used for safety assessment.

In case a 90-day repeated dose toxicity study is not available, a NOAEL or BMDL from a 28-day repeated dose toxicity study can be used in the MoS calculation for a cosmetic ingredient. In this case, a default assessment factor of 3 for exposure duration may be used in the calculation of the MoS.

### 3-5.1.2 THE PO\textit{D}sys VALUE

If the absorption by the oral route is 100%, then the external and internal doses of the oral route are the same. If the absorption by the oral route is less than 100%, which is often the case, the procedure may underestimate the risk of the exposure of the non-oral route.

It is considered that not more than 50% of an orally administered dose is systemically available. Thus, in the absence of data, **50% of the administered dose is used** as the default oral absorption value for a cosmetic ingredient and the PoDsys is derived from the PO\textit{D} by dividing with a factor 2. If there is information to suggest poor oral bioavailability, a default value of 10% oral absorption could be considered. However, whenever oral absorption data are available, these should be used, also when using other dose descriptors. Also, any other available kinetic data should be considered.

For chemicals with a high first-pass metabolism in the gut or liver, the situation is even more complex and, in addition, the target organ for toxicity has to be taken into consideration and route-to-route extrapolation may not be adequate.

In the case of oral to inhalation extrapolation, a default factor of 2\textsuperscript{9} is also proposed (default absorption oral route: 50%; inhalation 100%; ECHA, 2012a).

### 3-5.1.3 MoS ANALYSIS

The calculated MoS is compared with a reference MoS, which is comparable to the uncertainty/assessment factor used in risk and safety assessments to extrapolate from a group of test animals to an average human being, and subsequently from average humans to sensitive subpopulations (see Figure 9). A default value of 100 (10x10) accounting for inter- and intraspecies differences is generally accepted and a MoS of at least 100 therefore indicates that a cosmetic ingredient is considered safe for use.

\textsuperscript{9} Besides the default value of 50% for oral absorption, in this guidance, another default value of 50% for dermal absorption should be distinguished if no adequate dermal absorption data is available (see Section 3-3.5.2).
Figure 9: Schematic representation of the extrapolation from animal to man (Renwick, 1998).

As shown in Figure 9, the default value of 100 consists of a factor of 10 for the extrapolation from test animals to an average human being (interspecies extrapolation) and another factor of 10 taking into account the variations within the human population (intra-species extrapolation). These factors can be further subdivided as indicated in Figure 10.

When considerable qualitative/quantitative toxicokinetic differences are observed between test animals and humans, as well as within human individuals, e.g. from relevant toxicokinetic data for rat and/or humans (SCCS/1443/11, SCCS/1479/12), the interspecies and/or intra-species toxicokinetic default factor (see Figure 10) can be increased/decreased (case-by-case evaluation).

Regarding substance-specific information for variations in toxicodynamics, deviation from the default value is possible if sufficiently justified. For instance, in case of different susceptibility to HPT-axis disturbances in rats and humans, a change of the interspecies toxicodynamic default factor of 2.5 may be required (SCCS/1481/12).

Figure 10: Further subdivision of the uncertainty/assessment factor, taking toxicokinetics and toxicodynamics into account (based on WHO, 1994).

* including historical NOAEL values
Additional considerations:

i. Some cosmetic substances are not used on a daily basis, although their NOAEL values have been obtained in studies after daily administration of the substances. Combining these NOAEL values with daily exposures therefore results in a clear overestimation of the risk. The comparison of a NOAEL resulting from a daily exposure study with the SED of a certain cosmetic ingredient is therefore accepted as a conservative estimate, even if it is only applied e.g. once per week or once per month. However, the daily amount for product categories with low frequencies of application may not be adjusted by the frequency (i.e. not divided by 30, if applied once per month), as justified by: "The actual daily dose is independent of the exposure frequency. This means that if, for a certain scenario, worker or consumer exposure is only for a number of days per year, the exposure value is the actual dose on the exposure days, and not the daily dose averaged out (and thus divided!) over the whole year" (ECHA, 2012a). This reasoning, however, may be changed for example in the case of hair dyes (e.g. oxidative hair dyes only applied once per month) and a MoS slightly below 100. One could consider a substance as being safe due to the occasional use and the built-in conservatism of assessment but only after expert judgement.

ii. When there is sufficient evidence that the dermal absorption of a cosmetic ingredient is very low, systemic exposure may be negligible and the calculation of a MoS may not be justified or applicable (see Sections 3-6.11 and 3-5.2). See also for example UV filter HAA299 SCCS/1533/14.

iii. The SCCS will decide upon the relevance of MoS calculations on a case-by-case basis, taking into account the general toxicological profile of the substance under consideration, its toxicokinetic properties and its intended use.

iv. With regard to rounding and number of digits given for the MoS, this should be based on the precision of the underlying data. The biological variability of toxicity data in vivo generally is > 10%. The indication of more than decimal digits in the final MoS is therefore not recommended.

3-5.2 THE THRESHOLD OF TOXICOLOGICAL CONCERN (TTC)

3-5.2.1 GENERAL CONCEPT OF TTC IN RISK ASSESSMENT

The use of the TTC approach as a risk assessment tool for cosmetics and consumer products has been evaluated by the SCCS/SCHER/SCENHIR (SCCP/1171/08) as it is a pragmatic tool that is based on the principle of establishing human exposure threshold values for all chemicals below which there is a very low probability of an appreciable risk of systemic adverse effects to human health.

Use of the TTC concept for chemicals with specific data requirements for their regulatory approval under a specific European regulation is currently not acceptable as an alternative to a chemical-specific evaluation.

Nevertheless, the TTC concept has been acknowledged to be a science-based prioritisation and risk assessment tool by different organisations such as WHO IPCS, EFSA, SCCS, SCHER, Health Canada (Joint FAO/WHO Expert Committee on Food Additives, 1996; SCCS, SCHER, 2012; EFSA, 2016a & 2019a; SCCS NoG 2016; Health Canada, 2016).

EFSA (EFSA, 2012 & 2019a) concluded that the TTC approach should not be used for the following (categories of) chemicals: high potency carcinogens (i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, benzidines and also hydrazines); inorganic chemicals; metals and organometallics; proteins; steroids; chemicals that are known or predicted to bioaccumulate; nanomaterials; radioactive chemicals and mixtures of chemicals containing unknown chemical structures.
So far, this approach has been used in a regulatory context for food contact material migrants, food flavourings, fragrances, genotoxic constituents in herbal preparations and for pesticide metabolites in groundwater.

The TTC approach aims to screen and prioritise chemical compounds for which the chemical structure and exposure data are known, but for which no or limited toxicity data is available, using an algorithm developed by Cramer (Cramer, 1978) where the substances, depending upon their chemical structure, are grouped into three structural classes (low, medium, high safety concern) in comparison with the toxicity data from available databases. A database containing carcinogenicity data from animal studies for more than 3500 carcinogenicity experiments (Carcinogen Potency Database) (Gold et al., 1984) and a database containing 613 chemicals based on toxicity other than carcinogenicity (Munro database) (Munro et al., 1996) were available when the TTC approach was developed. Both are based on systemic effects after oral exposure.

As with any risk assessment tool, application of the TTC approach requires a high level of confidence in: 1) the quality and completeness of the databases; 2) the reliability of the exposure data for the intended uses of the compound under study; and 3) the appropriateness of any extrapolations.

### 3-5.2.2 TTC APPROACH FOR HUMAN HEALTH RISK ASSESSMENT OF CHEMICAL SUBSTANCES AND COSMETIC SUBSTANCES

#### a) Systemic toxicity

The Scientific Committees (SCs) consider the TTC approach, in principle, scientifically acceptable for human health risk assessment of systemic toxic effects caused by chemicals present at very low levels. The application of the TTC should, however, be done on a case-by-case basis and requires expert judgement. The TTC approach is also not applicable for a number of chemical classes, which are indicated in detail in SCCP/1171/08 (adopted in 2012).

Practical application of the TTC approach to chemicals with no genotoxicity alert is usually done by analysing the chemical structure and using Cramer classification as an indicator of systemic toxicity. A small number of misclassifications of compounds when using the Cramer decision tree in its present form have been revealed. Misclassification may also result in a classification to a higher toxicity class. (Bhatia et al., 2015; Yang et al., 2017) and hence still be conservative for safety evaluation.

The SCs concluded that the TTC value of Cramer Class II is not supported by the available databases and these substances should be treated as Class III substances. The SCs also accepted in principle the division of substances into Cramer Classes I or III (EFSA, 2016a). When assigning a chemical to the lowest toxicity Class I, 1800 µg/person/d corresponding to 30 µg/kg bw/d the classification should be carefully considered and justified. If classification in Class I cannot be justified, the SCs recommended a general default value equivalent to Class III compounds, being 90 µg/person/d, corresponding to 1.5 µg/kg bw/d for substances without genotoxicity alerts.

All the scientific information available today should be used to define the various toxicity classes before expanding their number, i.e. the classification scheme should be modified based on up-to-date toxicological knowledge (Boobis et al., 2017).

The SCCS agreed that, the default value of 0.15 µg/person/d, corresponding to 0.0025 µg/kg bw/d can be used for chemicals with genotoxicity alerts and hence possible DNA reactive carcinogens but recommends its scientific basis to be strengthened. This could be achieved by e.g., extending the database, analysing all available carcinogenicity
studies, using allometric adjustment factors and/or using the BMD$_5$ or BMD$_{10}$ as PoD for linear extrapolation.

Usually, TTC values are expressed as an amount per person per day. In order to be applicable to the entire population, including all age groups, it is advised to express TTC values in an amount per kg body weight per day and give special consideration to infants under the age of 6 months because of the potentially immature metabolism for some chemicals structures, in particular when the estimated exposure is close to tolerable exposures defined by the TTC values.

In the EU SEURAT-1 project COSMOS, work has been done on the TTC substances with non-genotoxic alerts that are used for cosmetic purposes. The COSMOS TTC dataset, which was quality controlled, contained 552 chemicals (495 cosmetic ingredients) with 219, 40, and 293 chemicals in Cramer Classes I, II, and III, respectively, to expand the chemical space and to provide more robust thresholds for cosmetic-related chemicals. A TTC of 7.9 µg/kg bw/d was suggested for Cramer Class III (which is 5-fold higher than the corresponding TTC value derived by Munro et al., 1996). Cramer Class II was insufficient for derivation of a robust TTC value. For Cramer Class I, a moderately increased TTC of 42 µg/kg bw/d was proposed. When considering the COSMOS-plus-Munro i.e. "federated" dataset, values of 2.3 µg/kg bw/d and 46 µg/kg bw/d were derived for Cramer Class III and I, respectively (Yang et al., 2017). Although the TTC values are based on general toxicity data, it seems that datasets specific for reproductive-developmental endpoints (Laufersweiler et al., 2012; van Ravenzwaay et al., 2017) are adequately covered (Rogiers et al., 2020). Furthermore, work of Patel et al. (2020) whereby 238, 76 and 162 fragrance chemicals in Cramer class I, II and III of the RIFM TTC-database were integrated in the federated dataset, resulted in TTC values for Cramer class I, II and III of 49.1, 12.7 and 2.9 µg/kg bw/ day, respectively. The different values reported are taken up in Table 9 (PoDs used for derivation of TTCs are taken up in APPENDIX 13).

It is important to note that an appropriate exposure assessment is essential for the application of the TTC approach.

TTC thresholds are external dose-based values referring to oral systemic toxicity. For cosmetics, the main exposure route is dermal. In the proposal from Kroes et al. (2007), an external exposure value was converted to an internal exposure value by use of an adjustment factor for percutaneous absorption. The latter value was then compared to the TTC value as if the TTC value is also an internal exposure value. This is the case under the assumption of 100% oral bioavailability, which in many cases is an overestimation. For proper route-to-route extrapolation, the NOAELs from the Munro database need to be corrected for oral absorption. It should, however, be mentioned that in only few cases quantitative information on absorption after oral administration is available.
Table 9: Overview of Threshold of toxicological concern (TTC) values (μg/kg bw/day).

<table>
<thead>
<tr>
<th>Cramer class</th>
<th>SCCP/1171/08 (Munro et al. 1996)</th>
<th>Cosmos-TTC (SEURAT-1; European commission, 2009)</th>
<th>Cosmos/Munro/ Federated DB (Yang et al., 2017)</th>
<th>RIFM/Munro/Cosmos/Federated DB (Patel et al., 2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotoxic compounds</td>
<td>0.0025</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I*</td>
<td>30</td>
<td>42</td>
<td>46</td>
<td>49.1</td>
</tr>
<tr>
<td>II*</td>
<td>Not supported**</td>
<td>-</td>
<td>Not supported**</td>
<td>12.7</td>
</tr>
<tr>
<td>III*</td>
<td>1.5</td>
<td>7.9</td>
<td>2.3</td>
<td>2.9</td>
</tr>
</tbody>
</table>

*Non-genotoxic compounds
**Chemicals of Cramer class II should be treated as Class III substances.

Values in bold are those currently recommended by the SCCS for use for cosmetics-related substances.

For botanical extracts, Kawamoto et al. (2019) reported that the Cramer class III TTC value of 90 μg/person/d might be adequately conservative. For potentially genotoxic substances a TTC value of 10 μg of plant material on a dry weight basis/person per day has been proposed (Mahony et al., 2020). These values are not taken up in the Table 9 as plant materials are composed of mixtures.

TTC thresholds are external dose-based values referring to oral systemic toxicity. For cosmetics, the main exposure route is dermal. In the proposal from Kroes et al. (2007), an external exposure value was converted to an internal exposure value by use of an adjustment factor for percutaneous absorption. The latter value was then compared to the TTC value as if the TTC value was also an internal exposure value. This is the case under the assumption of 100% oral bioavailability, which in many cases is an overestimation. For proper route-to-route extrapolation, the NOAELs from the Munro database need to be corrected for oral absorption. It should, however, be mentioned that only in a few cases is quantitative information on absorption after oral administration available.

The SCCS considers that at present the thresholds proposed by the ‘federated Yang et al. (2017)’ data set of 2.3 μg/kg bw/d and 46 μg/kg bw/d for Cramer classes III and I respectively, are appropriate for use in relation to cosmetics-related substances.

b) Inhalation toxicity

For inhalation exposure TTC, only limited information is available (Carthew et al., 2009; Escher et al., 2010; Schüürmann et al., 2016). Compared to the existing oral database, the pool of available repeated dose inhalation exposure studies is scarce (about 400 rodent studies and even fewer with accompanying local respiratory effects observations) (RIFM database). The development of inhalation TTC is not yet mature enough to be considered as a valid risk assessment tool.

3.5.2.3 TTC APPROACH

For cosmetic ingredients any risk assessment as well as the TTC approach should be based on internal doses (Partosch et al., 2014). Therefore, when the TTC approach is applied for cosmetic ingredients, an adjusted internal TTC value has to be defined considering both dermal and oral absorption. As such, several attempts have been made to arrive to an
internal TTC (iTTC) by adjusting the external NOAEL values of substances by *in silico* estimates of oral bioavailability (Partosch *et al.*, 2015, Reilly *et al.*, 2019). However, the estimates were still based on external dose and not an internal exposure metric such as plasma concentration.

Within the framework of a multi-stakeholder project, further work is currently ongoing towards the development of a set of robust iTTC values that could be utilised in human safety assessment. It is, however, clear that developing an iTTC database is complex and more research is required beyond current attempts where NOAELs were only adjusted for by applying *in silico* tools (Ellison *et al.*, 2019; Rogiers *et al.*, 2020). While work is ongoing to develop robust iTTC thresholds, an interim conservative iTTC of 1 μM plasma concentration for chemicals in consumer products has been proposed, which is supported by the published experience of the pharmaceutical industry, a literature review of non-drug chemical/receptor interactions, and analysis of ToxCast™ data. This is, however, with the additional exclusion to the original TTC exclusion criteria of the estrogen and androgen receptors as targets of concern for low dose exposures.

Efforts are still ongoing to further extend/ refine the TTC framework for inhalation TTC and internal TTC. From the point of view of NAMs, it is clear that the TTC and/or iTTC concepts will be of great value in the future.

**3-6 SPECIAL CONSIDERATION FOR CERTAIN COSMETIC INGREDIENTS**

**3-6.1 Multi-constituent natural ingredients**

Many cosmetic ingredients can be mixtures of multiple substances of natural origin, e.g. essential oils and fragrances; they often can considerably vary in their composition depending on their geographical origin, conditions of harvest, storage, further technical processing etc. In such cases, the cosmetic ingredient should contain the following information:

- qualitative identification and semi-quantitative concentrations of the substances in the mixture (*e.g.* <5%) using the preferred terminology as indicated in Section II of the Inventory of Cosmetic Ingredients and the INCI/CIN name if available;
- for mixtures of variable composition, an indication of the range and the maximum levels of components which may be present in the mixture, taking into account batch to batch variation;
- a clear indication of the cosmetic product category in which the mixture may be used and at what maximum concentration.
- Case by case, in the final safety evaluation, reference should be made to the semi-quantitative composition of the multi-constituent ingredient and the toxic potential of components should be considered.
- Specific labelling to reduce the incidence of contact-allergic reactions in fragrance-sensitive consumers has been foreseen by the inclusion of 26 potentially sensitising fragrance substances in Commission Regulation (EU) 2019/831 amended Annex III to Regulation (EC) No 1223/2009.

More specifically, the presence of these substances must be indicated in the list of substances on the label when their concentrations in the final product exceed 0.001% in leave-on products or 0.01% in rinse-off products (2003/15/EC).

The SCCS has adopted an Opinion on fragrance allergens in cosmetic products which enlarges the list of fragrance allergens considered relevant for consumers and which makes it possible to derive a general threshold for substances with a higher number of recorded cases (SCCS/1459/11).
3-6.2 **Identification of mineral, animal, botanical and biotechnological ingredients in a cosmetic product**

The nature and preparation of some substances may affect the type and amount of data necessary for their identification. The following points indicate the advised requirements for:

- **a) Complex substances of mineral origin**
  - starting material
  - description of:
    - the preparation process: physical processing, chemical modifications, possible purification,
    - characteristic elements of the composition: characteristic components, known toxic components (%).
  - physical and chemical specifications
  - microbiological quality
  - preservatives and/or other additives added.

- **b) Complex substances of animal origin**
  When animal-derived cosmetic substances are used, this should be clearly mentioned (see 3.6.3)
  - species (bovine, ovine, crustacean, ...)
  - organs, tissues, biological liquids (placenta, serum, cartilage, ...)
  - country of origin
  - description of:
    - the preparation process: conditions of extraction (solvent, pH, temperature, ...); type of hydrolysis (acidic, enzymatic, ...); other chemical modifications; possible purification;
    - commercial form: powder, solution, suspension, freeze-dried, ...
    - characteristic elements of the composition: characteristic amino acids, total nitrogen, proteins, polysaccharides, molecular mass, ...
  - physical and chemical specifications
  - microbiological quality including relevant viral contamination
  - additional external contamination
  - preservatives and/or other additives added.

- **c) Complex substances of botanical origin**
  - common or usual names of the plant, alga or macroscopic fungus
  - name of variety, species, genus, and family
  - in case more than one variety of source of a given species is used, each should be specified
  - organoleptic, macroscopic and microscopic evaluation
- morphological and anatomical description (including gender, if applicable) and a photograph of the plant or plant part, alga, or macroscopic fungus used
- natural habitat and geographical distribution of the plant, alga, or macroscopic fungus
- current sources of the plant, alga, or macroscopic fungus, including its geographical location and whether it is cultivated or harvested from the wild
- description of:
  - preparation process: collection, washing, drying, extraction, distillation, destructive distillation, possible purification, preservation procedures, ...;
  - handling, transportation, storage;
  - commercial form: powder, solution, suspension, ...;
  - characteristic elements of the composition: identification of characteristic components, known toxic components (%);
- physical and chemical specifications
- microbiological quality including relevant fungi
- additional external contamination
- preservatives and/or other additives added.

\[d)\] Complex substances derived from biotechnology

For special biotechnologically derived substances, where a modified microorganism or a potential toxic substance has not been fully removed, specific data must be available, which can comprise:

- description of organisms involved: donor organisms, recipient organisms, modified microorganisms
- host pathogenicity
- toxicity, and when possible, identity of metabolites, toxins produced by the organisms
- fate of viable organisms in the environment-survival-potential for transfer of characteristics to e.g. natural bacteria
- physical and chemical specifications
- microbiological quality
- additional external contamination
- preservatives and/or other additives added.

3-6.3 Animal-derived cosmetic substances

When animal derived cosmetic substances are used, this should be clearly mentioned. Entry no. 419 in Commission Reg. (EU) 2019/831 amended Annex II of Reg. 1223/2009/EU specifies several substances for which some concern exists for human health with respect to Transmissible Spongiform Encephalopathy (TSE).

"419. Category 1 material and Category 2 material as defined in Articles 8 and 9, respectively of Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 and substances derived therefrom\[10\]."

---

\[10\] OJ L 300, 14.11.2009, p. 1
As indicated, tallow derivatives of bovine origin are considered as an exception and are accepted as cosmetic substances provided they undergo a number of specific treatments. At present, there is no evidence that TSE may be transmitted by topical exposure.

Finally, taking into account EC Regulation No 1069/2009 laying down health rules concerning animal by-products not intended for human consumption, the SCCP was of the opinion that substances derived from category 1 (inter alia specific risk material) and category 2 (inter alia 'fallen stock') material raise concern in terms of biological risk for human health and therefore must not be present in cosmetic products (SCCP/0933/05). Category 3 material is not intended for human consumption, but it may be used as cosmetic substance in accordance with Regulation 1069/2009, Article 33. Non-animal derived supplements for in vitro testing should be used wherever possible. The chemically defined/serum-free cell culture media can be found in several in vitro test methods for skin corrosion, skin irritation and eye irritation testing (OECD 431, 439 and 492) (van der Valk et al., 2017).

3-6.4 Sun protection substances

For sunscreen lotion, an amount of 18.0 g/day is used in the MoS calculation. It is used as a standard exposure value in the safety evaluation carried out by the SCCS but is not meant as a recommended amount to be applied by the consumer (SCCNFP/0321/02). To reach a comparable level as indicated by the Sun Protection Factor (SPF), sunscreen products have to be applied in quantities similar to the ones used for SPF testing, i.e. 2 mg/cm² (total amount of approx. 36 grams) for the body of an average adult person (2006/647/EC). The quantity of 2 mg/cm², however, is the amount necessary to obtain reproducible SPF results under laboratory conditions. It is higher than the amount usually applied by consumers.

This observation has been reported frequently: when consumers use their own sun products (lotions, alcoholic solutions, gels, creams, sprays,...) and apply the products on the whole body surface, values for use of products between 0.5 - 1.3 mg/cm² have been found (Stenberg et al., 1985; Bech-Thomsen et al., 1993; Diffey, 1996; Gottlieb et al., 1997; Autier et al., 2001 and 2007). The values seem to depend on the study protocol used, the location on the body measured and several other factors. More recent publications still come to comparable values in the range of 0.39-1 mg/cm² (Danish Protection Agency No. 151, 2016, Ficheux et al., 2016a, Gomez-Berrada et al., 2017). When the product is applied only to the face, then the amount applied might be higher than 2 mg/cm² (Gomez-Berrada et al., 2017). The amount used by the SCCS in safety calculations reflects actual consumer use and takes the whole body area (17500 cm²) into account. The average exposed skin area of sunscreen users according to the recent report of the Danish authorities is 14,700 cm².

The use of 18g/d sunscreen corresponds with the values reported by Biesterbos et al. (Biesterbos et al., 2013), who found a mean use amount of 9.2 g/application, derived on the basis of pictures. If two applications are considered, this is about 18 g/d. Unpublished data by von Goetz (von Goetz, 2018) from a small-scale pilot study with weighing also provided a mean of 9 g for whole-body application (5 applications by 2 persons).

If a sun protection substance is applied in a sprayable product that may give consumer lung exposure by inhalation, other considerations should be taken into account (see 3-3.4.1.3). For lipcare products, 100% absorption of the substance should be considered for safety assessment.

3-6.5 Endocrine active substances (EAS)

3-6.5.1 Definitions

Some natural and synthetic chemical substances can interact, interfere or disrupt the function of the endocrine system that regulates various metabolic and developmental functions in the
The endocrine system comprises a complex array of signalling and feedback mechanisms, the disruption of which has been linked to various adverse health effects, such as reproductive effects, metabolic disorders, cognitive deficits and cancers. However, the endocrine system also involves numerous cycles and feedback loop mechanisms and adaptive responses that together regulate the secretion of hormones and maintain homeostasis. A substance interfering with the endocrine system may affect hormone secretion or other cellular factors, but it is possible that such perturbations remain within the homeostatic or metabolic detoxification capacity and therefore do not result in adverse effects in the intact organism. Some effects linked to endocrine disruption have also been shown to have critical window(s) of susceptibility, e.g. increased susceptibility of an organism within a certain developmental period.

The definition of Endocrine Disrupters (EDs) endorsed at the European level is the same as proposed by WHO/IPCS (WHO/IPCS, 2002) and is as follows: “An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub)populations”.

The OECD's revised conceptual framework (OECD TG 150) also has a prerequisite to identify the adverse effect in an intact organism for regarding a substance an endocrine disruptor. Thus, whilst a chemical may be regarded an EAS on the basis of activity/interaction towards one or more components of the endocrine system (e.g., a hormone receptor), it can only be regarded as an ED if there is evidence for a biologically-plausible causal relationship between the endocrine perturbation/activity and the adverse effect(s) in an intact organism.

The joint EFSA/ECHA/JRC draft guidance (EFSA and ECHA, JRC, 2018) has defined endocrine activity as 'Interaction with the endocrine system which can potentially result in an effect on the endocrine system, target organs and tissues'.

3-6.5.2 Identification of EDs and regulatory consequences

A number of chemicals have been identified, or are suspected, as EDs. However, "only a small fraction of these chemicals has been investigated in tests capable of identifying overt endocrine effects in intact organisms" (WHO-UNEP report, 2012).

Under REACH, EDs can be identified as Substances of Very High Concern (SVHC) alongside chemicals known to cause cancer, mutations and toxicity to reproduction. There are several substances identified as SVHC for their endocrine disrupting properties in the Candidate List of SVHC for authorisation (https://echa.europa.eu/candidate-list-table).

Amongst other actions, the Commission launched the Fitness Check: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1553617067256&uri=CELEX:52018DC0734 and regulated ED substances in specific areas, including chemicals (Regulation EC 1907/2006), Pesticides (Regulation EC 1107/2009), Biocides (Regulation EU 528/2012), Water quality (Water Framework Directive 2000/60/EC).

3-6.5.3 Stepwise approach for cosmetics and their ingredients

For cosmetics, the Commission adopted a review of the Cosmetics Regulation regarding substances with endocrine disrupting properties. It was concluded that adequate tools are available to regulate the use of cosmetic substances that present a potential risk for human

---

health, including when displaying ED properties. For environmental concerns, application of the REACH Regulation is considered. The SCCS is following this process closely and is actively engaged in the safety assessment of potential ED substances used in cosmetics.

Due to the animal testing ban under the Cosmetics Regulation, it is now out of scope to test cosmetic ingredients in vivo for endocrine disruption. Cosmetic ingredients therefore can be assessed for endocrine activity in a stepwise approach using data generated outside the cosmetic field or for a new cosmetic ingredient, using NAMs (in silico models, read across, in vitro assays, other mechanistic techniques such as ‘omics’).

Among the various endocrine modalities, Estrogen (E), Androgen (A), Thyroid (T) and Steroidogenic (S) - (EATS) pathways are the best characterised, whereas retinoid signalling and hypothalamo-pituitary-thyroid axis are poorly investigated (Kortenkamp et al., 2011; UNEP/WHO, 2012).

The OECD 150 guideline provides tools on how to assess endocrine properties of a substance. The general approach taken by this GD is primarily to consider the possible results that might be obtained from each endocrine disruption-responsive assay and to provide guidance about how these results might be interpreted in light of data that may or may not already be available from other in vitro or in vivo assays. This should include all available data such as publications in the peer-reviewed literature as well as TGs. In order to inform this interpretation, background data on the assays addressed, non-testing approaches and other considerations relevant to the assays are discussed. These include cross-species extrapolations, read-across and multiple Modes of Action (MoA). The nature, quantity and quality of the existing and new data in each of the scenarios for the endocrine disruption-responsive assays should be evaluated systematically in a WoE approach. There is generally no single “right” answer. Use of other technologies (e.g. “omics” data) may help in understanding the link between endocrine-related mechanisms and a WoE approach. This GD should therefore be used flexibly in light of local regulatory needs. The key questions addressed concern likely mechanisms of endocrine action and any resulting apical effects that can be attributed to such action. In Table 10 the conceptual framework for testing and assessment of EDs as provided in OECD guideline 150 is shown.
For a new cosmetic ingredient, due to the animal testing ban, characterisation will, however, be limited to the study of endocrine activity at **level 1** (existing data and using *in vivo* data if they have been generated before the animal ban or for another regulatory purpose than cosmetics) and **level 2** (*in vitro* assays) of the OECD’s revised Conceptual Framework as described below.

- **Lines of evidence level-1 (existing data and non-test information):**

  The first level of evidence for endocrine activity of a substance may be provided by: physical and chemical properties (*e.g.*, MW, reactivity, volatility, biodegradability), all available (eco)toxicological data from standardised or non-standardised tests, read-across, chemical categories, QSARs and other *in silico* predictions, and ADME model predictions for a new compound intended for use in a cosmetic product, the use of *in silico* models and read-across tools, together with physicochemical data.

  A number of *in silico* models and tools are available for the estimation of a substance’s potential for binding with hormone receptors, such as the Estrogen Receptor (ER), the Androgen Receptor (AR), and the Pregnane X Receptor (PXR). These include commercial programmes such as ADMET Predictor™ and MetaDrug™, as well as publicly available tools such as VEGA and Online Chemical Modeling Environment (OCHEM). Another open source docking tool, Endocrine Disruptome, is also available for virtual screening of EDs (see EFSA and ECHA, JRC, 2018).

  In addition, databases are available that provide some information on endocrine properties of chemical substances\(^\text{13}\). These may be subject to some criticism (*e.g.*, inaccurate information, some entries not enough documented). Endocrine Disruptor Screening Program (EDSP) Tier 1 screening assay results and the dataset from Collaborative Estrogen Receptor

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td><em>Existing data and non-test information</em>&lt;br&gt;eg: Physical and chemical properties / QSARs</td>
</tr>
<tr>
<td>Level 2</td>
<td><em>In vitro</em> assays providing data about selected endocrine mechanism(s) / pathways(s)&lt;br&gt;eg: Estrogen receptor transactivation (OECD TG 455) / Estrogen or androgen receptor binding affinity</td>
</tr>
<tr>
<td>Level 3</td>
<td><em>In vivo</em> assays providing data about selected endocrine mechanism(s) / pathway(s)&lt;br&gt;eg: Uterotrophic assay (OECD TG 440), Fish reproductive screening assay (OECD TG 229)</td>
</tr>
<tr>
<td>Level 4</td>
<td><em>In vivo</em> assays providing data on adverse effects on endocrine relevant endpoints&lt;br&gt;eg: Repeated dose 90-day study (OECD TG 408), Daphnia reproduction test (OECD TG 211)</td>
</tr>
<tr>
<td>Level 5</td>
<td><em>In vivo</em> assays providing more comprehensive data on adverse effects on endocrine relevant endpoints over more extensive parts of the life cycle of the organism&lt;br&gt;eg: 2-generation reproduction toxicity study (OECD TG 416) / Medaka extended one-generation reproduction test (OECD TG 240)</td>
</tr>
</tbody>
</table>

\(^\text{13}\) Endocrine active substances information system (EASIS) (EC JRC); ToxCast (US EPA); ToxCast ER prediction model (US EPA); SIN List (International chemical secretariat); The endocrine disruption exchange (TEDX); Endocrine disruptor screening program, EDSP21 (US EPA); Endocrine disruptor knowledge base, EDKB database (US FDA); Estrogenic activity database, EADB (US FDA); Toxicology data network (Toxnet); Developmental and Reproductive Toxicology database (DART); NURSA (nuclear receptor signalling atlas); OECD (Q)SAR toolbox (OECD, ECHA); AOP knowledge base (OECD); ToxRefDB (US EPA); eChem portal (OECD); COSMOS database - cosmetic ingredients; Danish (Q)SAR Database; (Q)SAR Data Bank
Activity Prediction Project (CERAPP) are also reported in Mansouri et al., 2016. These databases may also enable read-across for endocrine activity and provide a basis for further development of structure-activity based predictive models. Some of these databases also contain in vivo experimental data.

Amongst the available in silico tools, the OECD QSAR Toolbox offers a major software platform that incorporates several databases comprising chemical data, experimental (eco)toxicological data, and estimated values from QSAR tools, together with incorporated QSAR modelling tools and Expert Systems. For example, it contains:

- The OASIS Estrogen Binding Database, consisting of diverse compounds with relative Endocrine Receptor Binding Assay (ERBA) data. The Toolbox allows in silico screening of a compound’s endocrine activity through Danish EPA’s Relative ERBA (Q)SAR, which is based on ER binding in vitro.

- QSAR models, including MultiCASE ERBA QSAR, which is based on a hierarchical statistical analysis of a training set composed of ER binding data on a variety of chemical structures that are inactive, weak, or powerful ER binders.

- Structural-alert based ER-binding profilers to classify chemicals as non-binders or binders (weak, moderate, strong and very strong binders) depending on their MW and structural characteristics.

- Structural-alert based expert systems, such as the US EPA's rtnER expert system based on binding to the rainbow trout estrogen receptor.

The OECD QSAR Toolbox also provides a major platform for read-across between chemicals that share structural and/or functional similarities, using a substantial set of high quality databases. If compounds in the database are identified with the required structural and alert profile similarities to the target compound, they may be used as read-across candidates for the prediction of the ER binding of the target compound.

Other in silico systems based on molecular docking tools and 3D-(Q)SAR models are also available that allow virtual screening of chemical substances for affinity/binding with hormone receptors (Jacobs, 2004; Vedani et al., 2012; Galli, 2014). The identification of affinity/binding to a hormone receptor by virtual screening, however, needs to be seen in the context of the scoring function used for each target, because a universally applicable scoring function is not yet available (Vuorinen et al., 2013). Also, whilst in silico models can reliably predict simple endpoints, such as the binding free energy toward the receptor binding, they have a limitation for the prediction of more complex endocrine related in vivo endpoints, such as reproductive and developmental toxicity.

The available experimental data are still too scarce to allow comparison between the success rates of the results from different in silico methods (Vuorinen et al., 2013). The topic has been recently reviewed by Schneider et al. (2019), who highlighted that whilst in silico prediction approaches provide first stage indication of ED properties, further modeling of intermolecular interactions and cellular behavior is also essential to understand the potential effects on the endocrine system.

- Lines of evidence level-2 (in vitro assays providing data about selected endocrine mechanism(s)/ pathways(s) (mammalian and non-mammalian methods).

The currently available in vitro methods include estrogen, androgen, or steroidogenic receptor binding assays, whilst methods relevant to thyroid hormone are not sufficiently sensitive to completely exclude effects due to disruption of thyroid-related functions. A validation study on 17 methods for the detection of thyroid disruptors was launched by EURL ECVAM (JRC 2017). The available in vitro methods are listed below:
- Estrogen (OECD TG 493) or androgen receptor binding affinity (US EPA TG OPPTS 890.1150) (OPPTS stands for Test guidelines for pesticides and toxic substances).
- Estrogen receptor transactivation (OECD TG 455),
- Yeast estrogen screen (ISO 19040-1,2,83)
- Androgen receptor transcriptional activation (OECD TG 458)
- Steroidogenesis in vitro (OECD TG 456)
- Aromatase Assay (US EPA TG OPPT 890.1200)
- Thyroid disruption assays (e.g., thyroperoxidase inhibition, transthyretin binding)
- Retinoid receptor transactivation assays
- Other hormone receptors assays as appropriate
- High-throughput screens (See OECD GD No. 211 describing Non-Guideline In vitro Test Methods: OECD 2014c)

Whilst the results from Levels 1 and 2 approaches can be indicative of endocrine activity of a cosmetic ingredient, they will not definitively inform whether the substance will cause adverse effect(s) in the intact organism to be regarded an ED. In view of this limitation, it is important that all the evidence from physicochemical properties, available literature, in silico models, read-across, in vitro assays, and other techniques (such as “-omics”) is integrated in a systematic manner to generate sufficient WoE to exclude the potential toxicity of a cosmetic ingredient through the endocrine related effects. The integration of in silico methods and computational systems biology has been proposed as a means to more critically assess the endocrine activity of chemical substances (Ruiz et al., 2017). Some key characteristics of EDs have also been proposed following an expert consensus statement as a basis for hazard identification (Merill et al., 2020).

3-6.5.4 Cosmetic ingredients suspected to have ED properties

As yet there is no harmonised approach towards health risk assessment procedures for EDs within the different regulatory frameworks in the EU. The SCCS has issued a memorandum (SCCS/1544/14) to clarify its position on substances with potential ED properties when used as cosmetic ingredients. In the context of the animal testing ban, it is not possible for the SCCS to fulfill the criteria as laid out under the OECD Conceptual Framework for the identification of EDs for cosmetic ingredients in the context of the animal testing ban.

In the view of the SCCS, these substances should be treated like other substances of concern for human health and therefore be subject to risk assessment and not only hazard assessment.

This is in agreement with the past and current evaluations by the SCCS in regard to the safety assessment of cosmetic ingredients with suspected ED properties e.g., parabens (SCCP/1017/06, SCCP/1183/08, SCCS/1348/10, SCCS/1446/11, SCCS/1514/13), triclosan (SCCP/1192/08, SCCS/1414/11), homosalate (SCCP/1086/07), benzophenones, 4-methylbenzylidene camphor and 3-benzylidene camphor (SCCNFP/0483/01, SCCP/1183/08, SCCS/1513/13), melatonin (SCCS/1315/10), resorcinol (SCCS/1270/09), cyclomethicone (SCCS/1241/10), decamethylcyclopentasiloxane (cyclopentasiloxane) (SCCS/1549/15). Ingredients with potential endocrine disrupting properties used in cosmetic products are taken up in a list of 28 compounds to be considered by the SCCS for safety evaluation. 14 substances of this list are considered high priority and are currently being assessed by the SCCS. These are benzophenone-3, kojic acid, 4-methylbenzylidene camphor, propylparaben, triclosan, resorcinol, octocrylene, triclocarban, butylated hydroxytoluene (BHT), benzophenone, homosalate, benzyl salicylate, genistein and daidzein.

Another way forward could be to demonstrate what could be considered as biologically irrelevant exposure. For instance, in the case of melatonin, topical application (in real use conditions) did not perturb endogenous hormone levels in humans due to low systemic exposure (SCCS/1315/10). Toxicokinetic studies and PBPK modelling could help to bridge the
gap between in vivo and in vitro evidence by providing data on (internal) exposure in relation to concentrations that were found to be active in in vitro assays (Coecke et al., 2013; Bessems et al., 2014).

It also needs to be highlighted that the SCCS only assesses cosmetic ingredients in relation to safety of consumers’ health, and as such they are not assessed for effects on the environment. Data generated on the environmental effects may, however, be also useful to support EA/ED mode of action but not their potency. For example, some ecotox tests may be informative for the assessment of endocrine activity of a compound in humans or thyroid effects (e.g. Xenopus Eleutheroembryonic Thyroid Assay (XETA) (OECD 248), Amphibian Metamorphosis Assay (AMA) (OECD Test N° 231), Larval Amphibian Growth and Development Assay (LAGDA) (OECD Test N° 241).

A recent review has indicated a high degree of confidence in the conservation of the HPG-axis between fish and mammals, and the HPT-axis between amphibians and mammals (McArdle et al., 2020).

An ongoing EU project ERGO (https://ergo-project.eu/) is looking into the scientific basis that could bridge the current divide between human health and the environment in terms of non-mammalian testing for the identification of EDs (with a focus on the thyroid system) for the chemicals that affect endocrine axes across vertebrate classes.

3-6.6 CMR Substances

Based on their inherent properties, hazardous chemicals are classified accordingly on a worldwide (Globally Harmonised System) and European level (Regulation 1272/2008). Special attention is given to substances that are carcinogenic, germ and somatic cell mutagenic or toxic for reproduction for which three hazard classes exist according to these frameworks, i.e. Category 1A, 1B and 2. Cat 1A means that the substance is known to have the respective potential in humans, Cat 1B means that the substance is presumed to have the respective potential in humans, and Cat. 2 means that the substance is suspected to have the respective potential in humans.

CMR 1A, 1B and 2 substances are prohibited for use in cosmetics, unless the specific criteria set in Cosmetics Regulation (EC) No 1223/2009 are fulfilled, whereby criteria are stronger for CMR 1A and 1B substances compared to CMR 2 substances

CMR 2 substances may be used in cosmetics where they have been evaluated by the SCCS and found safe. These substances could be allowed to be used as cosmetic substances within Europe under specific conditions. Examples for CMR2 substances include trisodium nitriloacetate (SCCS/1391/10), trimethylbenzoyldiphenylphosphine oxide (TPO) (SCCS/1528/14) polyaminopropyl biguanide (PHMB) (SCCS/1581/16), lysmeral (SCCS/1591/17), salicylic acid (SCCS/1601/18), pigmentary TiO₂ (SCCS/1617/20).

CMR 1A or 1B substances may be used in cosmetics exceptionally where (1) they comply with the European food safety requirements14, (2) they cannot be replaced by suitable alternatives, (3) the application is made for a particular use of the product category with a known exposure and (4) the substances were evaluated and found safe by the SCCS for use in cosmetic products, in particular in view of exposure to these products and taking into consideration the overall exposure from other sources, taking particular account of vulnerable population subgroups (2009/1223/EC). Examples for CMR 1B substances include boron compounds (SCCS/1523/13), formaldehyde in nail hardener (SCCS/1538/14) and zinc pyrithione (SCCS/1614/19).

A guidance document has been developed by the EU Commission with the aim of enabling a harmonised approach to the development and use of aggregate exposure estimates in assessing the safe use of CMR substances as cosmetic ingredients (see Appendix 5).

14 Regulation (EC) No. 178/2002
However, as clarification and as agreed by the Commission, whereas the applicant is responsible for providing the exposure data on CMR substances, the procedure described in No. 16-19, 21 and 22 of the Guidance, is only foreseen in case that the applicant for any reason cannot obtain the data from the owner of the data required.

3-6.7 **LIFETIME CANCER RISK (LCR)**

In the safety assessment of carcinogenic substances, an appropriate dose descriptor, BMDL10 or T25, should be identified, whenever sufficient information is available (ECHA, 2019; EFSA, 2019b; COC, 2020). The SCCS recommends that, where possible, the BMD approach should be used for deriving a POD, as a starting point for human health risk assessment, including carcinogenicity by a genotoxic or non-genotoxic mode of action. This view is also supported by other bodies including the EFSA and the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC). In the absence of dose-response data allowing for the application of the BMD approach, the T25 is a simplified method to estimate the carcinogenic potency of a given substance.

The T25 (expressed as mg/kg bw/d) is defined as the dose which leads to the development of tumours at a specific tissue site in 25% of the animals after correction for spontaneous incidence and within the standard lifetime of the species (Dybing et al., 1997). The determination of BMDL10 (expressed as mg/kg bw/d) uses mathematical curve fitting techniques to calculate the lower 95% confidence level at a 10% benchmark response. Both BMDL10 and T25 can be used as starting points to determine an additional LCR or to calculate a MoE, which represents the ratio between a dose descriptor and the estimated human exposure dose. Basic steps in LCR calculations based on T25 are provided in Appendix 12.

Some countries and international organisations have considered that the LCR in the general population of less than $10^{-5}$ is considered tolerable (SCCS/1486/12). Under REACH, the "indicative tolerable cancer risk level" for the general population is $10^{-6}$ (ECHA 2012a). It should be noted that the tolerable LCR is a risk management issue and outside the scope of the mandate of the SCCS.

3-6.8 **NANOMATERIALS**

3-6.8.1 **DEFINITION OF NANOMATERIAL**

Regulation (EC) No 1223/2009 specifically covers the use of nanomaterials in cosmetic products. The Regulation provides a definition of nanomaterial, as well as a mechanism for notification, labelling, and safety evaluation of cosmetic products containing nanomaterials. Under Article 2 (1) (k), “nanomaterial” means an insoluble or bio-persistent and intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm”.

The Regulation therefore covers mainly those nanomaterials that are intentionally produced and are insoluble/poorly-soluble or biopersistent (e.g., metals, metal oxides, carbon materials, etc.), and not those that are either completely soluble or degraded and are not persistent in biological systems (e.g., liposomes, oil/water emulsions, etc.).

When dealing with the question of solubility, as provided in the current definition, it is important to note that any nano-specific risk may change (even diminish) when a nanomaterial is dissolved. But it is the time period during which the dissolution happens that determines the considerations for risk assessment based on either particle risk or soluble substance risk. Partial dissolution over a long period of time may lead to the mistaken claim
that the material is 'soluble', and therefore not a nanomaterial under the scope of the current definition provided in the Cosmetic Regulation (EC) No 1223/2009.

3-6.8.2 Potential safety issues of nanomaterials

The use of nanomaterials in cosmetics is subject to a high level of protection of human health under the EU Cosmetics Regulation. This is because nano forms of some substances may differ from their conventional (bulk) forms in terms of physicochemical properties, biokinetic behaviour, and/or biological effects. Any intended use of nanomaterials (other than colourants, preservatives and UV filters and not otherwise restricted by the EU Cosmetics Regulation) in cosmetic products must be notified to the Commission by the RP through the Cosmetic Product Notification Portal (CPNP) at least six months prior to placing them on the market, except if they were already on the market before 11 January 2013. In case of a safety concern over a nanomaterial, the Commission shall request the SCCS for a scientific Opinion on the safety of the nanomaterial for use in relevant categories of cosmetic products in consideration of the reasonably foreseeable consumer exposure.

The SCCS was recently mandated by the Commission to provide scientific advice to facilitate the identification of any safety concerns relating to the nanomaterials intended for use in cosmetic products, so that they can be prioritised for safety assessment. The advice has recently been published (SCCS/1618/2020), which provides the key scientific aspects of a nanomaterial that should trigger consumer safety concerns, and therefore the need for further evidence-based safety assessment.

Although there are currently no hard and fast rules for identifying the safety concerns for nanomaterials, as a general principle, each of the following attributes should add a further degree of safety concern. For example, where:

1. The nanomaterial has constituent particles that have sizes in the lower range of the nanoscale.
2. The nanomaterial is insoluble, or only partially soluble.
3. The chemical nature of the nanomaterial suggests the potential for a toxicological hazard.
4. The nanomaterial has certain physical/morphological features (e.g. needle shape, rigid long fibres) that point to the potential for harmful effects.
5. The nanomaterial has surface reactivity in terms of catalytic (including photocatalytic) activity, potential for radical formation, or other surface properties (e.g. potential allergenicity due to proteinaceous surface).
6. The nanomaterial has a different biokinetic behaviour than the conventional equivalent. For example, a surface modification/coating (e.g. hydrophobic coatings, encapsulation) has been applied to core nanoparticles to alter their ADME properties and as a result make them more accessible systemically, compared to the neat nanoparticles and/or their conventional chemical forms.
7. The nanomaterial is used as vehicle to carry other substances that have not been assessed for safety as individual components, or together in the form of nano-scale entity.
8. There is a likelihood of systemic exposure of the consumer to nanoparticles through the use of final products. The frequency of use, and/or the amounts of the relevant consumer product are relatively high.
9. There is evidence for persistence/accumulation of nanoparticles in the body.
10. Nanoparticles have other distinctive properties not present in conventional form of the same material, or have a new activity/function (e.g. a smart/functional nanomaterial).
11. The nanomaterial is so novel that it does not have a conventional comparator to allow assessment of changes in properties, behaviour or effects.

12. The nanomaterial is used in a product that is inhalable (taken up by inhalation into respiratory tract and lung), and the particles are respirable (can reach respiratory epithelium i.e. alveoli).

13. The assessment of genotoxicity is performed inadequately, e.g. *in vitro* studies are without information on stability of the test suspension, or evidence of cell exposure (internalisation).

Whilst this section only provides a brief guidance on nanomaterials in cosmetics, the SCCS has published a more detailed specific Guidance on Risk Assessment of Nanomaterials (SCCS/1611/19), which is an update of a previous guidance published in 2012 (SCCS/1484/12), a Memorandum on the Relevance, Adequacy and Quality of the Data Expected in Safety Dossiers on Nanomaterials (SCCS/1524/13, Revision of 27 March 2014), and a checklist for the applicants submitting dossiers on nanomaterials as cosmetic ingredients (SCCS/1588/17).

Safety assessors need to consult these documents to ensure that any testing to generate evidence on the safety of nanomaterials is carried out with special considerations of the nano-size related characteristics of the materials, and in compliance with the ban on animal testing of cosmetic ingredients. In this regard, it is important to note that, as indicated in the memorandum (SCCS/1524/13, Revision of 27 March 2014), the SCCS will only consider data that are relevant to the nanomaterial(s) under evaluation, are sufficiently complete, and are of appropriate quality to support the safety assessment.

The SCCS has also published a number of scientific opinions in the past few years on the nano-form of different materials. These include 1,3,5-triazine, 2,4,6-tris[1,1’-biphenyl]-4-yl-(ETH50) (SCCS/1429/11, revision of 13/14 December 2011); zinc oxide (SCCS/1489/12 revision of 11 December 2012); titanium dioxide (SCCS/1516/13, revision of 22 April 2014); carbon black (SCCS/1515/13, revision of 15 December 2015), 2,2’-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol), MBBT (SCCS/1460/11), silica (SCCS/1545/15), hydroxyapatite (SCCS/1566/15); additional coatings for titanium dioxide (SCCS/1580/16); and titanium dioxide in sprays (SCCS/1583/17). Styrene/Acrylates copolymer (nano) and Sodium styrene/Acrylates copolymer (nano) (SCCS/1595/18); Colloidal Silver (SCCS/1596/18); Solubility of Synthetic Amorphous Silica (SAS) (SCCS/1606/19). These opinions can provide further information on the type of scientific evidence needed in a safety dossier on nanomaterials intended for use as cosmetic ingredients.

In general, a number of reviews have concluded that the existing risk assessment paradigm, in use for conventional chemicals, should in principle be also applicable to engineered nanomaterials. However, it has also been pointed out that the current testing methods may need certain adaptations to take account of the special features of nanomaterials (Rocks et al., 2008; SCENIHR, 2009; OECD, 2009c; SCCS, 2012; EC, 2012; ECHA, 2017; EFSA, 2018).

**Special features of nanomaterials:**

i. Due to high surface energies, nanoparticles have a tendency to stick together to form agglomerates and aggregates, and/or bind with other moieties on the particle surface. This particle behaviour can change in the presence of certain stabilising/dispersing agents. Characterisation of nanomaterials, prior to and during a test, is therefore a key to ensuring that results obtained are valid.

ii. Most of the currently available test methods were developed for conventional substances that can be solubilised. In contrast, nanomaterials generally comprise insoluble or poorly soluble nanoparticles that are dispersed in a test medium in the form of a nano-suspension rather than a solution. The applied concentration of a nanomaterial may therefore drop during the test due to particle agglomeration, sedimentation, binding with other moieties.
in the medium, or sticking to the sides of the glass/plastic ware. This could lead to only a partial or no exposure of the test systems during the test. Nanomaterials are known to adsorb or bind different substances on their surfaces, including proteins (Šimon and Joner, 2008; Lynch and Dawson, 2008; Monopoli et al., 2012; Moore et al., 2015). They may also bind other substances in the test medium and carry them into the exposed test systems, leading to artefacts in the results.

iii. The toxicological hazards of chemical substances are currently measured and expressed in terms of weight or volume units (such as mg/kg, or mg/l). These conventional metrics may not be fully adequate to account for nanomaterial toxicity. It is therefore important that tests on nanomaterials are not only evaluated in terms of weight/volume concentration, but that results are also expressed in other dose-describing metrics, such as particle number concentration, surface area etc.

iv. Due to the insoluble particulate nature, and the nano-dimensions, nanomaterials may show an altered uptake and biokinetic profile in a biological system compared to equivalent conventional forms e.g. transport of insoluble particles across biological membrane barriers is not driven by concentration-gradient based diffusion partitioning, but by other mechanisms such as endocytosis and/or active (energy-driven) uptake and transport.

v. Currently, there are uncertainties in regard to whether the endpoints identified by the current testing methods will be sufficient to identify and characterise all the hazards that may be associated with a nanomaterial.

3-6.8.3 Required information for nanomaterials

The information required by the SCCS for the evaluation of nanomaterials as cosmetic ingredients is described in SCCS/1588/17 and SCCS/1611/19.

The following aspects deserve special attention:

i. Although most analytical methods used routinely for chemical substances have not yet been validated for nanomaterials, a careful choice of mainstream method(s) should provide sufficient means to gather adequate characterisation data for nanomaterials. The use of more than one method generally adds more confidence to the measured values e.g. for the measurement of particle size distribution, additional imaging by electron microscopy has been recommended by both SCCS (SCCS/1611/19) and EFSA (EFSA, 2011b; EFSA, 2018).

ii. Where there is evidence for systemic absorption, further investigations are required to confirm whether the absorbed material was in a nanoparticle form or in solubilised/ionic/metabolised form. Where the absorption of nanoparticles cannot be ruled out either by experimental measurements or justified on the basis of solubility/degradation of the nanomaterial, the SCCS may apply a default approach and assume that 100% of the absorbed material was in nano form.

iii. Surface modification/surface coating may bring about profound changes in a nanomaterial in regard to certain physicochemical properties and potentially the toxic effects.

iv. Therefore, a full dataset would be preferable. As a minimum, in addition to safety data on the core nanomaterial, the SCCS would require the following:

- Information/data on each material used for surface modification/coating of the nanomaterial to indicate that it is safe for use in the intended cosmetic product.
- Data on physicochemical properties of the surface-modified/coated nanomaterial to show that they have not significantly changed compared to either the same material when uncoated, or with a different surface modification/coating that has already been assessed safe by the SCCS.
- Data on dermal penetration, stability of the surface modification/coating, and (photo)catalytic activity, where relevant.
3-6.9 Hair dyes and hair dye components

In April 2003 the Commission, together with the Member States, agreed on a step-by-step strategy to regulate all hair dyes listed as substances in cosmetic products. The main element of the strategy was a tiered, modular approach, requiring industry to submit by certain deadlines safety dossiers for hair dye components and possible mixtures. This strategy was supported by SCCNFP (SCCNFP/0807/04) through its "Opinion on hair dyes without file submitted", in which the experts clearly expressed the demand for a safety dossier for all hair dyes, irrespective whether they had already been taken up in one of the annexes of the cosmetic legislation. Differentiation was made between temporary, semi-permanent and permanent hair dyes (SCCP/0959/05).

To ensure the safety of hair dye products, the Commission decided to ban all permanent, semi-permanent and temporary hair dyes for which industry did not submit any safety files and those for which the SCCP had given a negative opinion (IP/06/1047).

In 2013, the SCCS confirmed the views expressed in an earlier Memorandum (SCCP, 2006), that hair dye substances which fulfil the criteria for classification as Skin Sens 1, H317 (according to CLP) may not be safe for consumers and that this is particularly so for hair dye substances categorised as extreme and strong sensitisers (SCCS/1509/13).

3-6.9.1 MoS calculations for hair dye formulations

Intermittent exposure and MoS calculations: hair dyes are not intended to be applied on a daily basis. However, the MoS is calculated by dividing the PoD for daily application by the SED for a single application. Although this approach can be debated, this is used as a conservative approach.

Thus, the daily dose should not be averaged over the whole year (ECHA, 2012a).

3-6.9.2 Assessment of oxidative hair dye substances and reaction products

The SCCS is focused on the overall consumer health risk caused by ingredients as well as products and intermediates of oxidative hair dyes formed during hair dyeing processes (including their potential mutagenic/genotoxic/carcinogenic properties). The following conclusions were drawn in the SCCS’s opinion on reaction products of oxidative hair dye ingredients formed during hair dyeing processes (SCCS/1311/10):

- Precursors and couplers with a variety of substituents such as hydroxy, amino, imino carbonyl, hydroxyethyl, hydroxyethoxy and alkyl groups were included.

- The use of oxidative hair dye formulations results in consumer exposure to precursors and couplers as well as to their reaction products. Exposure to these reaction products is considered generally lower compared to that from precursors and couplers since dimers and trimers are formed with higher molecular weight. No exposure to intermediates or self-coupling products was detected under experimental conditions. Therefore, in the risk assessment of reaction products, toxicity is not considered a concern due to the low and intermittent exposure (on average once per month).

- The dermal absorption rates in the in vitro skin penetration studies of the 14 representative reaction products evaluated ranged from 3.27 to 717.79 ng/cm² (mean + 1 SD). This corresponds to 1.9 to 416 µg absorbed dose (i.e. dose potentially bioavailable) per hair dye application (i.e. 0.03 to 6.9 µg/kg bw).

- As no data were made available for sensitisation risk of the reaction products, this endpoint was not specifically addressed.
- The use of (Q)SAR in the case of reaction products is of limited value so far since the arylamine structure, a structural element of many hair dye precursors and reaction products, is automatically identified as an alert. It is desirable to use or to develop in the future SAR for in vivo genotoxicity which satisfies the OECD principles and has a known applicability domain.

- Although for precursors, couplers and reaction products, positive results are commonly observed in in vitro genotoxicity assays there is no clear evidence of genotoxicity in vivo (in case in vivo data are available). It is possible that genotoxic effects can only be found at concentrations where the N-acetylation (detoxifying) capacity of the cells is overwhelmed, indicating that a ‘first-pass’ effect in skin could be taken into account for risk assessment of the topically applied aromatic amines (Zeller and Pfuhler, 2014; Nohynek et al., 2015).

- The structures of the primary intermediates and trimer molecules reveal that they contain an aromatic secondary amino group, which if exposed to a nitrosating agent may form an N-nitroso derivative (Lewis et al., 2013). Although, such transformation is theoretically possible, no evidence was provided under real exposure conditions.

For all the above reasons, the SCCS performs the safety assessment of oxidative hair dyes based on the toxicological evaluation of the ingredients (i.e. precursors and couplers) and not the reaction products.

With regard to the animal testing ban for cosmetic ingredients, see Section 3-1 and the scheme in Appendix 4.

3-6.10 COSMETIC INGREDIENTS FOR BABY AND CHILDREN PRODUCTS

In certain cases it may be necessary to calculate the MoS of cosmetic ingredients for a specific subpopulation such as babies and children, e.g. exposure to leave-on cosmetic products designed for application on the nappy area or products intended for children with a higher sensitivity for certain endpoints. Also, differentiation between premature babies and full-term neonates must be made since important structural and functional skin differences are present. In particular, the barrier function in premature babies is impaired (Visscher et al., 2015, 2020a, 2020b). Also, pH differences play a prominent role (Fluhr and Darlenski 2018; Proksch 2018) which may be important for baby care products that are used often, such as wet wipes (Rodriguez 2020; Gustin et al., 2020).

Here, only intact skin of full-term babies has been considered.

In light of potential differences in metabolism between newborns/infants up to six months and adults, the question may be raised whether cosmetic ingredients would require a MoS higher than 100 to cover exposure for these groups.

3-6.10.1 DEFINITIONS

“Children” are defined as developing human beings who are at various stages of immaturity and maturation for up to nearly two decades, with age-dependent different susceptibilities and sensitivities (Makri et al., 2004; Lemper et al., 2009) compared to adults.

Terms usually covered by the word “children” include:

- full-term neonate < 1 week
- newborn 1 week – 2 months
- early infant 2 – 6 months
- crawler/toddler 6 months – 2 years
- child/pre-adolescent 2 – 12 years
- adolescent 12 – 18 years
The calculation of the MoS for children was discussed when the question was raised whether it would be advisable to adjust the default assessment factor of 100 for children by multiplying this factor by the difference in Skin Surface Area over Body Weight ratio (SSA/BW) between adults and children (SCCNFP/0557/02). In these calculations, the bodyweight values available at that time were used. Afterwards, updated values became available (EFSA, 2012b).

The ratio between the SSA/BW ratios of children and adults changes from 0 to 10 years and is as follows (Renwick, 1998):

2.3 at birth,
1.8 at 6 months,
1.6 at 12 months,
1.5 at 5 years,
1.3 at 10 years.

The ratio between the SSA/BW children of 0 to 1 year of age and that of adults is at maximum 2.3. A factor of 3.2 is generally applied by the WHO and also covers variability in human kinetics (see Section 3-5.1.3). Consequently, the inter-individual variation in SSA/BW is covered by the generally accepted default value of 100 for intact skin (Figure 10 in Section 3-5.1.3). However, for specific compounds under consideration the potential differences in metabolism between newborns/infants up to six months and adults could require extra consideration.

In general, the SCCS is of the opinion that there is no need for an additional UF for children 

**when intact skin is considered** (SCCNFP/0557/02).

For more information on UFs, see 3-4.8.1.

Risk assessment in the specific case of “children” has been discussed for parabens as preservatives in cosmetic products (SCCS/1446/11) and for phenoxyethanol (SCCS/1575/16).

The rationale of additional UFs for different age groups beyond the usual factor of 100 has been discussed in the scientific literature (e.g., Renwick et al., 1998 and 2000; Nielsen et al., 2001; Makri et al., 2004; ECHA, 2012a).

A number of potential risk factors may exist for newborns and early infants. They are reviewed in Annexes 2 and 4 of SCCS/1446/11. As dermal exposure in children is a topic of high importance for several cosmetic substances, the most important points are summarised here. An overview of potential risk factors for baby care products and their ingredients is also available in Desmedt et al., 2014).

3-6.10.2.1 DERMAL EXPOSURE OF THE NEWBORN AND EARLY INFANT

- When born at full-term, the skin possesses all skin structures of adult skin, and anatomically these structures do not undergo dramatic changes after birth. The dermal absorption in skin of newborns is similar to that observed in adult skin, when the skin is intact (see SCCS/1446/11) (Visscher et al., 2009 and 2015).

- Differences between newborns during their first weeks and months and adults are described below:

(I) The surface area/body weight ratio (mentioned above) is 2.3-fold higher in newborns than in adults, changing to 1.8- and 1.6-fold at 6 and 12 months, respectively. This is in general covered by the intra-species factor of 10 (3.2 x 3.2) used in the calculation of MoS.

(II) Toxicokinetic parameters may differ between various age groups of children and adults and can result in reduced metabolism, clearance and/or longer half-life that might either

The considerations in this section refer to neonates born at full-term and not to premature babies still under medical care.
increase or decrease the potential risk of an adverse reaction in newborns, depending on the substance (Renwick et al., 2000; Nielsen et al., 2001, Felter et al., 2015). For the CYP450s in the liver, lower activities in newborns/early infants as compared to adults have been described (Johnson, 2003). These data suggest that the extent of bioactivation or metabolic detoxification in children between one and ten years will in generally be lower than that in adults. It is also known that detoxification of xenobiotic substances or metabolites by phase II enzymes may be lower in newborns and infants compared to adults due to yet incomplete development of Xenobiotic Metabolising Enzymes (XME) in the liver (e.g., UDP GlucuronosylTransferase-1 (UGT1A1) and some esterases; see SCCS/1446/11). Therefore, depending on the cosmetic ingredient in question, the balance between activating and inactivating XME activities may be crucial for systemic exposure and should be considered case by case. In general, however, it is assumed that a specific assessment factor for age-related differences in toxicokinetics is not required (SCCS/1446/11). With respect to skin metabolism, it is recognised that some metabolic enzymes seem to be less expressed in the skin of children, in particular under the age of 1 year. Hence, neonates, newborns and early infants might have higher internal exposure to certain cosmetic ingredients after dermal application than adults. For a sound risk assessment, relevant human data regarding metabolism are necessary. These data could for instance be gained by an approach combining in vitro data on the metabolism of the cosmetic ingredient under investigation and PBPK/PBTK modelling. For such toxicokinetic modelling of the biotransformation in humans of different age groups, relevant in vitro data regarding phase I and phase II biotransformation are needed both in human skin and liver (SCCS/1446/11).

(III) In-use conditions of topical products should be considered in exposure-based risk assessment of the finished product. It should be noted that no comprehensive exposure data for newborns and early infants, representative for Europe, are available in the open literature. CoE is preparing aggregate exposure data for babies and children for different baby care cosmetics used in Europe (more information, see Table A.7, Appendix 7). Some information is available for the Netherlands at the RIVM, ConsExpo Fact Sheet (2006). Data for French children have been published by Ficheux et al., 2017, 2019. Exposure data for wipes used for Korean babies are available (Lee et al., 2017); also for the USA, DE and UK, deterministic as well as probabilistic modelling has been carried out to determine the transfer of wipes in babies and children (Dey et al., 2016a). Data for disposable diapers are available from the same authors (Dey et al., 2016b).

(IV) The nappy area: the skin barrier function in the nappy area and non-nappy regions are indistinguishable at birth but show differential behaviour over the first 14 days, with the nappy region having a higher pH and increased hydration. With respect to skin hydration in the nappy zone, newborns tend to have a somewhat higher water content in the horny layer than observed for early infants and crawlers/toddlers up to one year. Also, the variations in water content are higher. Skin pH is usually between 5-6, which is similar to the skin pH measured for adult skin. However, the nappy area is susceptible to inflammation and the buffering capacity is compromised (nappy dermatitis). This results in episodic acute skin inflammation (mean duration 2 to 3 days) caused as well by physical, chemical and enzymatic microbial factors in the nappy environment, for example acute skin inflammation of the nappy zone occurs during changes in diet (breast feeding, bottle feeding, solid food) and may occur in particular between 6-12 months of age.

See below for cosmetic products used in the nappy area.

(V) Susceptibility against microorganisms: this is in particular the case in the nappy area and is a consequence of changes in the barrier function when the skin is damaged. Therefore, baby cosmetics should be adequately preserved (as is the case for all cosmetics) and formulated with an appropriate buffered pH.

With respect to points (I) to (III), there is generally no need for an additional assessment factor for children when intact skin is involved. However, an additional assessment factor might be relevant when the skin in the nappy area is damaged and substance-
specific data clearly demonstrate that inter-individual variability would result in a value higher than the default value of 10.

3-6.10.2.2 Cosmetic products used in the nappy area

In the nappy area, special circumstances are present resulting from the close confining clothes and nappies, uncontrolled urination and defecation and resulting problems with potential damage of the skin in the nappy zone. Modern nappy technology has shown to provide increasingly good skin compatibility, leading to a decline in the frequency and severity of nappy dermatitis. In silico modeling of skin under the diaper has shown that healthy diapering practices will ensure there is no significant impact on skin health and barrier properties (Staadatmand et al., 2017). However, irritant nappy dermatitis cannot be completely avoided and might have an impact on dermal absorption of substances.

As cosmetic products are meant to be used on intact skin, medical consultation is necessary in the case of real skin damage and pharmaceutical products (and not cosmetics!) should be used.

For the development of baby cosmetic products and the safety evaluation of the products intended to be used in the nappy area, the potential impact of irritation on dermal absorption of the ingredients needs to be considered by the safety assessor. It is known that the physicochemical properties of the substances under consideration also play a role. A tiered quantitative approach to take the potential for diaper rash into consideration when doing a safety evaluation for products used in the nappy area has been proposed by Felter et al. (Felter et al., 2017).

3-6.11 Substances with very low dermal absorption

In the case where a cosmetic ingredient is a substance with a very low dermal absorption (see Section 3-3.5.1.1(c)), some studies could be waived since systemic exposure via dermal absorption is expected to be minimal. In such a case, the following minimum set of data should be made available in order to assess the safety of cosmetic ingredients with very low bioavailability:

- Experimentally determined physicochemical data
- Local toxicity
- Mutagenicity/Genotoxicity
- High quality in vitro dermal absorption study, according to the SCCS Basic Criteria {3-3.5.1.1 (b)}.

In these cases, the experimental mean value will be used for decision making.

3-7 Further remarks for applicants

- When preparing a safety dossier, it would be useful if Applicants follow the same format as adopted in the SCCS opinions (example given in Appendix 3).
- Whenever study results are submitted, a declaration should be made that the tests involved were conducted using a cosmetic ingredient with a comparable purity/impurity profile and physical and chemical characteristics of that to be included in the finished cosmetic product.
- For multi-constituent natural ingredients, with variable composition, it is essential that Applicants provide clearly defined specifications in view of the range of variability of the components e.g. batch-to-batch.
- Stability of the test substance under experimental conditions is of prime importance for the interpretation of test results.
- The stability of the test material under conditions of use should also be reported.
- The Applicant should ensure that files submitted for evaluation are complete and signed.

Data should be obtained by means of studies conducted in accordance with test guidelines reported in Regulation (EC) No 440/2008 (2008/440/EC) and amending ATP (Adaptation to Technical and scientific Progress) Regulations, as well as the OECD test guidelines, and complying with the principles of Good Laboratory Practice (GLP). All possible deviations from validated methods or from GLP must be indicated, explained and scientifically justified. There may be cases for which it is either not necessary or technically not possible to provide some of the information mentioned above: in such cases a scientific justification must be given by industry and/or relevant agencies.

- Together with the relevant experimental investigations, the following information should be provided:
  - for in vivo studies: the study date (whether in line with the Cosmetic Regulation) and/or the regulatory context for which the study has been performed;
  - any report on epidemiological and/or observational experiences (cosmetovigilance data);
  - an appraisal of all relevant published literature, along with a description of the bibliographical methods used; any information from "grey material" available.

- In their dossiers, the Applicants should indicate whether they consider any of the data/tables/substances names, etc. confidential (typically impurities etc.) for commercial reasons and provide relevant codes that can be used by the SCCS to anonymise the confidential information.

- Safety data must relate to the same form of ingredients as present in a product for final use keeping in mind that the formulation or preparation of the final product may change the nature of the ingredients (e.g. permanent hair dye preparation).

- In case there is a negative SCCS Opinion, the Applicant must consider whether sufficient new and relevant information is available to justify a resubmission. When a dossier is resubmitted, it is mandatory to provide it in the form of a full dossier (including references) and clearly indicate what is new compared to the previous submission(s).
4. **REFERENCE LIST**

Regulations and Decisions from the Commission are ordered by year.


Adler, S.; Basketter, D.; Creton, S.; Pelkonen, O.; van Benthem, J.; Zuang, V.; Andersen, KE.; Angers-Loustau, A.; Aptula, A.; Bal-Price, A.; Benfenati, E.; Bernauer, U.; Bessem, J.;


Bremmer HJ., Prud’Homme de Lodder LCH., van Engelen JGM. General Fact Sheet - Limiting conditions and reliability, ventilation, room size, body surface area. Updated version for


Calafat AM., Needham LL. What additional factors beyond state-of-the art analytical methods are needed for optimal generation and interpretation of biomonitoring data? Environ Health Perspect 117(10), 1481-1485 (2009). doi: 10.1289/ehp.0901108


COM (UK Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment) Communication from the Commission to the European Parliament and the Council on the animal testing and marketing ban and on the state of play in relation to alternative methods in the field of cosmetics, 2013, COM/2013/135


Danish Environmental Protection Agency, Survey of chemical substances in consumer products No. 151 (2016).


ECETOC Percutaneous absorption. European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Monograph No 20, Brussels (1993).


ESAC 2001 Statement on the scientific validity of the Embryonic Stem Cell Test (EST), the Micromass Test and the Postimplantation Rat Whole-Embryo Culture Assay – in vitro tests for embryotoxicity. Adopted by the ECVAM Scientific Advisory Committee (ESAC) at its 17th Meeting of 16-17 October 2001 at ECVAM, Ispra, Italy (2001).


EURL ECVAM. Recommendation concerning the cell transformation assays (CTA) using Syrian Hamster Embryo cells (SHE) and the BALB/c 3T3 mouse fibroblast cell line for in vitro carcinogenicity testing, including the ESAC opinion (Annex 1) based on the ESAC peer review of an EURL ECVAM-coordinated validation study of three CTA protocols for in vitro carcinogenicity testing (2012) Available at: https://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvamrecommendations/cta-recommendation


Ficheux AS. and Roudot AC. Exposition de la population Francaise aux produits cosmétiques, Université Bretagne, Loire and université de Bretagne Occidentale, p1-p670 (2017) - COSMED.


Kandarova H. Phototoxicity studies using reconstructed human tissue models, in ICH Steering Committee and Expert Working Group Meetings, EWG S-10 – Photo Safety Evaluation of Pharmaceuticals, Sevilla, Spain, November 5-10 (2011).


Martus, H. J., Froetschl, R., Gollapudi, B., Honma, M., Marchetti, F., Pfuhler, S., Schoeny, R., Uno, Y., Yauk, C. & Kirkland, D. J. Summary of major conclusions from the 7th


**Safford B, Api AM., Barrass C., Comiskey D., Daly EJ., Ellis G., McNamara C., O'Mahony C., Robison S., Smith B., Thomas R., Tozer S.,** Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. Regul Toxicol Pharmacol 72(3):673–682 (2015). doi: 10.1016/j.yrtph.2015.05.017


SCCNFP/0098/99: Status report on the inventory of cosmetic ingredients, approved by the plenary session of the SCCNFP on 17 February 1999.

SCCNFP/0120/99: Opinion concerning the predictive testing of potentially cutaneous sensitising cosmetic ingredients or mixtures of ingredients, adopted by the SCCNFP during the 11th plenary session of 17 February 2000.


SCCNFP/0245/99: Opinion concerning Basic Criteria of the protocols for the skin compatibility testing of potentially cutaneous irritant cosmetic ingredients or mixtures of ingredients on human volunteers, adopted by the SCCNFP during the plenary session of 8 December 1999.

SCCNFP/0299/00: Opinion on the 1st update of the inventory of ingredients employed in cosmetic products (Section I), adopted by the SCCNFP during the 13th plenary session of 28 June 2000.

SCCNFP/0321/00: Notes of Guidance for Testing of Cosmetic Ingredients for Their Safety Evaluation, 4th revision, adopted by the SCCNFP during the plenary meeting of 24 October 2000.

SCCNFP/0389/00: Opinion concerning the 1st update of the inventory of ingredients employed in cosmetic products. Section II: perfume and aromatic raw materials, adopted by the SCCNFP during the plenary session of 24 October 2000.

SCCNFP/0483/01: Opinion on the evaluation of potentially estrogenic effects of UV-filters, adopted by the SCCNFP during the 17th plenary meeting of 12 June 2001.

SCCNFP/0557/02: Position statement on the calculation of the Margin of Safety of ingredients incorporated in cosmetics which may be applied to the skin of children, adopted by the SCCNFP during the 19th plenary meeting of 27 February 2002.

SCCNFP/0633/02: Updated Basic Requirements for toxicological dossiers to be evaluated by the SCCNFP, adopted by the SCCNFP during the 22nd plenary meeting of 17 December 2002.

SCCNFP/0669/03: Opinion concerning Dihydroxyindoline HBr (Colipa noA147), adopted by the SCCNFP during the 23rd plenary meeting of 18 March 2003.

SCCNFP/0690/03: Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation, adopted by the SCCNFP during the 25th plenary meeting of 20 October 2003.

SCCP (Scientific Committee on Consumer Products), Memorandum on hair dye substances and their skin sensitising properties, 19 December 2006

SCCP/0919/05 (Scientific committee on consumer products), Memorandum on the classification and categorization of skin sensitizers and grading of test reactions, adopted by the SCCP during the 5th plenary meeting of 20 September 2005, SCCP/0919/05

SCCP/0933/05 (Scientific committee on consumer products), Opinion on risk of ingredients deriving from category 1-material and category 2-material as defined in Regulation 1774/2002 in cosmetic products, adopted by the SCCP during the 5th plenary meeting of 20 September 2005, SCCP/0933/05

SCCP/0949/05 (Scientific committee on consumer products), Opinion on biological effects of ultraviolet radiation relevant to health with particular reference to sunbeds for cosmetic purposes, adopted by the SCCP during the 8th plenary meeting of 20 June 2006, SCCP/0949/05

SCCP/0959/05 (Scientific committee on consumer products), Review of the SCCNFP opinion on Hair Dye Strategy in the light of additional information, adopted by the SCCP during the 8th plenary meeting of 20 June 2006, SCCP/0959/05

SCCP/0970/06 (Scientific committee on consumer products), Opinion on Basic Criteria for the in vitro assessment of dermal absorption of cosmetic ingredients - updated February 2006, adopted by the SCCP during the 7th plenary meeting of 28 March 2006, SCCP/0970/06

SCCP/1017/06 (Scientific committee on consumer products), Opinion on parabens (Colipa n° P82), adopted by the SCCP during the 9th plenary meeting of 10 October 2006, SCCP/1017/06

SCCP/1086/07 (Scientific committee on consumer products), Opinion on homosalate (Colipa n° S12), adopted by the SCCP during the 11th plenary meeting of 21 March 2007, SCCP/1086/07

SCCP/1153/08 (Scientific committee on consumer products), Opinion on dermal sensitisation quantitative risk assessment (citral, farnesol and phenylacetaldehyde), adopted by the SCCP during the 16th plenary meeting of 24 June 2008, SCCP/1153/08

SCCP/1171/08 (Scientific committee on consumer products), SCCS, SCHER, SCENIHR Joint Opinion on the Use of the Threshold of Toxicological Concern (TTC). Approach for Human Safety Assessment of Chemical Substances with focus on Cosmetics and Consumer Products, adopted 8 June 2012, SCCP/1171/08

SCCP/1183/08 (Scientific committee on consumer products), Opinion on parabens (Colipa no P82), adopted by the SCCP during the 16th plenary of 24 June 2008, SCCP/1183/08

SCCP/1192/08 (Scientific committee on consumer products), Opinion on Triclosan (Colipa no P32), adopted by the SCCP during the 19th plenary meeting of 21 January 2009, SCCP/1192/08

SCCS/1270/09 (Scientific Committee on Consumer Safety), Opinion on resorcinol, 23 March 2010, SCCS/1270/09

SCCS/1241/10 (Scientific Committee on Consumer Safety), Opinion on cyclomethicone D4/D5, 22 June 2010, SCCS/1241/10

SCCS/1291/10 (Scientific Committee on Consumer Safety), Opinion on o-aminophenol, 22 June 2010, SCCS/1291/10
SCCS/1311/10 (Scientific Committee on Consumer Safety), Opinion on reaction products of oxidative hair dye ingredients formed during hair dyeing process, 21 September 2010, SCCS/1311/10

SCCS/1315/10 (Scientific Committee on Consumer Safety), Opinion on Melatonin, 23 March 2010, SCCS/1315/10

SCCS/1348/10 (Scientific Committee on Consumer Safety), Opinion on parabens, 14 December 2010, revision of 22 March 2011, SCCS/1348/10

SCCS/1358/10 (Scientific Committee on Consumer Safety), basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients, 22 June 2010, SCCS/1358/10

SCCS/1392/10 (Scientific Committee on Consumer Safety), memorandum (addendum) on the in vitro test EPISKIN™ for skin irritation testing, 14 December 2010, SCCS/1392/10

SCCS/1400/11 (Scientific Committee on Consumer Safety), Opinion on 6- amino-m-cresol, 2-Amino-5-methylphenol, 26-27 June 2012, SCCS/1400/11

SCCS/1414/11 (Scientific Committee on Consumer Safety), Opinion on triclosan, ADDENDUM to the SCCP Opinion on Triclosan (SCCP/1192/08) from January 2009, 22 March 2011, SCCS/1414/11

SCCS/1443/11 (Scientific Committee on Consumer Safety), Opinion on p-phenylenediamine, 26-27 June 2012, SCCS/1443/11

SCCS/1446/11 (Scientific Committee on Consumer Safety), Clarification on Opinion SCCS/1348/10 in the light of the Danish clause of safeguard banning the use of parabens in cosmetic products intended for children under three years of age, 10 October 2011, SCCS/1446/11

SCCS/1459/11 (Scientific Committee on Consumer Safety), opinion on fragrance allergens in cosmetic products, 13-14 December 2011, SCCS/1459/11

SCCS/1479/12 (Scientific Committee on Consumer Safety), Opinion on toluene-2,5-diamine and its sulfate, 26-27 June 2012, SCCS/1479/12

SCCS/1481/12 (Scientific Committee on Consumer Safety), Opinion on kojic acid, 26-27 June 2012, SCCS/1481/12

SCCS/1484/12 (Scientific Committee on Consumer Safety), Guidance on safety assessment of nanomaterials in cosmetics, adopted by the SCCS at its 15th plenary meeting of 26-27 June 2012, SCCS/1484/12

SCCS/1486/12 (Scientific Committee on Consumer Safety), Opinion on NDELA in cosmetic products and nitrosamines in balloons, adopted at its 15th plenary meeting on 26-27 June 2012, SCCS/1486/12

SCCS/1501/12 (Scientific Committee on Consumer Safety), The SCCS’s Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation - 8th revision, adopted by the SCCS during the 17th plenary meeting of 11 December 2012, SCCS/1501/12
SCCS/1509/13 (Scientific Committee on Consumer Safety), Memorandum on hair dye Chemical Sensitisation, adopted by the SCCS at its 18th Plenary meeting of 26 February 2013, SCCS/1509/13

SCCS/1512/13 (Scientific Committee on Consumer Safety), Opinion on Zinc pyrithione, 18 June 2013, revision of 18 June 2014, SCCS/1512/13

SCCS/1513/13 (Scientific Committee on Consumer Safety), Opinion on 3-Benzylidene camphor (Colipa n° S61), adopted by the SCCS during the 2nd plenary meeting of 18 June 2010, SCCS/1513/13

SCCS/1514/13 (Scientific Committee on Consumer Safety), Opinion on Parabens - Updated request for a scientific opinion on propyl-and butylparaben (Colipa no P82), adopted by written procedure on 3 May 2013, SCCS/1514/13

SCCS/1524/13 (Scientific Committee on Consumer Safety), Memorandum on "Relevance and Quality of Data in Safety Dossiers on Nanomaterials", 12 December 2013, revision of 27 March 2014, SCCS/1524/13

SCCS/1532/14 (Scientific Committee on Consumer Safety), Addendum to the SCCS's Notes of Guidance (NoG) for the Testing of Cosmetic Ingredients and their Safety Evaluation, 8th Revision, adopted by the SCCS by written procedure on 9 April 2014, revision of 22 October 2014, SCCS/1532/14

SCCS/1533/14 (Scientific Committee on Consumer Safety), Opinion on 2-[(4-(2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl)-piperazine-1-carbonyl)-phenyl]-4-(diethylamino-2-hydroxyphenyl)-methanone (HAA299) as UV filter in sunscreen products. The SCCS adopted this opinion at its 6th plenary meeting, revision of 23 September 2014, SCCS/1533/14

SCCS/1538/14 (Scientific Committee on Consumer Safety), Opinion on the safety of the use of formaldehyde in nail hardeners, written procedure 7 November 2014, revision of 16 December 2014, SCCS/1538/14

SCCS/1539/14 (Scientific Committee on Consumer Safety), Opinion for clarification of the meaning of the term "sprayable applications/products" for the nano forms of Carbon Black CI 77266, Titanium Oxide and Zinc Oxide, adopted by the SCCS at its 7th plenary meeting on 23 September 2014, SCCS/1539/14

SCCS/1544/14 (Scientific Committee on Consumer Safety), Memorandum on Endocrine Disruptors, 16 December 2014, SCCS/1544/14

SCCS/1546/15 (Scientific Committee on Consumer Safety), Opinion on 2,2'-methylene-bis-(6(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol), 25 March 2015, SCCS/1546/15

SCCS/1567/15 (Scientific Committee on Consumer Safety), Memorandum on use of Human Data in risk assessment of skin sensitization, 15 December 2015, SCCS/1567/15

SCCS/1578/16 (Scientific Committee on Consumer Safety), Memorandum on the use of In silico Methods for Assessment of Chemical Hazard, 6 October 2016, SCCS/1578/16

SCCS/1589/17 (Scientific Committee on Consumer Safety) Opinion on Skin Sensitisation Quantitative Risk Assessment for Fragrance Ingredients (QRA2), 30 July 2018, SCCS/1589/17
SCCS/1594/18 (Scientific Committee on Consumer Safety), Opinion on the safety of cosmetic ingredients Phenylene Bis-Diphenyltriazine (CAS No 55514-22-2) - S86 - Submission II, preliminary version of 21-22 February 2018, final version of 30 July 2018, SCCS/1594/18

SCCS/1595/18 (Scientific Committee on Consumer Safety), Final Opinion on Styrene/Acrylates copolymer (nano) and Sodium styrene/Acrylates copolymer (nano), 22 February 2019, SCCS/1595/18

SCCS/1596/2018 (Scientific Committee on Consumer Safety), Opinion on Colloidal Silver, 24-25 October 2018, SCCS/1596/2018

SCCS/1602/18 (Scientific Committee on Consumer Safety), The SCCS's Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation - 10th revision, adopted by the SCCS during the plenary meeting of 2-5 October 2018, SCCS/1602/18


SCCS/1611/19 (Scientific Committee on Consumer Safety), Guidance on the Safety Assessment of Nanomaterials in Cosmetics, 30-31 October 2019, SCCS/1611/19

SCCS/1613/19 (Scientific Committee on Consumer Safety), Scientific advice on the safety of aluminium in cosmetic products, plenary meeting 3-4 March 2020, submission II, SCCS/1613/19

SCCS/1617/20 (Scientific Committee on Consumer Safety), Scientific advice on the safety of titanium dioxide used in cosmetic products that lead to exposure by inhalation, written procedure 6 October 2020, SCCS/1617/20

SCCS/1618/2020 (Scientific Committee on Consumer Safety), Scientific advice on the safety of nanomaterials in cosmetics, 6 October 2020, SCCS/1618/2020

SCCS/1627/21 (Scientific Committee on Consumer Safety), Scientific advice on the safety of octocrylene in cosmetic products, adopted by written procedure on 15 January 2021, SCCS/1627/21

SCCS Expert Methodologies meeting in Brussels on May 25, 2011, with P Langguth (University of Mainz, DE); L Turco (University of Barcelona, ES) and P Artursson (Uppsala University, SE).

SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), Risk assessment of products of nanotechnologies, 19 January 2009.


Electronic resources:

http://ec.europa.eu/health/scientific_committees/consumer_safety/requests/index_en.htm
http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm,
APPENDIX 1: INFORMATION ON REGULATION (EC) No 1223/2009 AND THE SCCS

1. INTRODUCTION TO COSMETIC REGULATION (EC) No 1223/2009

Since July 2013, Regulation (EC) No 1223/2009 harmonises the safety of cosmetics within the Member States, simplifies procedures and streamlines terminology. The most significant changes introduced by the Cosmetic Regulation include:

1. **Strengthened safety requirements for cosmetic products**
   Manufacturers need to follow specific requirements in the preparation of a product safety report prior to placing a product on the market.

2. **Introduction of the notion of a “responsible person” (RP)**
   Only cosmetic products for which a legal or natural person is designated within the EU as a “responsible person” can be placed on the market. The Cosmetics Regulation allows the precise identification of the RP and clearly outlines his/her obligations.

3. **Centralised notification of all cosmetic products placed on the EU market**
   The RP (mostly the manufacturer) will need to send the Product notification only once via the EU Cosmetic Product Notification Portal (CPNP).

4. **Introduction of reporting serious undesirable effects (SUE)**
   A RP and a distributor have the obligation to notify serious undesirable effects to national authorities. The authorities will also collect information coming from end users and health professionals. They will be obliged to share the information with other EU countries. More information on reporting of SUE.

5. **New rules for the use of nanomaterials in cosmetic products**

6. **A set of requirements for CMR (carcinogenic, mutagenic, toxic for reproduction) substances**

According to Article 2.1 (a) of Regulation (EC) No 1223/2009, a **cosmetic product** means any **substance** or **mixture** intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours.

"**Substance**“ is defined by Article 2.1 (b) of this Regulation as a chemical element and its compounds in the natural state or obtained by any manufacturing process, including any additive necessary to preserve its stability and any impurity deriving from the process used but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition, whereas Article 2.1 (c) defines “**mixture**” as a mixture or solution composed of two or more substances.

Article 3 of the Cosmetics Regulation specifies that a cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use. In practice, cosmetic products have rarely been associated with serious health hazards, which, however, does not mean that cosmetics are safe in use per se. Particular attention is needed for long-term safety aspects, since cosmetic products may be used extensively over a large part of the human lifespan and sensitive groups of the population may be involved. Therefore, the safety-in-use of cosmetic products has been established in Europe by controlling the substances, their chemical structures, toxicity profiles, and exposure patterns.
2. THE SCIENTIFIC COMMITTEE ON CONSUMER SAFETY, SCCS

2-1 Historical background

The Scientific Committee on Cosmetology (SCC) was established on 19 December 1977 by Commission Decision 78/45/EEC; the purpose was to assist the European Commission in examining the complex scientific and technical problems surrounding the drawing up and amendment of European Union (EU) rules governing the composition, manufacturing, packaging and labelling of cosmetic products marketed in EU countries. The Committee was to be renewed every three years.

In 1997, the Scientific Committee on Cosmetic Products and Non-Food Products intended for consumers (SCCNFP), was established. It was composed of independent scientists from different fields of competence, collectively covering the widest possible range of expertise.

In 2004, the SCCNFP was replaced by the Scientific Committee on Consumer Products (SCCP), as part of a larger-scale reorganisation of the EU Scientific Committees in the field of consumer safety, public health and the environment.

Three scientific committees were established:

i. Scientific Committee on Consumer Products (SCCP)
ii. Scientific Committee on Health and Environmental Risks (SCHER)
iii. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)

The coordination between the SCCP, the SCHER and the SCENIHR was done by the Inter-Committee Coordination Group (ICCG).

In 2008, the three above-mentioned Scientific Committees were renewed and the SCCP’s name was changed into SCCS. In addition to the SCCS, SCENIHR and SCHER, a Pool of scientific advisors on risk assessment was also established, with the specific task to assist the members of the Scientific Committees in their work. In 2013, the three above-mentioned Scientific Committees were renewed.

Finally, a new Commission Decision C (2015)5383 was adopted on 7 August 2015, establishing two scientific committees: the (SCCS); the Scientific Committee on Health, Environmental and Emerging Risks (SCHER). The composition of both Committees was renewed on April 2016, for a period of 5 years until 2021, and extended until the end of 2026 due to the Covid-crisis, which postponed the launch of the call for experts/members.

2-2 Mandate

The mission of the Scientific Committees is defined in Commission Decision C(2015)5383, which states that they shall 'provide the Commission with scientific advice and risk assessment in the areas of public health, consumer safety, environmental risks, including, when relevant, identification of research needs to address critical information gaps, assessment of proposed future research actions and of research results'.

---

The SCCS on request of Commission services shall provide opinions on questions concerning health and safety risks, notably chemical, biological, mechanical and other physical risks, of:

(a) non-food consumer products such as:
- cosmetic products and their ingredients, including nanomaterial, hair dyes, fragrance ingredients;
- personal care and household products such as detergents; and toys, textiles, clothing, etc.

(b) services such as tattooing, artificial sun tanning, etc.

In addition, the Commission may request from the Committee:
- advice on any matter of particular relevance to consumer safety and public health;
- rapid advice on the state of scientific knowledge concerning specific risks in case of urgent risks;
- the identification of research needs to address critical information gaps, to assess proposed future research and to assess research results in relation to the subject areas covered by its fields of competence;
- to be part of thematic networks or events with other Union bodies or scientific organisations, in order to monitor and contribute to the development of scientific knowledge in the fields of competence.

Also, upon its own initiative, the Committees shall draw the Commission's attention to a specific or emerging problem falling within its remit, if it is considered to pose an actual or potential risk to consumer safety, public health or the environment.

Finally, in agreement with the Commission, the Committees shall adopt their methodology for performing and providing risk assessment and keep it under review to reflect all relevant scientific factors. They shall ensure that the methodology reflect current risk assessment practice.

The work of the SCCS can be divided in two main domains, namely matters related to cosmetic substances and products and those related to other non-food consumer products.

Whenever cosmetic substances are concerned, the consultation of the SCCS is compulsory, whereas it is not compulsory in the domain of other non-food products.

In the preamble of Regulation (EC) No 1223/2009, different tasks for the SCCS are mentioned in several recitals:

(28) safety assessment of hair colorants (annex III)
(30) providing guidance in cooperation with relevant bodies on test methodologies which take into account specific characteristics of nanomaterials,
(32) continuously reviewing the safety of CMR substances, so that substances clarified as CMR 2 or CMR 1A or 1B can be used in cosmetics under well-restricted conditions when such use for CMR 1A and 1B has been found safe by the SCCS,
(34) taking into account the exposure of vulnerable population groups,
(35) giving opinions on the safety of use of nanomaterials in cosmetic products,
(42) consultation by the Commission as regards the applicability of validated alternative methods to the field of cosmetic products,
(49) identification of substances likely to cause allergic reactions in order that their use can be restricted and/or certain conditions can be imposed.

---

20 See Article 31 of Regulation (EC) No 1223/2009
providing assistance to the Commission as an independent risk assessment body.

The compulsory consultation of the SCCS is taken up under:

Art. 15, 2(d) and 3 for substances classified as CMR substances
Art. 16, 4 and 5 for nanomaterials
Art. 18, 2 for animal testing methodology
Art. 20, 2 for setting criteria for product claims
Art. 27, 3 for determination whether the provisional measures taken with respect to the safe clause are justified or not
Art. 31, 1 for amending Annexes II to VI for safety concerns
Art. 31, 2 for amending Annexes II to VI, VIII for technical and scientific progress
Art. 31, 3 for amending Annex I to ensure the safety of cosmetic products placed on the market.

Newly introduced modifications and improvements in the current structure and working procedures of the SCCS and the other Scientific Committee can be found in Commission Decision C(2015)5383 of 7 August 2015.

2-3 Rules of Procedure

The Rules of Procedure of the SCCS and SCHEER were jointly adopted by the Scientific Committees on 28 April products. These were amended according to the Commission Decision C(2015)5383.

In order to efficiently fulfill its extensive mandate, the SCCS sets up working groups on particular subjects of interest. These subgroups operate independently under an appointed chairperson (SCCS member) and consist of SCCS members complemented with external experts (either from the Database of Experts or via a specific call). Working groups, for example, deal with: Cosmetic Substances (individual substance evaluations), Methodologies (alternative methods and Notes of Guidance), Nanomaterials and other topics according to the needs.

The mandate on a specific substance or other issue is officially adopted by the members during a plenary meeting (or by written procedure) and published. A Rapporteur is nominated (SCCS member or external expert). Once the participants of the Working Groups have agreed on a final version of their opinion/scientific report(s), they present it to the next SCCS plenary meeting where members adopt the texts. In particular cases, an opinion may also be adopted by written procedure. The adopted preliminary opinions, once edited, are published on the Commission's website for a commenting period of a minimum of eight weeks to allow the applicant, and other stakeholders as well, to send their comments that are subsequently considered by the SCCS and, when considered appropriate, incorporated in a revised version of the opinion. The revised version becomes the final opinion once adopted at the next SCCS plenary meeting (or by written procedure) and is published on the website, with the date of the adoption of the final text. The final opinion replaces the preliminary opinion and informs about changes made in the first pages. The final opinions are not subject to further comments or revision requests.

---

24 http://ec.europa.eu/health/scientific_committees/open_consultation/index_en.htm
25 https://ec.europa.eu/health/scientific_committees/consumer_safety/requests_en
26 https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions_en#fragment0
27 https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions_en#fragment2
responding to comment submitted outside the commenting period. Any new data should be submitted directly to the responsible Commission unit mandating the SCCS for a new opinion.

This method of working with Working Groups not only lightens the workload of the members of the SCCS, but equally and importantly, facilitates discussion of the individual topics with the appropriate experts in the field of interest, thus enhancing the scientific quality of the opinions issued.

2-4 Opinions

Before 1997, the opinions adopted by the Scientific Committee on Cosmetology at the Commission’s request were included in EC-Reports (EUR 7297, 8634, 8794, 10305, 11080, 11139, 11303, 14208). Between 1997 and 2004, all SCCNFP opinions were published on the Internet and can be accessed through the Committee’s website. All SCCP / SCCS opinions can easily be located through the ingredient’s substance category and the adoption date.

It must be emphasised that the SCC(NF)P / SCCS opinions and statements not only refer to cosmetic substances included in Annexes II, III, IV, VI and VII of Council Directive 76/768/EEC or Annexes II, III, IV, V and VI of the Cosmetic Regulation (EC) No 1223/2009, but also to a broad range of scientific issues related to the safety of cosmetic substances and finished products.

3. COMPLYING WITH THE TESTING AND MARKETING BANS

The safety evaluation of cosmetic ingredients is exposure-driven and is historically based on toxicological data, which were obtained by using experimental animals. The testing and marketing bans in Regulation (EC) No 1223/2009 make the use of validated alternative replacement methods compulsory. Guidance on how to comply can be found in:

i. Recital 50 and article 18 of the Regulation,
ii. Commission Communication on the animal testing and marketing ban and on the state of play in relation to alternative methods in the field of cosmetics (COM/2013/135),
iii. a factsheet of ECHA (2014a) and
iv. the 2017 ECHA report (ECHA 2017) on the use of alternatives to testing on animals.

I. Recital 50 of Regulation (EC) No 1223/2009 states the following: “In the safety assessment of a cosmetic product it should be possible to take into account results of risk assessments that have been carried out in other relevant areas. The use of such data should be duly substantiated and justified.” The prohibitions in Article 18 of the Regulation are triggered when the animal testing in question is done “in order to meet the requirements of this [the Cosmetics] Regulation”. Article 18 of the Regulation (EC) No 1223/2009 creates, therefore, a relationship between the animal testing bans and the intention to meet the requirements of this Regulation; It is possible that animal testing needs to be conducted on ingredients

---

28 https://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04_en
29 COMMUNICATION on the animal testing and marketing ban and on the state of play in relation to alternative methods in the field of cosmetics (COM(2013) 135 final).
30 Article 18 of Regulation (EC) No 1223/2009 contains four prohibitions, two relating to the performance of animal testing (on finished cosmetic products and on ingredients of cosmetic products) and two relating to the placing on the market of cosmetic products (where the final formulation or an ingredient of a cosmetic product has been the subject of animal testing). However, an option for derogation from the animal testing ban is foreseen in Article 18, No 2, paragraph six “In exceptional circumstances, where serious concerns arise as regards the safety of an existing cosmetic ingredient, a Member State may request the Commission to grant a derogation from paragraph 1. The request shall contain an evaluation of the situation and indicate the measures necessary. On this basis, the Commission may, after consulting the SCCS and by means of a reasoned decision, authorise the derogation. That authorisation shall lay down the conditions associated with this derogation in terms of specific objectives, duration and reporting of the results”.
to be used in a cosmetic product for the purpose of complying with other regulatory framework (e.g., food, medicines, biocides).

II. In this respect, Commission Communication COM/2013/135 further elucidates: "If animal testing was involved and took place after the 2013 deadline, the product information file should allow verification on whether the testing was carried out in order to meet the requirements of the Regulation or for other purposes. To this end the file should contain documentation on any use of the substance in products other than cosmetic products (product examples, market data etc.), as well as documentation on compliance with other regulatory frameworks (e.g. REACH or other legal frameworks) and a justification of the need for the animal testing under that other framework (e.g. testing proposal under REACH)". As regards the use of data from animal testing conducted to ensure compliance with non-cosmetics related legislative frameworks, two different scenarios can occur:

a. With respect to ingredients that are equally in use in other consumer and industrial products, such as in pharmaceuticals, detergents and food, animal testing may be necessary to ensure compliance with the legal frameworks applicable to these products. In this case, the Commission considers that "the resulting animal testing data should not trigger the marketing ban and could subsequently be relied on in the cosmetics safety assessment. Reliance on such data is subject to its relevance for the cosmetics safety assessment and its compliance with data quality requirements". However, the Commission Communication COM/2013/135 also adds that it is "for Member States to assess and decide whether such testing for compliance with other frameworks is considered to be falling in the scope of the 2013 marketing ban";

b. Conversely, animal testing conducted on ingredients that have been specifically developed for cosmetic purposes and are exclusively used in cosmetic products would in the Commission's view always be assumed to be carried out in order to meet the requirements of the Regulation (EC) No 1223/2009, i.e. would always be assumed to fall under the scope of the Article 18 ban. It would not be possible, therefore, to use the results of such animal testing to prove safety of cosmetic ingredients.

III. With respect, in particular, to the interaction between REACH requirements and animal testing, ECHA published a factsheet aimed at clarifying the practical meaning and implications of the Commission Communication COM/2013/135 in the context of REACH. The interface between REACH and the Regulation (EC) No 1223/2009 has been illustrated in a scheme, see Appendix 4. It has to be noted that animal testing under REACH is not restricted, if: a) this testing is required for environmental endpoints; or b) the substance is also registered for non-cosmetic uses. Even if a substance is registered exclusively for cosmetic use, the animal testing requirements continue to apply to tests needed to assess the risks from exposure to workers in the Chemical Safety Assessment (ECHA, 2014a). For the first time, on 18 August 2020, the Board of Appeal (BoA) of ECHA took two

---

31 “Testing carried out for cosmetics relevant endpoints on ingredients that have been specifically developed for cosmetic purposes and are exclusively used in cosmetic products would in the Commission's view always be assumed to be carried out 'in order to meet the requirements of this Directive/Regulation'” (Commission Communication COM/2013/135, Page 8).


33 "Workers" in this context are to be understood as persons who are actively involved in a particular activity of a production or manufacturing site where they may be exposed directly or indirectly to chemical substances. On the other hand, professional users who use the cosmetic products as part of their professional activity (e.g. hairdressers) and consumers shall not be considered as "workers". In Regulation (EC) No 1223/2009 the term 'end user' means either a consumer or professional using the cosmetic product (Article 2, Definitions 1."

150
compliance check decisions on registration dossiers (for homosalate and 2-ethylhexyl salicylate, both UV filters used exclusively in cosmetics) (ECHA 2020a and 2020b) where it confirmed that, according to scientific evidence, ECHA may conclude that studies on vertebrate animals must be provided by the applicant to comply with REACH, even if the substance is used exclusively as an ingredient in cosmetics. This said, the considerations under point II above would apply, meaning that, as regards ingredients that have been specifically developed for cosmetic purposes and are exclusively used in cosmetic products, the results of a study on vertebrate animals required under REACH could not be relied upon in the cosmetic product safety report in order to demonstrate the safety for end users, as these would fall under the Article 18 ban.

However, such results will be available to the authorities for scrutiny in the cosmetic product information file under Article 11 of the Regulation (EC) No 1223/2009 and might call into question the safety of cosmetic products containing a registered substance, contradicting the cosmetic product safety report. In this case, as mentioned by the ECHA BoA in case A-010-2018, "if the safety of cosmetic products containing the substance can no longer be established, then it is possible that cosmetic products containing the substance in question as an ingredient can no longer be placed on the market" (paragraph 112). The need to take into account the consequence of the results of that study would be justified under Article 3 of the Regulation (EC) No 1223/2009, which provides that a cosmetic product made available on the market must be safe for human health when used under normal or reasonably foreseeable conditions of use.

IV. Additional information regarding the REACH legislation in the context of alternative methods can be found in the three reports on “The Use of Alternatives to Testing on Animals for the REACH Regulation”, in the 3rd report under Article 117(3), available online (https://echa.europa.eu/documents/10162/13639/alternatives_test_animals_2017_en.pdf)

The question of the interpretation of the animal testing ban as regards animal testing performed in third countries to comply with the cosmetics legislation of a third country was referred to the European Court of Justice in case C-592/14. The Court concluded that: “the results of animal tests, carried out outside the European Union in order to market cosmetic products in third countries, the results of which are used to prove the safety of those products for the purpose of their being placed on the EU market, must be regarded as having been carried out ‘in order to meet the requirements [of that regulation]’ [...]. "Article 18(1)(b) of Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products must be interpreted as meaning that it may prohibit the placing on the European Union market of cosmetic products containing some ingredients that have been tested on animals outside the European Union, in order to market cosmetic products in third countries, if the resulting data is used to prove the safety of those products for the purposes of placing them on the EU market".

The information provided in the NoG relates to the assessment of cosmetic ingredients from a general chemical safety point of view. However, safety assessment of chemical substances in certain physicochemical forms may need additional specific considerations, for example, the use of nanomaterials in cosmetics (SCCS/1611/19).

---

APPENDIX 2: LISTS OF SUBSTANCES

1. INTRODUCTION

Regulated cosmetic substances can be found as Annexes II, III, IV, V and VI to Regulation (EC) No 1223/2009. These annexes lay down clear limitations and requirements for the cosmetic substances concerned.

Another important list of cosmetic substances is the INCI (International Nomenclature Cosmetic Ingredient) inventory (96/335/EC) or CIN (2009/1223/EC), identifying a large number of substances with their possible function(s) in finished cosmetic products and with the nomenclature that needs to be used on the label of finished cosmetic products. DG GROW (Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs) has built up a free to use database of cosmetic substances called CosIng, http://ec.europa.eu/consumers/cosmetics/cosing (Cosmetic ingredients) which combines INCI names and synonyms of the listed substances with useful regulatory information. CosIng database is regularly updated with information on new cosmetics ingredients. The information contained in CosIng is indicative and does not have any legal value.

Finally, this section briefly mentions Annex I to the Dangerous Substances Legislation (67/548/EEC), since the “7th Amendment” of Directive 76/768/EEC (2003/15/EC) and the Recast (2009/1223/EC) directly refer to that list when excluding CMR Cat.1 & Cat.2 chemicals from cosmetic use (see 3-6.6). With the European Regulation on classification and labelling (2008/1272/EC), however, Annex I to Dir. 67/548/EEC now needs to be referred to as ‘Part 3 of Annex VI to Regulation (EC) No 1272/2008’, in which all existing European classifications are converted into new harmonised classifications using the new criteria.

It must be emphasised that none of the above lists reflects the complete set of substances used in cosmetic products.

2. ANNEXES II, III, IV, V AND VI TO THE COSMETIC PRODUCTS REGULATION

The Cosmetic Products Regulation defines Annexes II, III, IV V and VI, which have been described in Section 3-1.

3. INVENTORY OF SUBSTANCES USED IN COSMETIC PRODUCTS

Article 33 of Regulation (EC) No 1223/2009 states that the Commission shall compile and update a glossary of common ingredient names (CINs) employed in cosmetic products (2003/1223/2009).

On 8 May 1996, the European Commission established an Inventory and a common nomenclature of the substances employed in cosmetic products (96/335/EC, part of which amended by 2006/257/EC). This list was subdivided into 2 sections:

Section I: Inventory of ingredients employed in cosmetic products

Section II: Perfume and aromatic raw materials

The Inventory is indicative and does not constitute a list of substances authorised for use in cosmetic products. If an INCI name is available, it is to be used on the packaging and labelling, but the absence of an INCI name on the Inventory does not automatically exclude the use of the substance under consideration.
An entry in the Inventory provides identification of that particular substance through the following parameters:

- Common name: INCI; but botanicals get their systemic (Linné) Latin names and colourants a colour index (CI) number
- Chemical name
- Chemical Abstract Service (CAS) number
- European Pharmacopoeia (Ph. Eur.) name
- International Non-proprietary Name (INN) name, recommended by WHO
- International Union of Pure and Applied Chemistry (IUPAC) name
- EC number, meaning either:
  - European Inventory of Existing commercial Chemical Substances (EINECS) number (format 2xx-xxx-x)
  - European List of Notified Chemical Substances (ELINCS) number (format 4xx-xxx-x)
  - No Longer Polymer (NLP) number (format 5xx-xxx-x)
  - EC Number appointed under REACH procedure (format 6xx-xxx-x or 7xx-xxx-x)

In 1998 the European Commission issued a Mandate (DG24/XXIV/1891/98), indicating that the SCCNFP shall act as a resource of scientific expertise to the European Commission, in terms of advising on the:

- medical and professional expectations and requirements of the Inventory,
- scientific accuracy and validity of proposed entries,
- outstanding needs of the existing text /proposed improvements in subsequent updates.

After collaboration with the JRC (Joint Research Centre) of the Commission, the experts from European industry and Colipa (now called Cosmetics Europe), the SCCNFP issued a Status Report on the Inventory (SCCNFP/0098/99). In this report, 6 priorities were identified for a first update of the INCI list:

1) To accomplish the principle: each INCI name should refer to only one specific substance.
2) To correct the INCI names of Ethylhexyl derivatives and to adopt a final decision on Ampho-derivatives.
3) To identify botanical entries with greater transparency.
4) To solve problems on chemical identification associated to polymers.
5) To solve the problem of hair dyes/cosmetic colourants with respect to Colour Index (CI) identification and restrictions.
6) To improve the description of the functions of the substances.

Having taken into account this list of priorities, the SCCNFP published in June 2000 "The 1st Revision and Update of Section I of the Inventory of ingredients employed in cosmetics" (SCCNFP/0299/00). This update contains many improvements to the original edition of Section I, including 1466 new and 843 modified INCI names, as well as a number of necessary recommendations for updating the inventory in the future.
In October 2000, "The 1st Update of the Inventory of ingredients employed in cosmetic products: Section II: Perfume and aromatic raw materials" was issued (SCCNFP/0389/00). Again, many improvements were introduced (e.g. 650 new entries of botanicals) and recommendations for future updates were added.

In 2006, Commission Decision 2006/257/EC established the most recent official list containing the common nomenclature of ingredients employed in cosmetic products (2006/257/EC).

From 11 July 2013 on, the INCI list will be replaced by the so-called "Common Ingredients glossary" (2009/1223/EC). The new glossary will contain the harmonised names of approximately 26,000 cosmetic substances.

4. COSING - EC INFORMATION ON COSMETIC SUBSTANCES

The CosIng database is a publicly available information database in two parts, linked together whenever possible. One part aims at containing all the regulations introduced by the Cosmetic Directive/Regulation. This part contains the historical data since the beginning of the Cosmetics Directive in 1976. The scientific opinions, which are the basis for many of the authorised substances or the restrictions of the substances in the Annexes, are linked to the regulated substances. Each substance is provided with the chemical name, INN name or IUPAC-name, CAS- and EC number, Annex and entry number and the conditions and warnings for its use.

The other part of the database contains the EU-inventory, which is a list of assigned INCI-names to substances offered for sale to the cosmetic industry. In addition to the INCI-name, if possible the CAS- and EC number, chemical name or its description is added, together with the function in the cosmetic products and finally any restrictions imposed by the Cosmetics Directive. Every possible link between the 2 parts has been established.

5. PART 3 OF ANNEX VI TO REGULATION (EC) NO 1272/2008

Part 3 of Annex VI to Regulation (EC) No 1272/2008 provides the harmonised European classification of a large number of dangerous substances according to the principles laid down in Annex I to that same Regulation (2008/1272/EC). Annex VI Part 3 previously was Annex I to Directive 67/548/EEC, which was repealed in December 2010. The European harmonised classification Annex is updated on a regular basis and contains a large number of chemicals that can be found in the composition of cosmetic products. It is useful to check the harmonised classification of a compound of interest, but it is of particular importance with regard to Art. 15 of the Cosmetic Products, which states (2009/1223/EC):

The use in cosmetic products of substances classified as carcinogenic, germ cell mutagenic or toxic for reproduction, of category 1A, 1B and 2, under part 3 of Annex VI to Regulation (EC) No 1272/2008 shall be prohibited ... A substance classified in category 2 may be used in cosmetics if the substance has been evaluated by the Scientific Committee on Consumer Safety (SCCS) and found acceptable for use in cosmetic products.

APPENDIX 3: STANDARD FORMAT OF THE OPINIONS

Scientific Committee on Consumer Safety
SCCS

OPINION ON

The SCCS adopted this document at its plenary meeting/by written procedure on xx
ACKNOWLEDGMENTS

Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are:

The SCCS members:

..........................................................
..........................................................
..........................................................
..........................................................
..........................................................
..........................................................

The SCHEER members (if applicable):

..........................................................
..........................................................
..........................................................

External experts (if applicable):

..........................................................
..........................................................
..........................................................
..........................................................
..........................................................
..........................................................
..........................................................

The additional contribution of the following experts is gratefully acknowledged (if applicable):

XXXXXX

All Declarations of Working Group members are available on the following webpage: https://ec.europa.eu/transparency/regexpert/index.cfm
If relevant: This Opinion has been subject to a commenting period of XXX weeks (from ...... to ......) after its initial publication.

There were comments received and the final version of the Opinion includes information on XXXX (section concerned)....compared to the preliminary one.
There were changes/no change in the conclusions.

OR - There were no comments received and the final version of the opinion remained unchanged compared to the preliminary one.
1. ABSTRACT

Text from the rapporteur

Or

The SCCS concludes the following:

Q1
Response
Q2
Response
Q3
Response
etc

Keywords: SCCS, scientific opinion, INCI name, type of product, Regulation 1223/2009, CAS ........, EC .................

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on INCI name - Submission ...., preliminary version of (date), final version of (date), SCCS/....../XX..........................................................
About the Scientific Committees

Two independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

These Committees are: the Scientific Committee on Consumer Safety (SCCS) and the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) and they are made up of scientists appointed in their personal capacity.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCS

The Committee shall provide Opinions on questions concerning all types of health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example: cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

Scientific Committee members

Ulrike Bernauer, Laurent Bodin, Qasim Chaudhry, Pieter Jan Coenraads, Maria Dusinska, Janine Ezendam, Eric Gaffet, Corrado Lodovico Galli, Berit Granum, Eirini Panteri, Vera Rogiers, Christophe Rousselle, Maciej Stepnik, Tamara Vanhaecke, Susan Wijhoven

Contact

European Commission
Health and Food Safety
Directorate C: Public Health
Unit C2: Health information and integration in all policies
L-2920 Luxembourg
SANTE-C2-SCCS@ec.europa.eu

© European Union, 20XX

ISSN
ISBN

Doi:

The Opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The Opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm
2. MANDATE FROM THE EUROPEAN COMMISSION

Background

Terms of reference
Q1
Q2
Q3

Additional information

(If appropriate)
This chapter could provide additional background information relevant to the assessment (e.g. previous Opinions or other assessments issued by other bodies/organisations).
3. OPINION

3.1 CHEMICAL AND PHYSICAL SPECIFICATIONS

3.1.1 Chemical identity

3.1.1.1 Primary name and/or INCI name

3.1.1.2 Chemical names

3.1.1.3 Trade names and abbreviations

3.1.1.4 CAS / EC number

3.1.1.5 Structural formula

3.1.1.6 Empirical formula

3.1.2 Physical form

3.1.3 Molecular weight

3.1.4 Purity, composition and substance codes

3.1.5 Impurities / accompanying contaminants

3.1.6 Solubility

3.1.7 Partition coefficient (Log P<sub>ow</sub>)

3.1.8 Additional physical and chemical specifications

Where relevant:
- organoleptic properties (colour, odour, taste if relevant)
- melting point
- boiling point
- flash point
- vapour pressure
- density
- viscosity
- pKa
- pH
- refractive index
- UV/visible light absorption spectrum

3.1.9 Homogeneity and Stability

3.2 EXPOSURE ASSESSMENT & TOXICOKINETICS

3.2.1 Function and uses

3.2.2 Dermal / percutaneous absorption

3.2.3 Other studies on toxicokinetics

3.2.4 Calculation of SED/LED

3.3 TOXICOLOGICAL EVALUATION

3.3.1. Irritation and corrosivity

3.3.1.1 Skin irritation

3.3.1.2 Mucous membrane irritation / eye irritation

3.3.2 Skin sensitisation

3.3.3 Acute toxicity

3.3.3.1 Acute oral toxicity

3.3.3.2 Acute dermal toxicity

3.3.3.3 Acute inhalation toxicity

3.3.4 Repeated dose toxicity

3.3.4.1 Repeated dose (28 days) oral / dermal / inhalation toxicity

3.3.4.2 Sub-chronic (90 days) oral / dermal / inhalation toxicity

3.3.4.3 Chronic (> 12 months) toxicity
3.3.5 Reproductive toxicity

3.3.5.1 Fertility and reproduction toxicity

3.3.5.2 Developmental Toxicity

3.3.6 Mutagenicity / genotoxicity

3.3.6.1 Mutagenicity / genotoxicity in vitro

3.3.6.2 Mutagenicity / genotoxicity in vivo

3.3.7 Carcinogenicity

3.3.8 Photo-induced toxicity

3.3.8.1 Phototoxicity / photo-irritation and photosensitisation

3.3.8.2 Photomutagenicity / photoclastogenicity

3.3.9 Human data

3.3.10 Special investigations

3.4 SAFETY EVALUATION (INCLUDING CALCULATION OF THE MoS)

3.5 DISCUSSION

Physicochemical properties

Exposure & Toxicokinetics

Toxicological Evaluation

Irritation and corrosivity

Skin sensitisation

Acute toxicity

Repeated dose toxicity

Reproductive toxicity

Mutagenicity / genotoxicity

Carcinogenicity

Photo-induced toxicity

Human data
4. CONCLUSION
Q1 Response
Q2 Response
Q3 Response
etc

5. MINORITY OPINION

6. REFERENCES

7. GLOSSARY OF TERMS

8. LIST OF ABBREVIATIONS
APPENDIX 4: ANIMAL TESTING: INTERFACE BETWEEN REACH AND COSMETICS REGULATIONS

Reference: Interface between REACH and Cosmetics regulations (ECHA, 2014a)
APPENDIX 5: CMR GUIDANCE ON SAFE USE OF CMR SUBSTANCES IN COSMETIC PRODUCTS

GUIDANCE ON A HARMONISED APPROACH TO THE DEVELOPMENT AND USE OF OVERALL EXPOSURE ESTIMATES IN ASSESSING THE SAFE USE OF CMR SUBSTANCES IN COSMETIC PRODUCTS

I. Background


2. As a general rule, the substances classified as CMR substances of category 1A, 1B and 2 under Part 3 of Annex VI to Regulation (EC) 1272/2008 are prohibited for use in cosmetic products.

3. However, exceptions to this rule are foreseen by the Cosmetics Regulation. Indeed, a substance classified as a CMR substance of category 2 may be used in cosmetic products where the substance has been evaluated by the Scientific Committee on Consumer Safety (SCCS) and found safe for use in cosmetic products on the basis of the data submitted.

4. Also, CMR substances of category 1A or 1B may be used in cosmetic products by way of exception where, subsequent to their classification as CMR substances of category 1A or 1B under Part 3 of Annex VI to Regulation (EC) No 1272/2008, all of the following conditions are fulfilled:

   (a) they comply with the food safety requirements as defined in Regulation (EC) No 178/2002 of the European Parliament and the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety\textsuperscript{39};

   (b) there are no suitable alternative substances available, as documented in an analysis of alternatives;

   (c) the application is made for a particular use of the product category with a known exposure; and

   (d) they have been evaluated and found safe by the SCCS for use in cosmetic products, in particular in view of exposure to these products and taking into consideration the overall exposure from other sources, taking particular account of vulnerable population subgroups.

II. Scope and objectives

5. Article 15, paragraph 3 of the Cosmetics Regulation foresees that the Commission shall ensure that appropriate guidance is developed with the aim of enabling a harmonised approach to the development and use of overall exposure estimates in assessing the safe use of CMR substances.

6. To authorise the use of CMR substances of category 1A or 1B in cosmetic products, one of the conditions to be fulfilled is that they have been evaluated and found safe by the SCCS for use in cosmetic products, in particular in view of exposure to cosmetics products and taking into consideration the overall exposure from other sources and vulnerable population subgroups.

7. On a case-by-case basis and at the request of the SCCS, it may also be necessary to perform an overall exposure from other sources for CMR 2 substances. Therefore, the procedure developed below for the overall exposure assessment of CMR 1A and 1B substances should, where necessary, also apply to CMR 2 substances (condition (d) only).

8. Appropriate consultations with the SCCS and other relevant stakeholders have been carried out in order to develop this guidance. In addition, administrative agreements have been established with relevant EU Agencies - European Chemicals Agency (ECHA), European Food Safety Authority (EFSA), European Medicines Agency (EMA) - to ensure the appropriate exchange of data between them and the SCCS Secretariat.

III. Procedure

9. The aim of this guidance is to outline the mechanisms necessary for ensuring the generation and the exchange of the appropriate data for the assessment by the SCCS of the overall exposure to a CMR 1A or 1B substance stemming from other sources than cosmetics (such as food, biocides, etc.).

10. When a substance of interest for the industry is indicated in the Registry of Intentions for the purpose of its harmonised classification as CMR substance under Part 3 of Annex VI to Regulation (EC) No 1272/2008, it is for the industry to inform the Commission in due time of its intention to defend a substance under discussion to allow that any possible derogation measure is adopted by the Commission within the timeframe defined by Article 15 of the Cosmetics Regulation 1223/2009.

11. The Commission responsible Services should inform the SCCS that the industry intends to defend the substance. They should also inform the Member States of this intention, so that any relevant data available in public or state laboratories, or elsewhere, may be considered for the scientific assessment. In parallel, they may also organise a call for scientific data from anyone holding or being aware of further relevant information, in order to gather additional scientific data.

12. It is the industry’s responsibility to demonstrate that the first three conditions (a), (b) and (c) for derogation laid down in Article 15 paragraph 2 of Cosmetics Regulation are fulfilled. For justifying compliance with each of the above conditions, the industry should submit appropriate dossiers for examination by the Commission responsible Services.

13. The Commission responsible Services should verify the compliance with the food safety requirements, where necessary by consulting the EFSA, and verify the absence of suitable alternative substances and the fact that the application is limited for a particular use of the product category with a known exposure, where necessary by consulting the Standing Committee on Cosmetic Products.

14. Subsequently, the procedure for the exchanges of data between the relevant entities can be started as regards to the overall exposure assessment by the SCCS (condition d). Requests for data sharing with the relevant EU Agencies (ECHA, EFSA and EMA\(^{40}\)) should be initiated and managed by the SCCS Secretariat. On a case by case basis, the Commission responsible Services can, where relevant, ask for data to Member States or third countries.

\(^{40}\) The need to consult EMA will be checked by the Commission on a case by case basis.
15. The "Declaration of Commitment by the Commission with respect to security aspects for ECHA’s information systems" has been signed by the responsible Commission Services and sets up the conditions under which exchange of confidential data from REACH dossiers can be ensured with ECHA.

16. Upon request by the SCCS Secretariat, the Commission responsible Services should grant access to relevant data in REACH registration dossiers to a designated SCCS expert who adheres to the security rules for users of ECHA’s Information System.

17. The extraction of relevant data from REACH dossiers and their processing to establish aggregated exposure levels should be completed by the designated SCCS expert within the secure room of the Commission responsible Services and in accordance with all applicable security rules. In case an evaluation of the CMR substance has already been completed under REACH, exposure levels that have been established can also be used straightaway where appropriate.

18. The EFSA should be consulted by the SCCS Secretariat to provide, if available, data or estimates on exposure from food and other relevant sources.

19. Additionally, the EMA could be consulted by the SCCS Secretariat on a case-by-case basis on exposure from substances used as pharmaceuticals.

20. The applicant should include in their submission all of the exposure information that they have. In addition to the exposure information gathered as mentioned above, e.g., exchange of data with the Agencies, public call for information, consultation with Member States, the SCCS will consider the exposure information provided by the applicant.

21. It is necessary that the exchange of data takes place in a smooth and timely manner as, for CMR 1A and 1B substances, the measure necessary for the derogation must be adopted by the Commission within 15 months following the adoption of the classification as CMR substance.

22. The SCCS, once it has received the scientific data from ECHA, EFSA, EMA and has taken into consideration the data submitted by the industry and other available sources (such as information gathered from Member States or following public consultation), shall assess the specific CMR substance(s) for safety of use in cosmetic products taking into account the overall exposure from other sources and vulnerable population groups within a timescale of at least six months for finalising their Opinion after an adequate submission and a complete set of exposure data is received.

23. It should be noted that, where the work of other scientific/regulatory bodies contains information on exposure to humans via the environment, this may have been incorporated in their overall estimates of exposure. However, Cosmetic Regulation (EC) No 1223/2009 only covers the aspects of safety to human health. As indicated in recital 5 of that Regulation, the environmental concerns that substances used in cosmetic products may raise are considered through the application of Regulation (EC) No 1907/2006 (REACH).

24. As regards the scientific risk assessment of CMR substances of categories 1A and 1B used in cosmetics, the SCCS will determine the most appropriate methodology for their safety evaluation based on the best scientific knowledge and taking into account the exposure from the specific uses in cosmetic products and the overall exposure from other sources.

---

41 DG ENTR and DG ENV co-managed the REACH legislation.
25. In order to provide transparency on the applied methodology and guidance to the industry, the SCCS should develop and incorporate this methodology within the next revision of its "Notes of Guidance for the testing of cosmetic substances and their safety evaluation".  

IV. Final observations

26. This document is only meant to provide guidance for a harmonised approach to the development and use of overall exposure estimates in assessing the safe use of CMR substances in cosmetic products and it is by no means binding.

27. The SCCS evaluation will not automatically trigger action under any legislation other than the Cosmetics legislation. The SCCS conclusions will be publicly available.

28. This document may be revised in the future in light of further scientific developments.

---

APPENDIX 6: REQUIREMENTS FOR THE CERTIFICATE OF ANALYSIS FOR A COSMETIC INGREDIENT

The Certificate of Analysis for a cosmetic ingredient should include:

1. The name and address of the laboratory performing the tests.
2. The registration number of the certificate of analysis.
3. The name, description and number of the batch for which the certificate is issued, the date of manufacture, and the expiry date.
4. The date on which the batch for which the certificate is issued was received.
5. A reference to the test procedure used, including the acceptance criteria (limits).
6. The results of all tests performed on the batch for which the certificate is issued (in numerical form, where applicable) and a comparison with the established acceptance criteria (limits), including information on Appearance, Identity (IR, NMR, MS), Purity, Solubility, Impurities (% content), Heavy metals.
7. Any additional test results obtained on samples from the batch as part of a periodic statistically based testing program.
8. A statement indicating whether the results were found to comply with the requirements.
9. The date(s) on which the test(s) was (were) performed.
10. The signature of the head of the laboratory or an authorised person.
11. The name, address, and telephone and fax numbers of the original manufacturer. If supplied by repackers or traders, the certificate should show the name, address, and telephone and fax numbers of the repacker/trader and a reference to the original manufacturer.
12. A statement of the expected conditions of shipping, packaging, storage and distribution, deviation from which would invalidate the certificate.
13. A copy of the certificate generated by the original manufacturer, if the sample is supplied by a repacker or trader.
APPENDIX 7: DETAILED EXPOSURE DATA FOR COSMETIC PRODUCTS

During the last years, exposure data for several cosmetic product categories became available in the open literature. This can be useful for safety assessors and safety agencies when in some particular cases refinement of risk assessment is necessary to show product or ingredients safety. In Table A.7 a literature overview is provided of recent cosmetic product consumer exposure data (e.g. different categories of cosmetics with frequency of use, amount per application, amount per day) which are focused on consumers from one or more particular countries. In a number of cases, data are shown stratified by age and/or gender, and for different cosmetic formulations.

**Table A.7**: literature overview (2015-2020) of specific cosmetic consumer exposure data and assessments

<table>
<thead>
<tr>
<th>References</th>
<th>Country(ies)</th>
<th>Product categories</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Husoy et al., 2020</td>
<td>Norway</td>
<td>cosmetic products and toothpaste</td>
<td>Adults, both genders</td>
</tr>
<tr>
<td>Gomez-Berrada et al., 2018a</td>
<td>France</td>
<td>toothpaste</td>
<td>adults and children; both genders</td>
</tr>
<tr>
<td>Gomez-Berrada et al., 2018b</td>
<td>France</td>
<td>sunscreens</td>
<td>adults and children; both genders under real-life conditions</td>
</tr>
<tr>
<td>Bernard et al., 2018</td>
<td>France</td>
<td>face and oral care cosmetic products</td>
<td>probabilistic exposure assessment; both genders; different age groups</td>
</tr>
<tr>
<td>Gomez-Berrada et al., 2017</td>
<td>France/ (1 city: Rennes)</td>
<td>cosmetic products</td>
<td>children under 2 years consumption; exposure assessment</td>
</tr>
<tr>
<td>Ficheux and Roudot 2017</td>
<td>France</td>
<td>cosmetic products</td>
<td>general population; both genders; different age groups</td>
</tr>
<tr>
<td>Dornic et al., 2017a</td>
<td>France</td>
<td>perfumes in cosmetic products</td>
<td>adults and children</td>
</tr>
<tr>
<td>Dornic et al., 2017b</td>
<td>France</td>
<td></td>
<td>default values for skin surface area</td>
</tr>
<tr>
<td>Dornic et al., 2017c</td>
<td>France</td>
<td>cosmetic products</td>
<td>exposure data; both genders, different age groups</td>
</tr>
<tr>
<td>Lee et al., 2017</td>
<td>Korea</td>
<td>baby care products</td>
<td>children 0-3 years</td>
</tr>
<tr>
<td>Garcia-Hidalgo et al., 2017</td>
<td>Swiss</td>
<td>personal care products</td>
<td>use patterns both genders; different age groups</td>
</tr>
<tr>
<td>Rieder et al., 2017</td>
<td></td>
<td>cosmetic ingredient</td>
<td>case of tea tree oil</td>
</tr>
<tr>
<td>Strittholt et al., 2016</td>
<td></td>
<td>toothpaste</td>
<td>in children (2-7yrs)</td>
</tr>
<tr>
<td>Bernard et al., 2016a</td>
<td>France</td>
<td>hair dye products</td>
<td>both genders</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Product Type</td>
<td>Exposure Assessment Details</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ficheux et al., 2016a</td>
<td>France</td>
<td>different cosmetic products</td>
<td>children (0-3yrs)</td>
</tr>
<tr>
<td>Ficheux et al., 2016b</td>
<td>France</td>
<td>different hair cosmetic products</td>
<td>both genders</td>
</tr>
<tr>
<td>Ficheux et al., 2016c</td>
<td>France</td>
<td>different cosmetic products</td>
<td>consumption amounts; different age groups; both genders</td>
</tr>
<tr>
<td>Ficheux et al., 2019</td>
<td>France</td>
<td>different cosmetic products</td>
<td>probabilistic aggregate exposure for babies, children; both genders</td>
</tr>
<tr>
<td>Dey et al., 2016a</td>
<td>USA, Germany, UK</td>
<td>baby wipes</td>
<td>lotion transfer via baby wipes</td>
</tr>
<tr>
<td>Dey et al., 2016b</td>
<td>world</td>
<td></td>
<td>exposure factor of disposable diapers</td>
</tr>
<tr>
<td>Comiskey et al., 2015</td>
<td>EU, USA</td>
<td>fragrance ingredients</td>
<td>probabilistic aggregate exposure</td>
</tr>
<tr>
<td>Manová et al., 2015</td>
<td>Swiss, Germany</td>
<td>UV filter ethylhexylmethoxy-cinnamate</td>
<td>probabilistic aggregate exposure</td>
</tr>
<tr>
<td>Tozer et al., 2015</td>
<td>USA</td>
<td>Zn pyrithione in rinse-off personal cleansing products</td>
<td>probabilistic aggregate exposure</td>
</tr>
<tr>
<td>Dudzina et al., 2015</td>
<td>USA</td>
<td>siloxane D5</td>
<td>probabilistic aggregate exposure (PACEM)</td>
</tr>
<tr>
<td>Nijkamp et al., 2015</td>
<td></td>
<td>fragrance geraniol in personal care products</td>
<td>probabilistic aggregate exposure</td>
</tr>
<tr>
<td>Safford et al., 2015</td>
<td></td>
<td>fragrance ingredients in cosmetic and personal care products</td>
<td>probabilistic aggregate exposure</td>
</tr>
</tbody>
</table>
APPENDIX 8: KEY CHARACTERISTICS OF CARCINOGENS

In the overall WoE assessment of a cosmetic ingredient, 10 key characteristics commonly exhibited by established human carcinogens can be taken into account (Smith et al., 2019, Al-Zougholl, 2019). High-throughput assay systems, such as the US EPA’s ToxCast program (Chiu et al., 2018), which provide in vitro mechanistic data on several of the key characteristics, may be helpful.

Table A.8: Key characteristics of carcinogens (based on: Smith et al., 2019 and Al-Zougholl et al., 2019); AhR, aryl hydrocarbon receptor; ER, estrogen receptor; PPAR, peroxisome proliferator–activated receptor.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Is electrophilic or can be metabolically activated to electrophiles</td>
<td>Formation of protein adducts indicates the presence of reactive chemicals, which are sometimes also considered as indirect indicators/predictors of DNA damage (see characteristic 2, below) Requires biotransformation (metabolic activation) to produce reactive metabolites, e.g. alkylating agents, epoxide metabolites, aryl-nitrenium ion Evidence for ADME of the agent affecting its carcinogenicity</td>
</tr>
<tr>
<td>2. Is genotoxic</td>
<td>Direct evidence of DNA damage – this category includes nuclear and mitochondrial DNA damage (in vitro or in vivo): DNA adducts, DNA strand breaks (single- and/or double-strand breaks), DNA–protein cross-links, DNA–DNA cross-links. Indirect indicators or biomarkers of DNA damage (in vitro or in vivo). Disruption or breakages of chromosomes leading to sections of the chromosome being deleted, added, or rearranged. Reversions and forward mutations in microorganisms or mammalian cells. Mutations affecting oncogenes, tumour-suppressor genes, and other genes involved in cell cycle control.</td>
</tr>
<tr>
<td>3. Alters DNA repair or causes genomic instability</td>
<td>Effects on key DNA-repair mechanisms such as base-excision repair (BER) and nucleotide-excision repair (NER). Inherited abnormalities in DNA-repair function lead to enhanced cancer susceptibility.</td>
</tr>
<tr>
<td>4. Induces epigenetic alterations</td>
<td>Stable, long-term alterations in the transcriptional potential of a cell. These effects can be caused by factors such as altered methylation of DNA, micro-RNA expression, and changes in chromatin and histone structure.</td>
</tr>
<tr>
<td>5. Induces oxidative stress</td>
<td>Disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses within a cell.</td>
</tr>
<tr>
<td>6. Induces chronic inflammation</td>
<td>Chronic inflammation and/or irritation leading to oxidative DNA damage.</td>
</tr>
<tr>
<td>7. Is immunosuppressive</td>
<td>Measures of altered function of the immune system that may lead to increased cancer risk (e.g. HIV-related effects).</td>
</tr>
<tr>
<td>8. Modulates receptor-mediated effects</td>
<td>Interference with cell-signaling pathways leading to expression of carcinogenic trait/phenotype in the cell, e.g. facilitating cell invasion or induction of genes for inflammatory mediators, oncogenes Interference with the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body. External agents can...</td>
</tr>
</tbody>
</table>
interfere with the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body.

9. Causes immortalization
   A. Oncogenic transformation, *i.e.* anchorage-independent growth, loss of contact inhibition.
   B. Increased motility and invasiveness of cancer cell lines
   C. Cell transformation
   Activation of a telomerase that prevents loss of telomere length, leading to immortalization of cells.

10. Alters cell proliferation, cell death or nutrient supply
    Interference with cell-signaling pathways leading to expression of carcinogenic trait/phenotype in the cell *e.g.* facilitating cell invasion or induction of gene promotion for inflammatory mediators, oncogenes.
    Induced defects in programmed cell death (apoptosis). Evasion of apoptosis is a requirement for both neoplastic transformation and sustained growth of cancer cells.
    Detection of alterations in cell proliferation and cell-cycle effects (*e.g.* DNA replication changes, cell-cycle control, ploidy), mitogenesis. Altered nutrient supply affects cell viability.
    Change in pro-angiogenesis factors
    Disruption of gap-junction intercellular communication pathways that can cause a loss of ‘contact inhibition’ and abnormal cell growth.
    The bystander effect was first identified in radiobiology and refers to the situation where non-irradiated cells exhibit effects caused by radiation as a result of chemical signals (messengers) received from nearby irradiated cells. These effects are often mediated through gap-junction transfer of chemical agents.

Any of the 10 characteristics in this table could interact with any other (*e.g.*, oxidative stress, DNA damage, and chronic inflammation), which when combined provides stronger evidence for a cancer mechanism than would oxidative stress alone.

Any of the 10 characteristics in this table could interact with any other (*e.g.*, oxidative stress, DNA damage, and chronic inflammation), which when combined provides stronger evidence for a cancer mechanism than would oxidative stress alone.
APPENDIX 9: GUIDELINES ON MICROBIOLOGICAL QUALITY OF THE FINISHED COSMETIC PRODUCT

This part has been taken over from the 9th Revision of the NoG (SCCS/1564/15): https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_190.pdf

Although the NoG are concerned with the safety evaluation of ingredients, this appendix is concerned with the finished cosmetic product. The reason for this is the fact that in other pieces of legislation, reference has been made to it as being part of the NoG.

Preamble:
Skin and mucous membranes are protected from microbial attack by a natural mechanical barrier and various defence mechanisms. However, these may be damaged and slight trauma may be caused by the action of some cosmetics that may enhance microbial infection. This may become of particular concern when cosmetics are used around the eyes, on mucous membranes in general, on damaged skin, on children under 3 years, on elderly people and persons with compromised immune system. Consequently, two separate categories of cosmetic products are defined in the microbiological quality control limits:

Category 1: Products specifically intended for children under 3 years, to be used in the eye area and on mucous membranes.

Category 2: Other products.

Microbial contaminants usually come from two different origins: during production and filling, and during the use of the cosmetic by the consumer. From the moment the cosmetic unit is opened until the last use of the product by the consumer(s), a permanent, variable and additive microbial contamination of the cosmetic is introduced, caused by the domestic environment and contact with the skin of the consumer(s) (hands and body).

Reasons for microbial preservation of cosmetics are:
- to ensure the microbial safety of cosmetics for the consumer,
- to maintain the quality and specifications intended of the product,
- to confirm hygienic and high-quality handling.

Although only a small number of cases of microbiological contamination of cosmetics leading to microbial infections of the consumer has been reported, microbial contamination of cosmetic products may spoil them or seriously reduce the intended quality. In order to ensure the quality of the product and the safety for the consumer, it is necessary to carry out routine microbiological analysis of each batch of the finished product coming on the market. In some justified cases (e.g. alcohol content > 20%), end product testing is not necessary (ISO 29621, 2010). The parameters examined, the criteria and methods used, and the results obtained per batch should be specified in properly filed reports and be taken up in the TIF.

Quantitative and qualitative limits
Quantitative and qualitative limits are based on the European Standard EN ISO 17516:2014 Cosmetics – Microbiology – Microbiological limits. The European Standard EN ISO 17516:2014 was approved by CEN on 9 August 2014 and at present is widely used by the cosmetics industry as international standard (Table A9). It is reviewed and confirmed in 2020.
### Table A9: Microbiological limits for cosmetics. European Standard EN ISO 17516:2014

**Cosmetics – Microbiology – Microbiological limits**

<table>
<thead>
<tr>
<th>Types of microorganism</th>
<th>Products specifically intended for children under three years of age, the eye area or the mucous membranes</th>
<th>Other products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Aerobic Mesophilic Microorganisms (Bacteria plus yeast and mould)</td>
<td>$\leq 1 \times 10^2$ CFU per g or ml&lt;sup&gt;a&lt;/sup&gt;</td>
<td>$\leq 1 \times 10^3$ CFU per g or ml&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Absence in 1 g or 1 ml</td>
<td>Absence in 1 g or 1 ml</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>Absence in 1 g or 1 ml</td>
<td>Absence in 1 g or 1 ml</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Absence in 1 g or 1 ml</td>
<td>Absence in 1 g or 1 ml</td>
</tr>
<tr>
<td><em>Candida albicans</em></td>
<td>Absence in 1 g or 1 ml</td>
<td>Absence in 1 g or 1 ml</td>
</tr>
</tbody>
</table>

Due to inherent variability of the plate count method, according to USP Chapter 61 or EP Chapter 2.6.12, Interpretation of results, results considered out of limit if

- $a > 200$ CFU/g or ml,
- $b > 2000$ CFU/g or ml.

**NOTE** When colonies of bacteria are detected on Sabouraud Dextrose agar, Sabouraud Dextrose agar containing antibiotics may be used.

### Challenge testing (based on US Pharmacopoeia 2014, European Pharmacopoeia 2014)

Note that this chapter addresses microbiological contamination, i.e. unwanted presence of microorganisms. Total germ counts and challenge test are not directly applicable for the case of probiotic cosmetic formulations to which live or viable microorganisms have been deliberately added.

The efficacy of the preservation of a cosmetic product under development has to be assessed experimentally in order to ensure microbial stability and preservation during storage and use. This is done by challenge testing. The latter is mandatory for all cosmetic products that, under normal conditions of storage and use, may deteriorate or form a risk to infect the consumer.

A challenge test consists of an artificial contamination of the finished product, followed by a subsequent evaluation of the decrease in contamination to levels ensuring the microbial limits established for Categories 1 and 2. The microorganisms used in the challenge test may be issued from official collection strains from any state in the EU to ensure reproducibility of the test and are: *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Candida albicans* and *Aspergillus brasiliensis*.

It is well known today that the consistency of challenge tests relies more on the capability of the used microorganisms to contaminate a specific cosmetic product than on the taxonomic status of the microorganisms, their initial concentrations, or the conditions of incubation and media of recovery used. Microorganisms with the capability to contaminate specific cosmetics are the best candidates for use in a challenge test. The microbicidal activity of preservatives or any other compound in the finished cosmetic must be ruled out in the challenge test by dilution, filtration, addition of neutralisers or any other means.

The experimental performance of the microbial controls and the challenge tests must be carried out/oversupervised and validated by a microbiologist. As mentioned before, the responsible person must guarantee the efficacy of the preservation of his products experimentally by challenge testing. However, as no legal or universal challenge test method is currently available, it is up to the responsible person to decide on the details of the test to be used.
Good Manufacturing Practice (GMP)

In order to comply (mandatory but no certification required) with Good Manufacturing Practice and Microbial Quality Management, manufacturers of cosmetics have to define and follow specific cleaning, sanitation and control procedures to keep all apparatus and materials appropriately clean and free of pathologic microorganisms. Procedures also include microbiological control of raw materials, bulk and finished products, packaging material, personnel, equipment and preparation and storage rooms. Compliance should be checked with the currently available European Committee for standardization (CEN) standards (available through http://www.cenorm.be/cenorm/index.htm) and/or ISO standards (available through http://www.iso.org/iso/en/ISOOnline.frontpage). According to Article 8 of Regulation (EC) No 1223/2009, good manufacturing shall be presumed where the manufacture is in accordance with the relevant harmonised standards, the references of which have been published in the Official Journal of the European Union.
APPENDIX 10: FREE ACCESS TO IN SILICO MUTAGENICITY / GENOTOXICITY AND CARCINOGENICITY DATABASES

- The Danish QSAR database (http://qsar.food.dtu.dk/) which includes QSAR models based on structural alerts for DNA reactivity; *in vitro* Ames test in S. typhimurium, chromosome aberration in Chinese Hamster Lung (CHL) and ovari (CHO) cells; Comet assay in mouse; micronucleus test in mouse erythrocytes; sister chromatid exchange in mouse bone marrow cells; mutations in HGPRT locus in Chinese hamster ovari (CHO) cells; mutations in thymidine kinase locus in mouse lymphoma cells; and sex-linked recessive lethal test in Drosophila melanogaster.

- The OECD QSAR Toolbox (https://qsartoolbox.org/), which also incorporates the models and tools from the Danish QSAR database, provides a versatile suite of programs for chemical profiling, categorisation, and data gap filling by (Q)SAR models and read-across for various toxicological endpoints, including mutagenicity. The system also includes metabolic simulators that further enable the prediction and genotoxicity assessment of metabolites. The Toolbox also provides profilers for mutagenicity that are based on structural alerts for *in vitro* mutagenicity (Ames test), *in vivo* mutagenicity (micronucleus) chromosomal aberration and micronucleus test, and DNA and protein binding. The predictions from the profilers can provide supporting information when used in conjunction with QSAR predictions. The Toolbox also provides a few profilers that combine several structural alerts for the purpose of category formation on the basis of carcinogenicity potential of chemical substances. A notable one is the ISS profiler that combines 58 structural alerts for carcinogenicity (both genotox and non-genotox) from the Toxtree software (http://toxtree.sourceforge.net/). Around 20 of the alerts are for non-genotoxic carcinogenicity, and the remaining ones for genotoxic carcinogenicity (mutagenicity). A recent study (Aljallal, 2020) has indicated that some of the structural alerts and the profilers provided in the OECD QSAR Toolbox need further refinement, and their use in conjunction with QSAR models and read-across would be required to improve the accuracy of predictions.

- VEGA QSAR platform (www.vegahub.eu/) provides QSAR models for mutagenicity developed in line with the OECD principles using high quality datasets with the aim to use for regulatory purposes;

- The US-EPA’s Toxicity Estimation Software Tool (T.E.S.T.) (www.epa.gov/nrmrl/std/qsar/qsar.html) is an Expert system that uses an ensemble of QSARs to estimate toxicity - including mutagenicity (Ames test in S. typhimurium);

- Toxtree (http://toxtree.sourceforge.net/) enables estimation of toxicity hazard by applying a decision tree approach;

- Lazar (https://lazar.in-silico.ch/predict) is an automated system of read across to calculate toxicity predictions.

- OpenTox for carcinogenicity through OpenTox platform (ToxPredict) (www.opentox.net/library/toxicity-prediction)

APPENDIX 11: INHALATION PARAMETERISATION

Table A. 11: Example for the parameterisation of a 2-Box model for sunscreens based on Rothe et al., 2011 and SCCS recommendations. Product-dependent parameter values in this example are specific for sunscreens and denoted with an asterix * (see also 3-3.5.4.1 calculation of the inhalation SED)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Parameter description</th>
<th>Propellant spray</th>
<th>Pump spray</th>
<th>Unit</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a_{\text{product}})*</td>
<td>amount per application*</td>
<td>9</td>
<td>9</td>
<td>g/application</td>
<td>SCCS, NoG</td>
</tr>
<tr>
<td>(f_{\text{air}})</td>
<td>air-borne fraction of spray mist</td>
<td>1</td>
<td>0.2</td>
<td>fraction</td>
<td>Bremmer et al., 2006</td>
</tr>
<tr>
<td>(V_1)*</td>
<td>Box 1 (Near-field around the head)*</td>
<td>1000</td>
<td>1000</td>
<td>L</td>
<td>SCCS, Octocrylene</td>
</tr>
<tr>
<td>(t_1)*</td>
<td>duration of exposure in Box 1 (near field)*</td>
<td>2</td>
<td>2</td>
<td>min</td>
<td>SCCS, Octocrylene</td>
</tr>
<tr>
<td>(r_{\text{inh}})</td>
<td>inhalation rate</td>
<td>13**</td>
<td>13**</td>
<td>L/min</td>
<td>US-EPA 2011</td>
</tr>
<tr>
<td>(V_2)*</td>
<td>Box 2 (Far-field, e.g. bathroom)*</td>
<td>10000</td>
<td>10000</td>
<td>L</td>
<td>SCCS, Octocrylene</td>
</tr>
<tr>
<td>(t_2)*</td>
<td>duration of exposure in Box 2 (far field)*</td>
<td>10</td>
<td>10</td>
<td>min</td>
<td>SCCS, Octocrylene</td>
</tr>
<tr>
<td>(f_{\text{resp}})</td>
<td>respirable fraction</td>
<td>experimental data</td>
<td>experimental data</td>
<td>fraction</td>
<td></td>
</tr>
<tr>
<td>(f_{\text{ret}})</td>
<td>substance retention fraction in the lungs (25% exhaled)</td>
<td>0.75</td>
<td>0.75</td>
<td>fraction</td>
<td>Rothe et al., 2011</td>
</tr>
<tr>
<td>(f_{\text{appl}})*</td>
<td>frequency of application*</td>
<td>2</td>
<td>2</td>
<td>per day</td>
<td>SCCS, NoG</td>
</tr>
<tr>
<td>(bw)</td>
<td>bodyweight</td>
<td>60</td>
<td>60</td>
<td>kg</td>
<td>SCCS, NoG</td>
</tr>
</tbody>
</table>

* Product-dependent parameter value;
**highest median among several adult age categories;
SCC/1627/21 opinion on octocrylene; SCCS NoG = SCCS Notes of Guidance.
APPENDIX 12: LIFETIME CANCER RISK (LCR) APPROACH

The "T25 method" (Sanner et al., 2001) is used as a simple method for quantitative risk assessment of carcinogens in the REACH Regulation (ECHA, 2017). It should be noted that, in six cases where high quality epidemiology and animal carcinogenicity studies were available, quantitative risk characterisation based on epidemiological data and data based on animal studies using the T25 method differed by factors of less than three (Sanner and Dybing, 2005).

Determination of the LCR is carried out in different steps. After having decided what animal data set to use and type of tumour to consider, the dose descriptor T25 is determined, which is described in detail (ECHA, 2012a; Dybing et al., 1997).

The animal dose descriptor (T25) is converted to the human dose descriptor (HT25) based on comparative metabolic rates (Sanner et al., 2001):

\[
HT25 = \frac{T25}{(\text{body weight}_{\text{human}}/\text{body weight}_{\text{animal}})^{0.25}}
\]

Based on the daily lifetime SED, the LCR is calculated by linear extrapolation by use of the following formula:

\[
\text{LCR} = \frac{\text{SED}}{HT25/0.25}
\]

Subsequently, a statement is generated describing whether the actual risk may be higher or lower than the risk calculated for a specific scenario. The procedure and the following elements are reported and discussed in detail (Sanner et al., 2001; ECHA, 2012a).
APPENDIX 13: PoD USED FOR TTC DERIVATION

Table A.13: Chemical classes and 5th percentile Cramer Class PoDs of selected published TTC datasets. n = number of substances / PoDs in the dataset. 5th percentiles were derived from log-normal parametric distributions, except by Pinalli et al., (2011); van Ravenzwaay (2017) and Kalkhof et al. (2012) who did not report the calculation method. NO(A)EL = No Observed Adverse Effect Level; PoD = Point of Departure; CC = Cramer Class; DB = data base; dev. = developmental

<table>
<thead>
<tr>
<th>References</th>
<th>Dominant chemical classes</th>
<th>n</th>
<th>5th percentile NO(A)ELs adjusted to chronic (PoD, mg/kg bw/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cramer Class I</td>
</tr>
<tr>
<td>Yang et al., 2017, ‘federated’</td>
<td>Cosmetic-related, packaging and pesticides</td>
<td>977</td>
<td>4.57</td>
</tr>
<tr>
<td>Munro et al., 1996</td>
<td>Food contact, pesticides</td>
<td>612</td>
<td>3.0</td>
</tr>
<tr>
<td>Yang et al., 2017, Munro et al., 1996 ‘Munro-2016’</td>
<td>Some Cramer Classes and other errors corrected, harmonised assessment factors</td>
<td>612</td>
<td>4.90</td>
</tr>
<tr>
<td>Yang et al., 2017, COSMOS 2017</td>
<td>Cosmetic-related &amp; packaging</td>
<td>552</td>
<td>4.20</td>
</tr>
<tr>
<td>Tluczkiewicz et al., 2011</td>
<td>Industrial chemicals and pesticides</td>
<td>521</td>
<td>0.62</td>
</tr>
<tr>
<td>Kalkhof et al., 2012</td>
<td>German pre-REACH DB, industrial chemicals</td>
<td>813</td>
<td>2.5 (n=69)</td>
</tr>
<tr>
<td>Pinalli et al., 2011</td>
<td>Food contact materials</td>
<td>232</td>
<td>CCI/II not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feigenbaum et al., 2015</td>
<td>Pesticides without carbamates and organophosphates</td>
<td>279</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Munro+ Pinalli+ pesticides with carbamates and organophosphates</td>
<td>840</td>
<td></td>
</tr>
<tr>
<td>Laufersweiler et al., 2012</td>
<td>Only reproductive and developmental endpoints. From Kroes et al. (2000), Bernauer et al. (2008), plus literature.</td>
<td>283</td>
<td>13.1 (n=69)</td>
</tr>
<tr>
<td>Van Ravenzwaay et al., 2017</td>
<td>Chemicals &amp; pesticides, developmental studies only</td>
<td>1505§/ 537*</td>
<td>§rabbits: 5/9.5 maternal/dev</td>
</tr>
<tr>
<td>Patel et al., 2020 ‘RIFM’</td>
<td>Fragrance chemicals</td>
<td>476</td>
<td>5.39 (n=238)</td>
</tr>
<tr>
<td>Patel et al., 2020 ‘RIFM/COSMOS/Federated’</td>
<td>Fragrance chemicals, Cosmetic-related, packaging and pesticides</td>
<td>1327</td>
<td>4.91 (n=421)</td>
</tr>
</tbody>
</table>
ABBREVIATIONS AND GLOSSARY OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D</td>
<td>Two Dimensional</td>
</tr>
<tr>
<td>3D</td>
<td>Three Dimensional</td>
</tr>
<tr>
<td>3R</td>
<td>Refinement, Reduction, Replacement</td>
</tr>
<tr>
<td>3T3 NRU PT</td>
<td>3T3 Neutral Red Uptake Phototoxicity Test</td>
</tr>
<tr>
<td>A</td>
<td>Androgen</td>
</tr>
<tr>
<td>Å</td>
<td>Angström</td>
</tr>
<tr>
<td>ADME</td>
<td>Absorption, Distribution, Metabolism, Excretion</td>
</tr>
<tr>
<td>ADRA</td>
<td>Amino acid Derivative Reactivity Assay</td>
</tr>
<tr>
<td>Adverse</td>
<td>An adverse response is defined as any treatment-related response that results in change in the morphology, physiology, growth, development or life-span of an organism, which results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other environmental influences (WHO 2004)</td>
</tr>
<tr>
<td>AEL</td>
<td>Acceptable Exposure Level</td>
</tr>
<tr>
<td>AhR</td>
<td>Aryl hydrocarbon Receptor</td>
</tr>
<tr>
<td>AIC</td>
<td>Akaike Information Criterion</td>
</tr>
<tr>
<td>A.I.S.E.</td>
<td>International Association for Soaps, Detergents and Maintenance Products</td>
</tr>
<tr>
<td>Alternative methods</td>
<td>All those procedures which can completely replace the need for animal experiments, which can reduce the number of animals required, or which can reduce the amount of pain and stress to which the animal is subjected in order to meet the essential needs of humans and other animals (Rogiers et al., 2000; Russell et al., 1959)</td>
</tr>
<tr>
<td>AMA</td>
<td>Amphibian Metamorphosis Assay</td>
</tr>
<tr>
<td>AOP</td>
<td>Adverse Outcome Pathway</td>
</tr>
<tr>
<td>AR</td>
<td>Androgen Receptor</td>
</tr>
<tr>
<td>Art.</td>
<td>Article</td>
</tr>
<tr>
<td>AhR</td>
<td>Aryl hydrocarbon Receptor</td>
</tr>
<tr>
<td>ATM</td>
<td>Alternative Test Method</td>
</tr>
<tr>
<td>ATP</td>
<td>Adaptation to Technical and scientific Progress</td>
</tr>
<tr>
<td>AUC</td>
<td>Area Under the Curve</td>
</tr>
<tr>
<td>BCOP</td>
<td>Bovine Corneal Opacity and Permeability</td>
</tr>
<tr>
<td>BCRP</td>
<td>Breast Cancer Resistance Protein</td>
</tr>
<tr>
<td>BHT</td>
<td>Butylated HydroxyToluene</td>
</tr>
<tr>
<td>BMD</td>
<td>The BenchMark Dose is proposed as an alternative for the classical NOAEL and LOAEL values. The BMD is based on a mathematical model being fitted to the experimental data within the observable range and estimates the dose that causes a low but measurable response (the benchmark response BMR) typically chosen at a 5 or 10% incidence above the control.</td>
</tr>
<tr>
<td>BMDL</td>
<td>BMD Lower limit refers to the corresponding lower limit of a one-sided 95% confidence interval on the BMD.</td>
</tr>
<tr>
<td>BMDU</td>
<td>BMD Upper limit refers to the corresponding upper limit of a one-sided 95% confidence interval on the BMD.</td>
</tr>
<tr>
<td>BMR</td>
<td>BenchMark Response</td>
</tr>
<tr>
<td>BoA</td>
<td>Board of Appeal</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>BrdU</td>
<td>5-Bromo-2-deoxy-Uridine</td>
</tr>
<tr>
<td>BSE</td>
<td>Bovine Spongiform Encephalopathy</td>
</tr>
<tr>
<td>BW</td>
<td>Body Weight</td>
</tr>
<tr>
<td>C</td>
<td>Concentration</td>
</tr>
<tr>
<td>CAS n°</td>
<td>Chemical Abstracts Service registry number</td>
</tr>
<tr>
<td>Cat.</td>
<td>Category</td>
</tr>
<tr>
<td>CC</td>
<td>Cramer Class</td>
</tr>
<tr>
<td>CEBS</td>
<td>Chemical Effects in Biological Systems</td>
</tr>
<tr>
<td>CEL</td>
<td>Consumer Exposure Level</td>
</tr>
<tr>
<td>CEN</td>
<td>European Committee for Standardization</td>
</tr>
<tr>
<td>CERAPP</td>
<td>Collaborative Estrogen Receptor Activity Prediction Project</td>
</tr>
<tr>
<td>CFU</td>
<td>Colony Forming Unit</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for Medicinal Products for Human use</td>
</tr>
<tr>
<td>CI</td>
<td>Colour Index</td>
</tr>
<tr>
<td>CIN</td>
<td>Common Ingredient Name</td>
</tr>
<tr>
<td>CLP</td>
<td>Classification, Labelling and Packaging of Substances and Mixtures</td>
</tr>
<tr>
<td>CMR</td>
<td>Carcinogenic, Mutagenic, toxic to Reproduction</td>
</tr>
<tr>
<td>CM</td>
<td>Cytosensor Microphysiometer</td>
</tr>
<tr>
<td>COC</td>
<td>Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment</td>
</tr>
<tr>
<td>Colipa</td>
<td>The European Cosmetic and Perfumery Association</td>
</tr>
<tr>
<td>COM</td>
<td>Committee on Mutagenicity of Chemicals in Food, Consumer Products, and the Environment</td>
</tr>
<tr>
<td>COM</td>
<td>Communication from the Commission</td>
</tr>
<tr>
<td>COMET</td>
<td>CONSortium for METabolicomic Toxicology</td>
</tr>
<tr>
<td>CPDB</td>
<td>Carcinogenic Potency DataBase</td>
</tr>
<tr>
<td>CPSR</td>
<td>Cosmetic Product Safety Report</td>
</tr>
<tr>
<td>CVM</td>
<td>Collagen Vitrigel Membrane</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>DA</td>
<td>Defined Approach</td>
</tr>
<tr>
<td>DART</td>
<td>Developmental and Reproductive Toxicity Database</td>
</tr>
<tr>
<td>DB</td>
<td>Data Base</td>
</tr>
<tr>
<td>Dev.</td>
<td>Developmental</td>
</tr>
<tr>
<td>DG</td>
<td>Directorate General</td>
</tr>
<tr>
<td>DIMDI</td>
<td>German Institute for Medical Documentation and Information</td>
</tr>
<tr>
<td>DPRA</td>
<td>Direct Peptide Reactivity Assay</td>
</tr>
<tr>
<td>E</td>
<td>Estrogen</td>
</tr>
<tr>
<td>EADB</td>
<td>Endocrine Activity Database</td>
</tr>
<tr>
<td>EASIS</td>
<td>Endocrine Active Substances Information System</td>
</tr>
<tr>
<td>EATS</td>
<td>Estrogenic, Androgenic, Thyroid, Steroidogenic</td>
</tr>
<tr>
<td>EC</td>
<td>European Commission</td>
</tr>
<tr>
<td>ECB</td>
<td>European Chemicals Bureau</td>
</tr>
<tr>
<td>ECETOC</td>
<td>European Centre for Ecotoxicology and Toxicology of Chemicals is an industry-funded expert not-for-profit think tank whose sole purpose is to enhance the quality of chemicals risk assessment so that chemicals management decisions are informed, reliable and safe.</td>
</tr>
<tr>
<td>ECHA</td>
<td>European CHemicals Agency</td>
</tr>
<tr>
<td>ECVAM</td>
<td>European Centre for the Validation of Alternative Methods</td>
</tr>
<tr>
<td>ED</td>
<td>Endocrine Disruptor</td>
</tr>
<tr>
<td>Ed.</td>
<td>Edition</td>
</tr>
<tr>
<td>E_dermal</td>
<td>Exposure dermally</td>
</tr>
<tr>
<td>EDKB</td>
<td>Endocrine Disruption Knowledge Base</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>EDSP</td>
<td>Endocrine Disruption Screening Program</td>
</tr>
<tr>
<td>EEC</td>
<td>European Economic Community</td>
</tr>
<tr>
<td>EFSA</td>
<td>European Food Safety Authority</td>
</tr>
<tr>
<td>EINECS</td>
<td>European INventory of Existing commercial Chemical Substances</td>
</tr>
<tr>
<td>EIT</td>
<td>Eye Irritation Test</td>
</tr>
<tr>
<td>ELINCS</td>
<td>European LIst of Notified Chemical Substances</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-Linked ImmunoSorbent Assay</td>
</tr>
<tr>
<td>EMA/EMEA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EOGRTS</td>
<td>Extended One-Generation Reproductive Toxicity Study</td>
</tr>
<tr>
<td>(US) EPA</td>
<td>(United States) Environmental Protection Agency</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen Receptor</td>
</tr>
<tr>
<td>ERBA</td>
<td>Endocrine Receptor Binding Assay</td>
</tr>
<tr>
<td>ESAC</td>
<td>ECVAM Scientific Advisory Committee</td>
</tr>
<tr>
<td>EDS</td>
<td>Endocrine Disruptor Screening Program</td>
</tr>
<tr>
<td>EST</td>
<td>Embryonic Stem cell Test</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EUURL-ECVAM</td>
<td>European Union Reference Laboratory - European Centre for the Validation of Alternative Methods</td>
</tr>
<tr>
<td>F</td>
<td>Frequency of application</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration (federal agency of the United States Department of Health and Human Services)</td>
</tr>
<tr>
<td>Finished cosmetic product</td>
<td>The cosmetic product in its final formulation, as placed on the market and made available to the end user, or its prototype (2009/1223/EC)</td>
</tr>
<tr>
<td>FL</td>
<td>Fluorescein Leakage test</td>
</tr>
<tr>
<td>fret</td>
<td>Retention factor</td>
</tr>
<tr>
<td>GC-MS</td>
<td>Gas Chromatography–Mass Spectrometry</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practice</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>GPMT</td>
<td>Guinea Pig Maximisation Test</td>
</tr>
<tr>
<td>GR</td>
<td>Glucocorticoid Receptor</td>
</tr>
<tr>
<td>GST</td>
<td>Glutathione S-Transferase</td>
</tr>
<tr>
<td>GUM</td>
<td>Gesellschaft für Umweltmutationsforschung</td>
</tr>
<tr>
<td>Hair product</td>
<td>A cosmetic product which is intended to be applied on the hair of head or face, except eyelashes (2009/1223/EC)</td>
</tr>
<tr>
<td>HBM</td>
<td>Human BioMonitoring</td>
</tr>
<tr>
<td>HCA</td>
<td>High Content Analysis</td>
</tr>
<tr>
<td>HCE</td>
<td>Human Corneal Epithelium</td>
</tr>
<tr>
<td>hCLAT</td>
<td>human Cell Line Activation Test</td>
</tr>
<tr>
<td>HESS</td>
<td>Hazard Evaluation Support System</td>
</tr>
<tr>
<td>HET-CAM</td>
<td>Hen’s Egg Test-Chorio Allantoic Membrane</td>
</tr>
<tr>
<td>HET-MN</td>
<td>Hen’s Egg Test for MicroNucleus</td>
</tr>
<tr>
<td>HPG</td>
<td>Hypothalamus-Pituitary-Gonad</td>
</tr>
<tr>
<td>HPLC</td>
<td>High-Performance Liquid Chromatography</td>
</tr>
<tr>
<td>HPLC-PDA</td>
<td>High-Performance Liquid Chromatography/Photo-Diode Array detection</td>
</tr>
<tr>
<td>HPRT</td>
<td>Hypoxanthine-guanine PhosphoRibosyl Transferase</td>
</tr>
<tr>
<td>HPT</td>
<td>Hypothalamus-Pituitary-Thyroid</td>
</tr>
<tr>
<td>HSDB</td>
<td>Hazardous Substances Data Bank</td>
</tr>
<tr>
<td>HT25</td>
<td>Human dose descriptor, derived from T25 and based on comparative metabolic rates (Sanner et al., 2001)</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
</tr>
</tbody>
</table>
**IATA** | Integrated Approaches to Testing and Assessment  
**ICCR** | International Cooperation on Cosmetics Regulation  
**ICE** | Isolated Chicken Eye  
**ICH** | International Conference on Harmonisation  
**ICRP** | International Commission on Radiologic Protection  

**In silico methods** | Computational approaches that use (quantitative) structure-activity relationship modelling, and read-across between substances on the basis of structural or functional similarities (ICCR, 2014).

**In vitro test method** | Biological method: using organs, tissue sections and tissue cultures, isolated cells and their cultures, cell lines and subcellular fractions.  
Non-biological method: such as computer modelling, chemical interaction studies, receptor binding studies etc. (based on Rogiers et al., 2000)

**In vivo test method** | Test method using living (experimental) animals  
[Rogiers et al., 2000]

**IL-1α** | InterLeukin-1α

**INCI** | International Nomenclature of Cosmetic Ingredients

**INN** | International Non-proprietary Name

**IPCS** | International Programme on Chemical Safety

**IR** | Infra Red

**IRE** | Isolated Rabbit Eye

**ISSMIC** | In vivo MICronucleus database

**ISSSTY** | In vitro mutagenesis in Salmonella Typhimurium

**ISO** | International Organization for Standardisation

**ITTC** | internal Treshold of Toxicological Concern

**IUPAC** | International Union of Pure and Applied Chemistry

**IWGT** | International Workshop on Genotoxicity Testing

**JRC** | Joint Research Centre

**kDPRA** | kinetic Direct Peptide Reactivity Assay

**KE** | Key Event

**kNN** | k-Nearest Neighbour (algorithm)

**LAGDA** | Larval Amphibian Growth and Development Assay

**LC_{50}** | Median Lethal Concentration 50%: a time dependent, statistically derived estimate of a test article concentration that can be expected to cause death during exposure or within a fixed time after exposure in 50% of animals exposed for a specified time {expressed as mass of test article per unit volume of air (mg/L, mg/m^3) or as a unit volume of test article per unit volume of air (ppm, ppb)} (OECD 2009b).

**LC-MS** | Liquid Chromatography–Mass Spectrometry

**LCR** | Lifetime Cancer Risk

**LD50** | Median Lethal Dose 50%: a statistically derived single dose of a substance that can be expected to cause death in 50% of the dosed animals (expressed in mg/kg body weight) (EC B.1 bis)

**LED** | Lowest Effective Dose, e.g. LED10

**LLBO** | Laser Light-Based Opacitometer

**LLNA** | Local Lymph Node Assay

**LO(A)EL** | The Lowest Observed (Adverse) Effect Level is the outcome of repeat-dose long-term toxicity studies, such as 28-day or 90-day tests with rats, mice, rabbits or dogs,
chronic toxicity tests, carcinogenicity tests, teratogenicity tests, reproduction toxicity tests, etc. It is the lowest dose where (adverse) effects can be observed. In the calculation of the MoS, the lowest obtained LOAEL value may be used when a NOAEL is not available. The LOAEL should be expressed as mg/kg bw/d. (ECB, 2003)

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>LoD</td>
<td>Level of Detection</td>
</tr>
<tr>
<td>LoQ</td>
<td>Level of Quantification</td>
</tr>
<tr>
<td>MDCK</td>
<td>Madin-Darby Canine Kidney cells</td>
</tr>
<tr>
<td>MDR</td>
<td>Multi Resistance Protein</td>
</tr>
<tr>
<td>MEC</td>
<td>Molecular Extinction Coefficient</td>
</tr>
<tr>
<td>MEGA</td>
<td>Multi-Endpoint Genotoxicity Assay</td>
</tr>
<tr>
<td>MIE</td>
<td>Molecular Initiating Event</td>
</tr>
<tr>
<td>MLA</td>
<td>Mouse Lymphoma Assay</td>
</tr>
<tr>
<td>MM</td>
<td>MicroMass</td>
</tr>
<tr>
<td>MMAD</td>
<td>Mass Median Aerodynamic Diameter</td>
</tr>
<tr>
<td>MN</td>
<td>MicroNucleus</td>
</tr>
<tr>
<td>MoA</td>
<td>Mode of Action</td>
</tr>
<tr>
<td>MoE</td>
<td>Margin of Exposure</td>
</tr>
<tr>
<td>MoS</td>
<td>Margin of Safety</td>
</tr>
<tr>
<td>MR</td>
<td>Mitotic Recombination</td>
</tr>
<tr>
<td>mROS</td>
<td>micellar Reactive Oxygen Species</td>
</tr>
<tr>
<td>MRP</td>
<td>Multidrug Resistance-associated Protein</td>
</tr>
<tr>
<td>MS</td>
<td>Mass Spectrometry</td>
</tr>
<tr>
<td>MTT</td>
<td>3-(4,5)-diMethyl-2-Thiazolyl-2,5-dimethyl-2H-Tetrazolium bromide</td>
</tr>
<tr>
<td>MW</td>
<td>Molecular Weight</td>
</tr>
<tr>
<td>N</td>
<td>Data points</td>
</tr>
<tr>
<td>NAM</td>
<td>New Approach Methodology</td>
</tr>
<tr>
<td>Nanomaterial</td>
<td>An insoluble or bio-persistent an intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm. (2009/1223/EC). Deviating definitions in other regulatory fields may also exist.</td>
</tr>
<tr>
<td>NAT1</td>
<td>N-AcetylTransferase 1</td>
</tr>
<tr>
<td>NESIL</td>
<td>No Expected Sensitising Induction Level</td>
</tr>
<tr>
<td>NGC</td>
<td>Non-Genotoxic Carcinogen</td>
</tr>
<tr>
<td>NGRA</td>
<td>Next Generation Risk Assessment</td>
</tr>
<tr>
<td>NIH</td>
<td>US National Institute of Health</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>NLM</td>
<td>US National Library of Medicine</td>
</tr>
<tr>
<td>NLP</td>
<td>No Longer Polymer</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear Magnetic Resonance</td>
</tr>
<tr>
<td>NOAEC</td>
<td>No Observable Adverse Effect Concentration</td>
</tr>
<tr>
<td>NO(A)EL, NO(A)EL_{sys}</td>
<td>The No Observed (Adverse) Effect Level is the outcome of repeated dose toxicity studies, such as 28-day or 90-day tests with rats, mice, rabbits or dogs, chronic toxicity tests, carcinogenicity tests, teratogenicity tests, reproduction toxicity tests, etc. It is the highest dose for which no (adverse) effects can be observed (based on EC B.26). The NOAEL should be expressed as mg/kg bw/d. In the calculation of the MoS, the lowest obtained NOAEL value is used, in order to take into account the most sensitive species, as well as the relevant effect occurring at the lowest dose possible. Whereas the NOAEL is a dose</td>
</tr>
</tbody>
</table>
For an external dose, the **NOAEL**<sub>sys</sub> is a dose descriptor of the systemic exposure to a substance and is calculated from the NOAEL by use of the proportion of the substance systemically absorbed.

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NoG</td>
<td>Notes of Guidance</td>
</tr>
<tr>
<td>NR</td>
<td>Neutral Red</td>
</tr>
<tr>
<td>NRU</td>
<td>Neutral Red Uptake</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>NURSA</td>
<td>Nuclear Receptor Signaling Atlas</td>
</tr>
<tr>
<td>OCHEM</td>
<td>Online Chemical Modeling Environment</td>
</tr>
<tr>
<td>OD</td>
<td>Optical Density</td>
</tr>
<tr>
<td>OI</td>
<td>Ocular Irritation</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
</tr>
<tr>
<td>OPPTS</td>
<td>Office of Prevention, Pesticides and Toxic Substances</td>
</tr>
<tr>
<td>P&lt;sub&gt;50&lt;/sub&gt;, P&lt;sub&gt;90&lt;/sub&gt;</td>
<td>50&lt;sup&gt;th&lt;/sup&gt;, 90&lt;sup&gt;th&lt;/sup&gt; Percentile</td>
</tr>
<tr>
<td>PACEM</td>
<td>Probabilistic Aggregate Exposure</td>
</tr>
<tr>
<td>PBMDC</td>
<td>Peripheral Blood Monocyte Derived Dendritic Cells</td>
</tr>
<tr>
<td>PBPK</td>
<td>Physiologically Based Pharmacokinetics</td>
</tr>
<tr>
<td>PBPK modelling</td>
<td>Physiologically Based Pharmacokinetic modelling</td>
</tr>
<tr>
<td>PBTK</td>
<td>Physiologically Based Toxicokinetics</td>
</tr>
<tr>
<td>PBTK modelling</td>
<td>Physiologically Based Toxicokinetic modelling</td>
</tr>
<tr>
<td>PDA</td>
<td>Photometric Diode Assay</td>
</tr>
</tbody>
</table>

### Personal care products

- **Consumer products used:** for beautification (make up products) and in personal hygiene (shower gel, skin cream, shampoo, feminine hygiene products, diapers, toilet paper etc.)

- **PhEUR** | European Pharmacopoeia |
- **PHMB** | PolyHexaMethylene Biguanide |
- **PIF** | Product Information File |
- **PMS** | Post-Marketing Surveillance |
- **PoD** | Point of Departure |
- **Pow** | n-octanol/water Partition coefficient |
- **PPD** | P-PhenyleneDiamine |
- **PPAR** | Peroxisome Proliferator-Activated Receptor |
- **ppm** | parts per million (*e.g.* mg/kg) |
- **PPRA** | Peroxidase Peptide Reactivity Assay |

### Prototype

- **A first model or design that has not been produced in batches, and from which the finished cosmetic product is copied or finally developed.** (2009/1223/EC)

- **PXR** | Pregnane X Receptor |
- **QMRF** | QSAR Model Reporting Format |
- **QRA** | Quantitative Risk Assessment |
- **QSAR** | Quantitative Structure Activity Relationship |
- **RA** | Risk Assessment |
- **REACH** | Registration, Evaluation, Authorisation and restriction of Chemicals |

### Reference material

- **Material sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process (ISO, 2008).**

- **RhCE** | Reconstructed human Cornea-like Epithelium test |
- **RhE** | Reconstructed human Epidermis |
- **RhT** | Reconstructed human Tissue |
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVM</td>
<td>RijksInstituut voor Volksgezondheid en Milieu</td>
</tr>
<tr>
<td>rLLNA</td>
<td>reduced Local Lymph Node Assay</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive Oxygen Species</td>
</tr>
<tr>
<td>RP</td>
<td>Responsible Person</td>
</tr>
<tr>
<td>RSMN</td>
<td>Reconstructed Skin MicroNucleus assay</td>
</tr>
<tr>
<td>RTEC</td>
<td>Registry of Toxic Effects of Chemical substances</td>
</tr>
<tr>
<td>SAF</td>
<td>Sensitisation Assessment Factors</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure Activity Relationship</td>
</tr>
<tr>
<td>SAS</td>
<td>Synthetic Amorphous Silica</td>
</tr>
<tr>
<td>SC</td>
<td>Stratum Corneum</td>
</tr>
<tr>
<td>SCC</td>
<td>Scientific Committee on Cosmetology</td>
</tr>
<tr>
<td>SCCNFP</td>
<td>Scientific Committee on Cosmetic products and Non-Food Products intended for consumers</td>
</tr>
<tr>
<td>SCCP</td>
<td>Scientific Committee on Consumer Products</td>
</tr>
<tr>
<td>SCCS</td>
<td>Scientific Committee on Consumer Safety</td>
</tr>
<tr>
<td>SCENIHR</td>
<td>Scientific Committee on Emerging and Newly Identified Health Risks</td>
</tr>
<tr>
<td>SCHEER</td>
<td>Scientific Committee on Health, Environmental and Emerging Risks</td>
</tr>
<tr>
<td>SCs</td>
<td>Scientific Committees</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation of the mean</td>
</tr>
<tr>
<td>SED</td>
<td>Systemic Exposure Dose</td>
</tr>
<tr>
<td>SHE</td>
<td>Syrian Hamster Embryo</td>
</tr>
<tr>
<td>SI</td>
<td>Stimulation Index</td>
</tr>
<tr>
<td>SIT</td>
<td>Skin Irritation Test</td>
</tr>
<tr>
<td>Spray, sprayable cosmetic product</td>
<td>A formulation is either dispensed by the use of propellant gas as defined in Directive 75/324 (propellant spray), or by a spray bottle with a pump dispenser that forces a liquid through a nozzle generating a spray stream or a mist of a liquid (pump spray) (SCCS/1539/14).</td>
</tr>
<tr>
<td>SSA</td>
<td>Skin Surface Area</td>
</tr>
<tr>
<td>STE</td>
<td>Short Time Exposure</td>
</tr>
<tr>
<td>S</td>
<td>Steroidogenic</td>
</tr>
<tr>
<td>S₀</td>
<td>Fraction (supernatant) containing cytosol and microsomes of cells after centrifugation at 9000g</td>
</tr>
<tr>
<td>Substance</td>
<td>A chemical element and its compounds in the natural state or obtained by any manufacturing process, including any additive necessary to preserve its stability and any impurity deriving from the process used but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition (2009/1223/EC)</td>
</tr>
<tr>
<td>SVHC</td>
<td>Substance of Very High Concern</td>
</tr>
<tr>
<td>SUE</td>
<td>A Serious Undesirable Effect is an undesirable effect which results in temporary or permanent functional incapacity, disability, hospitalization, congenital anomalies or an immediate vital risk or death (2009/1223/EC)</td>
</tr>
<tr>
<td>SPF</td>
<td>Sun Protection Factor</td>
</tr>
<tr>
<td>T25</td>
<td>Animal dose descriptor; chronic dose rate that will give 25% of the animal's tumours at a specific tissue site after correction for spontaneous incidence (Dybing et al., 1997)</td>
</tr>
<tr>
<td>T</td>
<td>Thyroid</td>
</tr>
<tr>
<td>TER</td>
<td>Transcutaneous Electrical Resistance</td>
</tr>
<tr>
<td>TEER</td>
<td>TransEpithelial Electrical Resistance</td>
</tr>
<tr>
<td>TEST</td>
<td>Toxicity Estimation Software Tool</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>TG</td>
<td>Test Guideline</td>
</tr>
<tr>
<td>TGR</td>
<td>TransGenic Rodent</td>
</tr>
<tr>
<td>TIF</td>
<td>Technical Information File</td>
</tr>
<tr>
<td>TopKat</td>
<td>Toxicity prediction by Komputer Assisted technology</td>
</tr>
<tr>
<td>Toxicodynamics</td>
<td>Cover the process of interaction of chemical substances with target sites and the subsequent reactions leading to adverse effects (ECB, 2003)</td>
</tr>
<tr>
<td>Toxicokinetics</td>
<td>Describe the time-dependent fate of a substance within the body and include absorption, distribution, biotransformation and/or excretion (ADME) (ECB, 2003)</td>
</tr>
<tr>
<td>TOXNET</td>
<td>TOXicology data NETwork</td>
</tr>
<tr>
<td>TPO</td>
<td>TrimethylbenzoyldiPhenylphosphine Oxide (SCCS/1528/1)</td>
</tr>
<tr>
<td>TSE</td>
<td>Transmissible Spongiform Encephalopathy</td>
</tr>
<tr>
<td>TTC</td>
<td>Threshold of Toxicological Concern</td>
</tr>
<tr>
<td>UDS</td>
<td>Unscheduled DNA Synthesis</td>
</tr>
<tr>
<td>UF</td>
<td>Uncertainty Factor</td>
</tr>
<tr>
<td>UGT</td>
<td>Uridine diphosphate GlucuronosylTransferase</td>
</tr>
<tr>
<td>Undesirable effect</td>
<td>An adverse reaction for human health attributable to the normal or reasonably foreseeable use of a cosmetic product (2009/1223/EC)</td>
</tr>
<tr>
<td>UN GHS</td>
<td>United Nations Globally Harmonised System of Classification and Labelling of Chemicals</td>
</tr>
<tr>
<td>U SENS</td>
<td>Myeloid U937 Skin Sensitisation Test</td>
</tr>
<tr>
<td>USA</td>
<td>United States of America</td>
</tr>
<tr>
<td>USP</td>
<td>USA Pharmacopoeia</td>
</tr>
<tr>
<td>UV</td>
<td>UltraViolet (wavelengths UV-A:315-400 nm, UV-B: 280-315 nm, UV-C: 100-280 nm) (EC B.41)</td>
</tr>
<tr>
<td>Valid method</td>
<td>A technique that has not necessarily gone through the complete validation process, but for which sufficient scientific data exist demonstrating its relevance and reliability (Rogiers, 2003)</td>
</tr>
<tr>
<td>Validated method</td>
<td>A method for which the relevance and reliability are established for a particular purpose (in most cases according to the criteria established by EURL-ECVAM, taking into account that a prediction model needs to be present from the start of the validation procedure). (based on Balls et al., 1997 and Worth et al., 2001) These methods are taken up in Regulation (EC) No 440/2008 and/or published as OECD Technical Guidelines*</td>
</tr>
<tr>
<td>VIS</td>
<td>VISible light (wavelength 400-800 nm)</td>
</tr>
<tr>
<td>WEC</td>
<td>Whole Embryo Culture</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
<tr>
<td>WoE</td>
<td>Weight of Evidence</td>
</tr>
<tr>
<td>XETA</td>
<td>Xenopus Eleutheroembryo Thyroid Assay</td>
</tr>
<tr>
<td>XME</td>
<td>Xenobiotic substances Metabolising Enzyme</td>
</tr>
<tr>
<td>Xprt</td>
<td>Xantine-guanine phosphoribosyl transferase gene</td>
</tr>
<tr>
<td>yH2AX</td>
<td>Phosporylated for of H2AX histone</td>
</tr>
</tbody>
</table>